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Chapter 1 
Introduction 
 
Autosomal dominant polycystic liver disease (ADPLD) is a hereditary disorder causing 
multiple fluid-filled cysts in the liver, which may cause significant discomfort to affected 
patients (1) (also see: Lay extra, page 140). A gene defect leads to production of a faulty 
protein, causing an abnormal cellular response and finally random expansion of parts of the 
biliary tract (2). In severe cases, the liver becomes deformed, causing a greatly enlarged 
abdomen. Clinically, the mass effect from this abdominal distension causes pain, nausea, 
anorexia, shortness of breath and a generally decreased quality of life. The disease is of great 
biomedical interest for multiple reasons (1, 2): not all genes causing the disease are known, a 
remarkable mechanism appears to be responsible for the stochasticity of cyst development, 
and no curative pharmacological treatment has yet been developed. In this chapter I will go 
into the biomedical background of the disease and will highlight the aims of this thesis. 
Liver cysts 
The human liver 
 
The human liver is the largest internal organ of the human body and the second largest 
organ after the skin. Present in the right, upper, part of the abdomen, it can weigh up to 
1.5kg in healthy adults (3). The liver consists of a right lobe and a left lobe, the first being six 
times larger than the latter, on average (4). Hepatic functions are critical to support most 
other organs, and therefore to sustain human life. Most importantly, the liver facilitates 
detoxification of metabolites (‘waste processing’), production of bile (‘waste removal’), 
energy and vitamin storage, and protein synthesis (e.g. blood clotting components). Bile 
produced by the hepatic cells is excreted into the biliary tract. The main biliary tract starts in 
the right and left lobe of the liver with two hepatic ducts, which join to form a common 
hepatic duct. There the cystic duct from the bile-storing gallbladder joins to form a common 
bile duct, which finally leads into the duodenum. 
Bile and the biliary tract 
 
The cells that make up liver parenchyma are hepatocytes and cholangiocytes, both of which 
are of epithelial origin (4). These cells lie in hexagon-shaped lobules, which consist of 
hepatocytes and a portal triad. Each portal triad contains a hepatic artery, portal vein and 
bile duct.  
Bile production in the liver starts in tiny canals called canaliculi, lying in between neighboring 
hepatocytes. The hepatocytes excrete bile salts, e.g. cholic acid and chenodeoxycholic acid, 
and toxic metabolites into these canaliculi. The bile flows into small bile ducts called 
ductules, before converging into intralobular ducts and subsequently into the hepatic ducts 
described previously. Besides the excretion of hepatocytes, cholangiocytes in the ducts also 
add to the volume, pH and composition of the bile. These cells excrete alkaline fluid to 
promote micelle formation and to neutralize stomach acid arriving in the duodenum. The 
fluid consists mostly of HCO3
-, Na+, K+, and Cl-. Around 250 to 1000ml of bile is produced per 
day in a healthy adult, the variation being dependent upon the amount of bile salts being 
excreted from hepatocytes (5).  
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It is from the intrahepatic part of the biliary tract that cysts, fluid-filled sacs of cells, are 
thought to form. In PLD, cysts occur separated from the biliary tract. Sporadic cysts are 
benignly present in 2.5-18% of the general population (6), these cysts represent a frequent, 
but mostly harmless abnormality. Cysts however may continue to expand to sometimes 
even more than two liters in volume. In these instances, problems related to abdominal 
distension may occur, that require clinical intervention.  
 
Figure 1. Affected organs and genes in autosomal dominant polycystic liver disease (ADPLD) and 
autosomal dominant polycystic kidney disease (ADPKD).  
A.) In normal health, no liver or kidney cysts occur. Only a small percentage of the population may 
have single, sporadic liver or kidney cysts. 
B.) PRKCSH, SEC63, LRP5 and GANAB mutations underlie ADPLD, whereby only the liver develops 
multiple liver cysts. The kidney is often relatively spared. 
C.) PKD1 and PKD2 mutations underlie >95% of ADPKD cases. Both the liver and kidney develop 
multiple cysts. 
Note: There are indications that LRP5 and GANAB mutations may also cause ADPKD. 
Polycystic liver disease 
 
Polycystic liver disease (PLD) occurs as part of the phenotype of autosomal dominant 
polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD). 
In dominant autosomally inherited disease, one mutation in any of the two alleles of a gene 
is sufficient for expression of the disease, thus an affected patient has a 50% chance of 
producing a child with the disease. ADPLD is rare and occurs in 0.05-0.53% of the population 
(7). ADPKD occurs more frequently, and is present in 0,1-0,25% of the general population (8). 
83-94% of ADPKD patients will develop liver cysts during their life time (9, 10) .  
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PLD is often arbitrarily defined as more than twenty fluid-filled sacs spread out in the liver, 
but the disease occurs in many shapes and sizes. Polycystic livers from ADPLD and ADPKD 
are indistinguishable from each other (2), in contrast to those from related disease such as 
autosomal recessive polycystic kidney disease (ARPKD) and ciliopathies, where hepatic 
scarring (‘fibrosis’) and other symptoms (often in the form of a syndrome) may co-occur at a 
young age. Furthermore, the cysts in ARPKD and ciliopathies are likely in continuity with the 
biliary tract, whereas those in ADPKD and ADPLD are not. ADPLD and ADPKD patients usually 
present with complaints from the enlarged liver due to organ displacement (‘abdominal 
distension’) as middle-aged adults. Women are earlier, more frequently and more severely 
affected, likely due to the effect of female hormones such as estrogen (1, 11). Liver sizes of 
20 liters (‘hepatomegaly’) are not unheard of, and symptoms include abdominal distension, 
early satiety, and limited mobility (12). Biomarkers such as alkaline phosphatase, gamma-
glutamyltransferase and Ca19.9 (carbohydrate antigen 19-9) may be used to detect disease 
occurrence or prognosis (13, 14). Although disease progression is regarded as benign, 
symptoms often extend to the level that they significantly affect quality of life. Treatment is 
therefore indicated in symptomatic patients.  
Treatment 
 
Several treatment options exist for liver cysts. Conservative, medical management involves 
administration of somatostatin analogues. This group of therapeutics includes lanreotide, 
octreotide and pasireotide, which have been used to suppress cyst expansion by their effects 
on cell growth (‘proliferation’) and fluid secretion. The somatostatin analogues function 
through the somatostatin receptors (SSTRs), which affect adenylyl cyclases (AC) to reduce 
levels of cyclic AMP (cAMP) (15, 16). This molecule was found to be dysregulated in PLD in 
some studies (17-22), and altered levels cause dysregulation of Ca2+ signaling.  
Surgical interventions include aspiration sclerotherapy (AS) (23) and laparoscopic cyst 
fenestration (15). AS is performed by an intervention radiologist who uses a needle to 
aspirate fluid from the cyst under ultrasound guidance. The treatment is recommended for 
simple, sporadic cysts or polycystic liver disease where a single, large or dominant cyst is 
present. Cyst fluid can be captured and frequently contains cells that have detached from 
the inner wall (‘epithelium’) of the cyst. Following fluid withdrawal, a sclerosing agent is 
injected to destroy the cyst epithelium to prevent further expansion. The most commonly 
used sclerosant is <150ml 96-100% ethanol (23). 
Laparoscopic cyst fenestration is a surgical intervention performed through small incisions or 
keyholes to treat superficial liver cysts. During the procedure, cysts located at the surface of 
the liver are drained and their domes removed. This allows any secreted fluid to drain into 
the abdominal cavity where it is taken up by the surrounding cells of the membrane 
(peritoneum).  
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PRKCSH 
PRKCSH, an acronym for protein kinase C 
substrate 80 K-H, encodes the protein product 
glucosidase II beta (GIIB). Mutations in this 
gene are the most frequently occurring cause of 
isolated polycystic liver disease. Approximately 
15% of ADPLD patients possess a mutation in 
PRKCSH  (24, 25). The gene is located on 
chromosome 19 and has a length of 15,712 
bases (4). PRKCSH isoform 1 has 18 exons with 
2,079 bases [NM_002743.3]. The protein 
product GIIB consists of 528 amino acids with a 
molecular weight of 59 kDa (26, 27). GIIB 
consists of an N-terminal signaling sequence, 
low-density lipoprotein receptor domain 
(LDLa), two putative calcium-binding EF-Hand 
domains, a glutamic acid repeat, a variable 
protein domain, a mannose-6-phosphate 
receptor domain and a C-terminal HDEL 
endoplasmic reticulum (ER)-retention signal. 
This latter signal is responsible for keeping the 
glucosidase complex (GIIA and GIIB) in the ER. 
Glucosidase II functions as an n-linked glycan-
processing enzyme, with GIIA as the catalytic 
component and GIIB as a structural component.  
It cleaves off two glucose residues in two 
separate steps, which are tightly linked to 
protein quality control. Incorrectly folded 
proteins undergo multiple rounds of glycan 
processing, and depending on the folding 
outcome may be processed towards their final 
location or destroyed in the proteasome 
following excretion out of the ER.  
GANAB 
Glucosidase II alpha subunit (GANAB) is one of 
the most recently found genes in ADPLD and 
ADPKD (28, 29). Mutations in GANAB 
accounted for 1.9% of ADPLD patients and 0.3% 
of ADPKD patients. Located on chromosome 11, 
the gene has a length of 21,901 bases. GANAB 
isoform 3 contains 25 exons across 4,026 bases 
[NM_198335.3]. Spanning 944 amino acids, 
GIIA, GANAB’s protein product, weighs 107 
kDa. It contains glycoside hydrolase and 
galactose mutarotase-like domains (26). 
For the protein function, please refer to the 
gene card of PRKCSH. GIIA, containing the 
catalytic domain of glucosidase II, joins with 
GIIB to create an active glucosidase. 
 
ALG8 
ALG8, an abbreviation of alpha-1,3-
Glucosyltransferase,   encodes ALG8. 
Discovered in 2017 in a large exome-sequencing 
cohort, it is one of the latest known cyst 
disease genes. About 3.1% of ADPLD cases are 
likely caused by the gene (29).  It is found on 
chromosome 11 spanning a length of 38,725 
bases. 526 Amino acids are found in isoform 1 
[NM_024079], which weigh approximately 60 
kDa.  
The protein is responsible for adding the 
second glucose residue to the oligosaccharide 
precursor group on proteins during N-
glycosylation. As this is one of the two glucose 
residues cleaved by glucosidase II, a role in liver 
cyst development had been hypothesized for 
ALG8 even before exome sequencing 
 SEC63 
SEC63, short for SEC63 homologue (S. 
cerevisiae), encodes the SEC63 protein 
(SEC63p). It was discovered in 2004 as the 
second gene to cause isolated polycystic liver 
disease (26, 31). Around 5.7% of ADPLD 
patients possess SEC63 mutations (1). The gene 
is present on chromosome 6 with a length of 
90,523 bases. SEC63 isoform 1 spans 21 exons 
and contains 6,500 bases [NM_007214.4]. 
Although multiple splice variants exist, the 
main splice variant of SEC63p has 760 amino 
acids and weighs 88 kDa. SEC63p consists of 
three transmembrane domains, a luminal DnaJ-
like domain (between segment 2-3), and a large 
cytoplasmic, negatively charged C-terminal 
domain. It functions with the SEC61 complex, 
together with SEC62 in as part of the 
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determined it as a cause (2, 30).        
 
 
SEC62/SEC63 complex, where it is responsible 
for protein ER transfer and membrane insertion 
of transmembrane proteins. The SEC61 complex 
is also important in protein quality control (2, 
31-34). It transfers proteins bound for 
proteasomal degradation out of the ER and into 
the proteasome. 
SEC61B 
Sec61 Translocon Beta Subunit (SEC61b), codes 
for SEC61B protein. Despite belonging to the 
molecular complex of SEC63, it was only 
discovered in 2017 as a cause for ADPLD (29).  
Approximately 1.3% of cases are likely related 
to mutations in the gene.  This gene is found on 
chromosome 9 and has a length of 8,556 bases.  
The mature protein has 4 exons with 545 
nucleotides that encode 96 amino acids 
[NM_006808] weighing 9974 Da.  
SEC61B forms a heterotrimeric SEC61 complex 
with SEC61A1 and SEC61G, where it forms the 
core of the endoplasmic translocon complex. Of 
the three components, it is the least universally 
conserved and not essential for the complex’s 
function (29, 35). Its function is poorly 
understood in comparison to that of its 
complex partners, but likely includes 
associations of non-translating ribosomes with 
the ER to enhance protein translation (29), 
facilitating cotranslational protein transport 
and interacting with the signal peptidase during 
translocation (29).  
LRP5 
LRP5, an acronym for low-density lipoprotein 
receptor related 5, encodes LRP5. Only 
published in 2014, it is a recent gene revealed 
to cause ADPLD. In a cohort of 150 unrelated 
ADPLD patients without mutation in PRKCSH, 
SEC63 or PKD2, only 3 cases were found. LRP5 is 
located on chromosome 11 with 150,410 bases, 
its isoform 1 spans 23 exons for a total length of 
5,168 bases [NM_002335.3] (26). The protein 
size is 1,615 amino acids that weigh 179 kDa.  
LRP5 is a co-receptor in Wnt signaling. LRP5’s 
extracellular part contains four beta-propeller 
domains composed of six YWTD repeats, an 
epidermal growth factor-like domain, and three 
low-density-lipoprotein receptor-like ligand-
binding domains (36). Together with a Frizzled 
(Fz) receptor, LRP5 binds Wnt ligands (37-40). 
Through conformational change and 
phosphorylation of its PPPSP motifs, a docking 
site for axin1 and the Wnt ‘destruction 
complex’ is created. After several more 
signaling steps this eventually leads to beta-
catenin activation and transcription of genes 
with a TCF/LEF regulatory site. Its role in 
canonical Wnt signaling is especially well 
known. 
PKD1 
Polycystic kidney disease 1 (PKD1), is the first 
gene proven to cause hepatic and renal cyst 
development (41). Approximately 85% of all 
ADPKD patients possess mutations in PKD1 (2). 
The gene is located on chromosome 16 with 
47,191 bases. Isoform 1 spans 46 exons for a 
total of 14,138 bases [NM_001009944.2]. PKD1 
encodes polycystin-1 (PC1), a very large protein 
weighing 462.529 kDa, with a size of 4,303 
amino acids.  
PC1 is a membrane glycoprotein with a large N-
terminal extracellular region, multiple 
transmembrane regions and a cytoplasmic C-
terminal region. Protein processing by GIIB, 
GIIA and SEC63p are essential for protein 
PKD2 
Polycystic kidney disease 2 (PKD2), is the 
second gene discovered to cause hepatic and 
renal cystogenesis. Mutations in the gene are 
responsible for disease in approximately 15% of 
all ADPKD patients (2). Located on chromosome 
4, the gene has a length of 70,141 bases. 
Isoform 1 contains 15 exons spanning 5,089 
bases [NM_000297.3]. With 968 amino acids 
and a weight of 109.691 kDa protein product 
polycystin-2 (PC-2) is considerably smaller than 
PC1, with which it forms a heterodimer (48). N-
glycosylation is essential to determine the 
abundance of the protein (49). Similar to PC1, it 
is a ciliary membrane protein, in PC2’s case 
containing 6 transmembrane domains with 
 Introduction | 11  
 
function, and current experimental data favor  
PC1 as the central, downstream component for 
all cyst-causing genes except LRP5 (28, 42). 
Polycystin-2 seems to be crucial for ciliary 
trafficking of PC1, as well as its proper 
maturation (42, 43).  
PC1 contains proline, glumatic acid, serine and 
threonine amino acids that may facilitate 
ubiquitin-mediated degradation. Leucine-rich 
repeats, a C-type lectin domain, 16 
immunoglobulin-like repeats and 4 type II 
fibronectin-related domains implicate the 
protein in cell-cell or cell-matrix interactions 
(44). The protein is notably located in the 
primary cilium, with additional localization on 
the lateral domain of plasma membranes and 
to adhesion complexes in polarized epithelial 
cells (45, 46). At around 200 amino acids, PC1’s 
C-terminal tail contains a g-protein binding 
domain and a coiled-coil domain (46). It also 
contains an N-terminal g-protein coupled 
receptor proteolytic site (GPS), whose cleavage 
is necessary for its function (47). PC1 was long 
thought to be a mechanosensitive ciliary 
calcium ion channel, responsive to urine flow, 
but recent data suggest that this is incorrect 
(48). Its exact ciliary function therefore remains 
elusive.  
cytoplasmic N and C termini (44). PC2 functions 
as a calcium permeable nonselective cation 
channel, although the previously considered 
role as a mechanosensitive ion channel 
currently seems unlikely. Its interaction with 
PC1 is crucial for ciliary localization of the 
heterodimeric complex, with the main 
interaction taking place at their c-terminal 
cytoplasmic domains (44, 50). The majority of 
cellular PC2 is located in intracellular 
compartments other than the primary cilium 
however, where it likely modulates intracellular 
calcium stores. 
 
PKHD1 
Polycystic kidney and hepatic disease 1 
(PKHD1), is a novel gene causing a phenotype 
similar to ADPLD in mutation carriers. The gene 
is primarily known in causing autosomal 
recessive polycystic kidney disease (ARPKD) in 
humans, yet was found in a cohort of 
unresolved ADPLD patients (29). 6-11% of 
ADPLD cases are expected to be caused by the 
gene based on this study. 
The gene is 472,941 bases long on chromosome 
6. Its 16.282 nucleotides isoform 1 
[NM_138694] encode 4.074 amino acids, giving 
the protein a molecular weight of 446.702 kDa. 
The fibrocystin protein contains a highly 
glycosylated N-terminal extracellular domain, a 
single transmembrane domain, a calcium 
binding site and multiple plexin-transcription-
factor domain (51)s. Although its precise 
function is unknown, it is another cilium-
localized molecule. Like PC1 and PC2, 
fibrocystin is likely involved in calcium, cAMP, 
MAPK and EGF(R) signaling (51).  
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Pathophysiology 
Polycystic livers start out as a simple genetic abnormality in one of two alleles of the 
fertilized oocyte (‘egg’). This single genetic error eventually leads to a faulty protein or 
protein production, an unknown disturbed pathway, causing a cholangiocyte stem cell with a 
defective response (possibly through an abnormal primary cilium) and finally a liver cyst. 
These mechanisms of disease are further elucidated below. 
 
Genes and proteins  
 
A plethora of genes are involved in liver cyst development (also see Gene cards box). 
Mutations are found in genes PRKCSH, SEC63, and LRP5 in up to 35% of ADPLD patients (27, 
29, 40), while mutations in PKD1 and PKD2 cause ADPKD in virtually all cases (8) (gene 
cards). A recent study found GANAB mutations in a small number of ADPKD patients as well 
(0.3%) (28). The prevalence of mutations in ADPLD patients is unclear, 2 out of 9 unresolved 
families in this study had a GANAB mutation, and 3 out of 159 ADPLD patients (1.9%) in a 
later study (29). The gene may cause either severe ADPLD or mild to moderate ADPKD (28). 
ARPKD, another liver cyst disease, is caused by mutant PKHD1. The disease displays a 
recessive disease pattern. In another recent study, PKHD1 mutation carriers (i.e. not 
patients) showed a clinical phenotype similar to that of ADPLD (29). It was estimated that 6-
11% of ADPLD cases may be caused by PKHD1. The group additionally found two genes on 
the same biosynthetic route as PRKCSH and SEC63B; ALG8 and SEC61B respectively. ALG8 
mutations likely occur in 3.1% of patients, while SEC61B mutations explain another 1.3%. In 
total, it is estimated that known genes can explain about 50% of ADPLD cases (29). 
Ciliopathies with PLD may also occur due to mutations in IFT88, MKS, TSC1, TSC2, and OFD1 
(more information below).  
The protein products of these genes have several commonalities. GIIB, GIIA, ALG8, SEC61B 
and SEC63p function in the endoplasmic reticulum (ER), where they are responsible for 
processing newly formed proteins. These ER proteins are essential for polycystin (PC) 1 and 
PC2 processing (29, 42, 49), which are the protein products of PKD1 and PKD2 genes. 
Complete loss of PRKCSH, GANAB, ALG8, SEC61B and SEC63 reduces PC dosage to a critically 
low level. This is most likely due to a close interplay between PRKCSH, GANAB, ALG8, 
SEC61B, SEC63, PKD1, and PKD2. One feature of ADPLD that remains unexplained is the low 
penetrance and mild phenotype in some family members with known mutations in genes 
underlying the disease (28, 52-54).  Evidence of familial clustering of severe PLD indicates 
that genetic modifiers may play a role. 
PC1, PC2 and PKHD1 function in the primary cilium, the cell’s antenna. Additionally, PC1 
localizes to the lateral domain of the plasma membrane and to adhesion complexes in 
polarized epithelial cells (46). The majority of cellular PC2 is located in intracellular 
compartments other than the primary cilium, where it likely modulates intracellular calcium 
stores (44, 50). It remains unclear which processes involving the cilium are dysregulated to 
cause liver cysts. The finding of LRP5 mutations in ADPLD (40), suggest that the Wnt signaling 
pathway is likely implicated.  
Genes and proteins: loss-of-heterozygosity 
 
ADPLD is recessive at a tissue level (2, 55-57). A liver cyst occurs when a single cell expands 
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vigorously due to loss of both normal wild-type alleles. This abnormal stem cell gives rise to a 
cyst comprised of mutated daughter cells. In PLD the chance of this process occurring is 
greatly increased, since all cells already have lost the function of their first allele. In the body, 
somatic second hits occur that then cause loss-of-heterozygosity (LOH) and reduction of the 
cognate protein activity below the threshold of pathogenicity.  
LOH is detectable in ~79% of liver cysts from PRKCSH mutation cases, ~7% of cysts of a SEC63 
mutation patient, and in 80% of cysts from a PKD2 carrier (55-57). Additionally, Janssen and 
colleagues showed that loss of PKD2 occurs in sporadic cysts (55). A single, sporadic cyst of a 
patient had both alleles of PKD2 inactivated, whereas two normal PKD2 copies were present 
in the germline. A strong indication that sporadic cyst formation occurs through the same 
pathophysiological pathway as polycystic cyst formation, while having to pass through a 
greater stochastic barrier by having to mutate not one, but two alleles. In kidney cysts, LOH 
similarly occurs with PKD1 and PKD2 (58, 59). No descriptions of LOH for GANAB, ALG8, 
SEC61B, PKHD1 or LRP5 yet exist. 
 
Figure 2. Loss-of-heterozygosity initiates cyst formation.  
Somatic loss of the wild type allele (green) leads to a cholangiocyte stem cell with two mutated 
alleles (red). This cholangiocyte displays aberrant growth, leading to cyst formation. 
Pathways 
 
Multiple pathways are implicated in liver cyst development. Suggested pathways and cellular 
processes include: Ca2+ (20, 21), cAMP (17-22), PKA/Src/Raf/MEK/ERK1/2 signaling (17, 20, 
21, 60, 61), CFTR/AQP1/AE2/fluid secretion (21), pleiotropic growth factors/receptor 
tyrosine kinases (EGF/EGFR/VEGF/IGF-1/IL-6) (20, 21, 62), mTOR (20, 21, 60), cyclins/CDC25a 
(21, 63, 64), estrogens/FSH, HDAC6/epigenetics (1, 20), MMPs/ECM remodeling (20, 21), and 
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cell adhesion (62).  
Of foremost importance are calcium and cAMP signaling, which are regulated by the 
somatostatin analogues that can treat the disease. Ca2+ signaling is coupled to protein 
products of multiple cyst related genes. Fibrocystin loss likely disturbs intracellular calcium 
signaling (51).  The polycystins may function as nonselective cation channel. It is currently 
unclear whether this includes Ca2+ signaling in the primary cilium (see paragraph ‘hepatic 
cystogenesis: paradigm shift’ in the discussion). Other causes for disturbed ciliary signaling 
may be present. GIIB and PKD2 display effects on Ca2+ signaling from the ER (46, 65-67). The 
calcium pathway is tightly interrelated with cAMP signaling: increased Ca2+ decreases cAMP, 
and Ca2+ and cAMP influence proliferation and fluid secretion. 
Wnt signaling is a pathway which is implicated in ADPLD by the discovery of disease 
associated mutations in the LRP5 gene (40). The protein product of LRP5 is a receptor that 
interacts with Frizzled (Fz) receptors, of which 10 subtypes exist in mammals (reviewed in 
(68)). Similarly, 19 Wnt subtypes are present in mammals. LRP5 only has one homologue in 
the form of LRP6, with which it shares partially redundant functions. Frizzled and LRP5 bind 
Wnt ligand proteins, causing them to activate the Wnt pathway through the Axin2 
destruction complex. The final effect of this canonical Wnt signaling pathway is activation of 
beta-catenin. Beta-catenin then binds TCF/LEF promoters to activate (transcribe) Wnt-
sensitive genes (68).  
The different Wnt and Fz subtypes are relevant due to their differences in activated 
pathways. Besides the canonical beta-catenin pathway, Wnt also signals through non-
canonical pathways. A particular Wnt-Fz-LRP combination may activate beta-catenin and / or 
non-canonical pathways (68). The non-canonical pathways are divided into two branches, 
which are both independent from beta-catenin (69). The first is the planar cell polarity (PCP) 
pathway, which determines the orientation of the mitotic spindle and thus the direction of 
the planar cell expansion, as well as the organization and orientation of cellular structures 
such as cilia. The second is the Wnt/Ca2+ pathway, which regulates intracellular Ca2+ release 
from the endoplasmic reticulum to regulate tissue patterning. Although it is considered a 
distinct pathway, it shares components with the PCP pathway, and may modulate both 
canonical and PCP Wnt signaling to induce its effects.  
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Figure 3. Schematic representation of the pathways involved in polycystic liver disease development 
according to current literature.  
ER: Endoplasmic reticulum; ECM: extracellular matrix; DNA: Deoxyribonucleic acid. 
Fz: Frizzled; LRP5/6: LDL Receptor Related Protein 5/6; APC: adenomatous polyposis coli; GSK-3β: 
Glycogen synthase kinase 3 beta; SEC61 c.: SEC61 complex; PC1/2: Polycystin-1/2; Cl-: Chloride; H2O: 
dihydrogen monoxide; AQP1: Aquaporin-1; TK: Tyrosine Kinase Receptor; PKA: Protein kinase A; SRC: 
Proto-oncogene tyrosine-protein kinase Src; Raf-1: RAF proto-oncogene serine/threonine-protein 
kinase;  MEK: Mitogen-activated protein kinase kinase; ERK: Extracellular signal–regulated kinases; 
TSC: Tuberous Sclerosis protein; mTOR; Mammalian target of rapamycin; PDE: Phosphodiesterase; 
cAMP: Cyclic adenosine monophosphate; Ca2+: Calcium;  AC: Adenylyl cyclase; SSTR: Somatostatin 
receptor; MMP: Matrix metalloproteinase; ER: estrogen receptor. 
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Figure 4. Schematic representation of a primary cilium. 
Nonmotile primary cilia have a 9+0 microtubule architecture within the ciliary axoneme, which 
means nine doublet microtubules organized in a circle. These cilia form from a basal body, which is 
the older of two centrioles. Intraflagellar transport complexes are responsible of transporting 
molecular cargo along the axonemal microtubule tracks, and thereby promote the unique protein 
and lipid composition of cilia. At the ciliary base, the BBSome protein complex connects to IFT to 
actively shuttle proteins and vesicles across the barriers at the ciliary base. 
Primary cilia and cholangiocytes 
 
Outside of PLD, diseases involving liver cysts are mostly caused by genes involving the 
primary cilium. Normal biliary ducts have solitary, cylindrical primary cilia on virtually all 
cells, with a length >4µm (49, 50). Each of these nonmotile cilia has a 9+0 microtubule 
architecture within the ciliary axoneme (2). That means nine doublet microtubules organized 
in a circle, without the central singlet microtubule pair and associated dynein-based motility 
apparatus observed in motile cilia. In quiescent cells, cilia form from a basal body, the older 
of two centrioles. The link between cilia and the centriole indicates that cilia can only occur 
during nondividing phases of the cell cycle. The ciliary compartment and membrane have a 
distinct protein and lipid composition and several barriers that separate this organelle from 
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the cell’s cytoplasm and membrane, respectively (70, 71). Intraflagellar transport (IFT) 
complexes assemble and maintain a cilium by active, molecular motor-based transport of 
molecular cargo along the axonemal microtubule tracks. This transport is bidirectional: 
heterotrimeric kinesin-2 motors power the IFT-B particles to move from the ciliary base 
towards the tip (anterograde transport), while movement of IFT-A particles in the opposite, 
retrograde direction is powered by cytoplasmic dynein 1b/2 motors. At the ciliary base, 
another protein complex called the BBSome connects to IFT to actively shuttle proteins and 
vesicles across the barriers at the ciliary base (72).  
In the liver parenchyma, only cholangiocytes possess primary cilia. Cholangiocyte cilia are 
thought to be cellular sensors, involved in mechano-, osmo-, and chemo-reception of bile 
flow (73-76). An old hypothesis states that cilia mechanically bend in response to fluid flow, 
whereby a mechanosensory calcium channel produces influx of Ca2+ as a second messenger. 
In recent years, this hypothesis has become more controversial however (see paragraph 
‘hepatic cystogenesis: paradigm shift’ in the discussion). 
Cholangiociliopathies 
 
A plethora of crucial ciliary components are affected in different cholangiopathies. To group 
these diseases together, researchers have aptly coined the term cholangiociliopathies (75). 
The polycystins are the most important with regard to liver cysts, although their function, 
and thus, their role in cystogenesis remains poorly understood. In ADPKD, cells lining the 
medium-sized hepatic cysts (1-3cm diameter) project cilia (into the lumen) that are short 
(1.25 ± 0.29 μm) and rare (1/200 cells), and the organelles are completely absent from larger 
cysts (>3cm diameter) (77, 78). Mutations in genes underlying other ciliary components are 
infrequent and display a milder phenotype. Polycystic livers have also been detected in 
animals or patients with IFT88, cystin-1, Meckel-Gruber syndrome (MKS), and orofaciodigital 
disease 1 (OFD1) mutation (2). Most likely, more ciliopathies may develop a phenotype with 
multiple liver cysts.  
The presence of multiple liver cysts is not limited to ADPLD and the cholangiociliopathies, 
but occurs in a wider spectrum of monogenic diseases. For example, failure to form 
peroxisomes due to monogenic mutation in peroxisomal biogenesis factor genes leads to a 
syndrome sometimes involving liver cyst formation (79). GIIB, SEC63p and SEC61B interact 
with peroxisomal proteins and are crucial for peroxisome development (80). As such, cyst 
formation appears to be a complex, heterogeneous process, possibly not relying solely upon 
disruption of a single pathway. PC1, ciliopathies, Wnt and even peroxisomal biogenesis 
disorders could represent different routes to a liver cyst. 
Biliary stem cells and tissue development 
 
During development of the cholangiocytes in the biliary tract, multiple signaling pathways 
become active, and their disturbance leads to liver cysts. Most important are Notch, Tumor 
Growth Factor (TGF)-β, and, crucially, Wnt signaling (2, 81-87), all of which are also 
associated to ciliary signaling (88-91). In embryonic development, and during liver damage, 
portal veins in the liver secrete Wnt ligands. These induce nearby hepatoblasts, ‘bipotent’ 
cells with potential to become hepatocyte or biliary cells, to become prebiliary cells (2). The 
cells express stem cell marker SOX9, epithelial cell marker KRT18 and biliary cell marker 
KRT19. The biliary precursors first form a ductal plate surrounding the portal veins, which 
then doubles to shape two cell layers. Maturation of these layers causes a lumen to form, 
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generating primitive ductular structures, which after further development become the bile 
ducts. Not all cells of the ductal plate participate in this process, and those that do not 
involute or become hepatocytes. Abnormalities in this process of remodeling give rise to 
ductal plate malformations such as the biliary microhamartomas called von Meyenburg 
complexes. These abnormal ductal plate remnants might continue growing throughout life, 
causing cysts to develop (see chapter 1). It is thought that the cause for this abnormal 
behavior of cells is the previously described loss-of-heterozygosity of PRKCSH, SEC63, PKD1, 
PKD2, and possibly LRP5, GANAB, ALG8, SEC61B and PKHD1. 
In adulthood, oval shaped cells within the biliary tract are generally thought to be the local 
stem cell reservoir. These stem cells are SOX9+, KRT19+ and retain bipotency, allowing them 
to proliferate and differentiate into hepatocytes and cholangiocytes when required due to 
circumstances such as biliary damage. The oval cells likely derive from the aforementioned 
hepatoblasts during embryonic development (92). Upon damage, some of these 
cholangiocytes also start expressing stem cell marker LGR5+ (93-95), which is known to 
occur in stem cells of other parts of the intestinal tract (96). LGR5 is part of the Wnt signaling 
pathway, and actually associates with ADPLD-related protein LRP5 in a complex (97, 98). 
SOX9+, LGR5+ stem cells may not only contribute to normal tissue homeostasis of the biliary 
tract, but also to the abnormal expansion of liver cysts upon LOH. 
Molecular toolbox to study polycystic liver disease 
Genomic and protein research have made a large leap forward during the past decades, and 
especially the past years. This progress warrants a few paragraphs dedicated to the new 
techniques, as it is important to understand the subject by starting from the basics.  
 
Polymerase chain reaction, Sanger sequencing, and SNP arrays 
 
After discovery of the DNA double helix, enzymes have enabled sequencing and 
manipulation of DNA (99). Polymerases, ligases, and endo-/exonucleases are at the core of 
this progress. These enzymes can copy, link together, and cut DNA respectively.  
Polymerase chain reaction amplifies fragments of DNA or RNA to thousands or millions of 
copies, allowing easy detection. The nucleotide sequence of these copies can subsequently 
be determined by a final amplification round with fluorescent nucleotides using Sanger 
sequencing. The standard deoxynucleotides (dNTPs) are replaced by chain-terminating 
dideoxynucleotides (ddNTPs). Incorporation of each fluorescent ‘A’, ‘C’, ‘G’, or ‘T’ nucleotide 
can be recognized by sensors due to the strong fluorescent signal of many pieces of DNA.  
These techniques have been applied to broadly scan large segments of DNA in ADPLD 
families, and study whether any of the large segments, i.e. markers therein, correlate with 
the phenotype in the family members. Using a method called linkage analysis, the DNA 
segment with the highest odds to be linked to the phenotype is determined.  Within this 
linked region, all genes are then individually sequenced to look for pathogenic variants (see 
glossary). In this manner, PRKCSH and SEC63 were found to be a cause for ADPLD in 2003 
and 2004 (31, 100, 101).  
Next-generation sequencing: exomes, molecular inversion probes, and RNA sequencing 
 
Methods to sequence DNA have kept improving, and ‘next-generation’ sequencing currently 
allows cheap and fast determination of the entire gene coding DNA of humans with whole 
exome sequencing (WES). Instead of sequencing the whole genome of 3 billion bases, only 
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1% thereof, or 30 million coding bases are sequenced (102). WES is especially effective in 
rare Mendelian disorders. Since the expected variant is rare, nonpathogenic variants can 
easily be excluded by sequencing multiple family members. For autosomal dominant 
disease, two far-removed, disease-affected family members often only share few candidate 
variants.  By specifically looking at the variant – phenotype correlation in additional family 
members, a candidate variant may be established as the disease cause. The candidate gene 
can then be validated as a disease cause using cellular and animal models by knocking out 
the gene and studying the model’s phenotype.  
Using WES in 2014 (40), Cnossen and colleagues sequenced DNA of two affected pedigrees 
of an ADPLD family. Amongst several other mutations, they found a mutation in the LRP5 
gene, and subsequently used Sanger sequencing to confirm that the other affected family 
members shared this abnormality. GANAB, ALG8, SEC61B and PKHD1 discovered in 2016 and 
2017, was discovered by using the same technique (28, 29). 
Currently, there is a paucity in finding additional genes by applying WES in affected families. 
This can be caused by several factors, such as the lack of complete sequence coverage 
(sensitivity) or the presence of mutations in deep-intronic regulatory sequences that are 
missed by focusing on the coding sequences in WES. To resolve the sensitivity issue, 
molecular inversion probe (MIP) sequencing (103, 104) is being considered as an alternative. 
MIP technology uses small DNA probes with PCR to amplify specific segments of the human 
genome, which are subsequently circularized. After exonucleases break down all DNA that is 
not circular, only the circular MIPs remain. In this manner, MIPs allow 30-100 genes to be 
targeted and sequenced at a lower cost than the 20.000+ genes of the whole genome for 
hundreds of patients at the same time. This technique will likely be deployed for ADPLD in 
the near future. Mutations in non-coding deep-intronic regulatory sequences can be 
detected by sequencing of the entire genome (whole genome sequencing, WGS). This 
however requires an entirely different bioinformatic analysis pipeline due to the huge 
expansion of the data load and the search for regulatory patterns. Currently, the cost of this 
procedure is still often a bottleneck, but it is expected to replace WES in the coming years as 
the prices go down and the efficiency goes up. 
Next-generation sequencing can also be applied to RNA (105). RNA isolated from cells or 
tissues can be enriched for the messenger (m)RNA. After reverse transcription of the RNA 
into copy DNA, sequences can be detected as with WES. RNA sequencing not only allows the 
nucleotide sequence to be determined, but also the amount of mRNA that is expressed per 
gene. By comparing groups of tissues, e.g. polycystic versus normal cholangiocytes, 
individual genes or pathways that are differentially expressed are detected. 
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Figure 5. CRISPR-Cas9 gene editing. 
The Cas9 enzyme is guided to a DNA target site by a gRNA, at which location it will induce a double-
stranded break in the target DNA. In this thesis this technique has been applied to develop genetic 
knockouts of ADPLD genes in cell lines and zebrafish. 
Genome editing: CRISPR-Cas 
 
Although genome editing has existed for many decades, efficient, precisely targeted 
methods have only been around for several years. At the core of this progress lies a 
surprisingly simple method discovered in 2012 (99, 106). CRISPR-Cas9 has enabled 
researchers to efficiently and accurately target and edit genomic DNA of almost any 
eukaryotic cell, including stem cells. The technique makes use of the plasmids and cloning 
methodology readily available in every biomedical laboratory, which has allowed it to spread 
quickly. Its medical implications cause difficult bioethical conundrums, as even germline 
human DNA may be edited.  
Cas9 is a targeted endonuclease (see glossary) that cuts both strands of DNA at sites 
complementary to a guide (g)RNA (figure 5). Bacterial cells use CRISPR, short for Clustered 
Regularly Interspaced Short Palindromic Repeats, as a gRNA. For laboratory use, artificial 
gRNAs are used. These gRNAs contain a targeting sequence of 20 nucleic acids in an RNA 
scaffold, which is recognized by the Cas enzyme. Repair of the double-stranded breaks 
induced by CRISPR-Cas frequently leads to mutations, and loss of gene function. The ease of 
use and GPS-like precision of the research tool has led to successful, accurate genetic editing 
in a variety of fields from agriculture to medicine. We have applied this technique to genes 
underlying ADPLD in cells and organisms to generate new disease models (chapters 5 and 7). 
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Figure 6. Tandem affinity purification combined with mass spectrometry allows identification of 
protein complexes. 
Image inspired by 
http://web.science.uu.nl/developmentalbiology/boxem/interaction_mapping.html. 
1. A protein mixture is obtained by lysis of cells, tissues, or organisms. 
2. The protein of interest, with associated complex, is purified using a receptor specific for a tag or 
other part of the protein. This allows enrichment of the protein of interest in the resulting protein 
mixture. In this thesis, tag A corresponds to a streptavidin tag. 
3. A secondary purification step is performed using a receptor specific for another tag or other part 
of the protein of interest. Further enrichment of the protein of interest occurs. In this thesis, tag B 
corresponds to a FLAG tag. 
4. In preparation of mass spectrometry, components are separated on an SDS-PAGE gel. Protein 
bands are then cut out and digested by trypsin. 
Part of the enriched protein mixture can additionally be checked on a blot. For example, western 
blotting with a silver stain can verify the success of the attempted protein purification. 
5.  Analysis by LC-MS/MS allows the digested proteins to be recognized by mass, charge and relative 
abundance. 
6. A database search allows identification of known and (before analysis) unknown proteins present 
in the protein complex, based on the mass and charge found. 
Affinity proteomics and immunofluorescence 
 
Affinity proteomics is a method to study protein complexes. To direct expression of the 
protein of interest in cells, the coding sequence of the cognate genes (e.g. PRKCSH) is cloned 
as complement DNA (cDNA) into plasmid expression vectors. These vectors enable 
multiplication of the plasmids in bacteria and translation and production of the protein in 
laboratory strains of mammalian host cells. To facilitate protein purification and detection, 
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the proteins are equipped with molecular affinity tags. In this thesis, the use of tandem 
streptavidin and FLAG tags allow the isolation of highly purified proteins and their associated 
complexes in a straightforward and quick purification procedure (107), and allows detection 
with specific antibodies against the epitope tag. Incorporation of a green fluorescent protein 
(GFP) tag is often selected instead when only the localization of the proteins is required, as 
GFP, and thus its fused protein of interest, can be readily visualized under fluorescence 
microscopes without additional immunostaining procedures. Additionally, proteins 
containing these tags can be recognized by fluorescence-assisted cell sorters (FACS).  
Following transfection of the plasmids into cells (e.g. transfection of PRKCSH-Strep-FLAG in 
biliary cells) (107), isolation followed. By fishing out the proteins in two steps (in tandem) 
with Strep and FLAG tags, a very pure isolation of the protein and interacting proteins can be 
obtained (tandem affinity purification, TAP). Mass spectrometry can subsequently determine 
the identity of the interacting proteins. In chapter 5, we performed this technique to 
determine the interacting proteins around PRKCSH, SEC63, and LRP5. 
Research models 
Several research models were employed during the course of this thesis. As mentioned, cyst 
development was studied at multiple levels, and appropriate models were used as required. 
Cell lines 
 
The H69 SV40-virus immortalized cell line is a human cholangiocyte cell line (108), while 
HEK293T is a well-known model cell line from human embryonic kidney. H69 cholangiocytes 
develop primary cilia at a high frequency (76). The cell lines have the great advantage that 
they are easy to work with and can be kept in culture almost endlessly. The disadvantage is 
that they have lost the genetic signature of healthy primary cells, indicating that the 
interpretation of test results should proceed with care. The cell lines were applied to the 
study of the protein interaction network of GIIB, SEC63p and LRP5 in chapter 5. Thus far, few 
human cell lines exist carrying mutations in the PLD genes, and application of CRISPR-Cas9 
technology to develop them was one of the research goals of the thesis.  
Primary cells 
 
At the start of this PhD-project, primary liver cyst cells could not be kept in culture. From 
2008 to 2015, stem cell scientists have discovered methods to isolate and culture human 
adult stem cells of the intestine, stomach and liver (93-95, 109-111). It became possible to 
create, maintain and expand adult stem cells, while they retain multi-lineage potential. This 
has led to the development of so-called organoids, which is defined as a 3D cellular cluster 
derived from primary tissue. Adult liver stem cells form organoids consisting of hepatocytes 
and biliary cells.  
Aspiration sclerotherapy and cyst fenestration are two interventional treatment options for 
PLD, whereby parts of cysts are removed. The tissue material from these procedures is 
valuable as one of the few sources to study human cystogenesis. Cyst epithelium and fluid 
prove capable of expanding as bipotent cholangiocyte cells, using culture conditions for 
adult liver stem cells (chapter 6). As controls, we cultured cholangiocytes from the healthy 
liver derived from surgery for liver cancer metastasis. A biobank of cells of different patients 
was established, which could be characterized by DNA & RNA sequencing, 
immunohistochemistry and more.  
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Figure 7. Growing organoids from cyst epithelium. 
1. Cyst epithelium is collected during surgeries such as laparoscopic cyst deroofing. 
2. Cholangiocytes from the epithelium are loosened by EDTA. 
3. When placed into circumstances suitable for the growth of liver stem cells, approximately 1% of 
cholangiocytes will form organoids. 
4. Organoids can be collected for further experiments or storage. Examples include DNA, RNA, and 
protein isolation and follow-up techniques. 
Zebrafish 
 
Zebrafish are a convenient model organism for the study of many diseases. The fish are easy 
to maintain, readily reproduce, and have short generation times. Development of zebrafish 
embryos is rapid. Within 5 days organs such as the heart, kidney, and liver grow. As the 
embryos are translucent, any issue in their development can easily be seen under a 
microscope. 
For ADPLD research, researchers have partially knocked down gene underlying the disease 
during the embryonic development window of 5 days (112). They observed liver cysts and 
abnormally curved bodies. This contrasts to the phenotype of fish with a spontaneous Sec63 
mutation described by another study group (113). Fish did not have liver cysts or abnormal 
curvature, but displayed decreased length, fatty livers, nerve conduction problems, and 
swim bladder defects. Development of a genetic animal model was attempted by injecting 
24 |  Chapter 1 
 
CRISPR-Cas9 constructs targeting Prkcsh, Sec63, and Lrp5 in single-cell zebrafish embryos in 
chapter 7 of this thesis. 
 
Aim and outline of this thesis 
The aim of this thesis is to gain a better understanding of the pathological mechanisms 
involved in ADPLD. Clinicians struggle to explain why cysts develop in most of the patient 
cohort, as the genes underlying >75% of patients are not known. Biomedical scientists 
remain ambiguous of which pathway gets disrupted following loss of ADPLD protein 
expression, and how primary cilia are involved. Despite recent progress with somatostatin 
analogues, there is a struggle to treat patients pharmacologically. Novel disease models are 
required to unravel the cystogenic pathways, and screens for treatment options. For this 
reason, novel, suitable cellular and animal models are developed in this thesis, and these 
models are interrogated at DNA, RNA, protein, organelle, cellular, and organismal level. The 
research presented here is guided by the following research questions: 
Research questions 
1.) Which underlying germline and somatic genomic abnormalities are present in ADPLD? 
(chapters 3, 4) 
We isolated DNA from biliary cells obtained from 46 cyst fluid and cyst epithelium samples 
from 23 patients, and analyzed these using high-density SNP arrays to detect LOH. Since all 
known cyst genes are recessive on a somatic level, homozygous regions can correspond to 
regions of interests.  We hypothesized that somatic abnormalities, detectable by these SNP 
arrays, could point the way to novel liver cyst genes. In case of somatic abnormalities, 
germline DNA was additionally studied. Three types of cyst genes were expected to lie in the 
abnormal regions. First, genes similar to PRKCSH and PKD1 that lay at the root of disease. 
Second, in line with the genetic interaction network postulated by Fedeles and colleagues, 
transheterozygous genes, which are a somatic second-hit in another gene than the germline 
defect of the patient. Third, modifier genes that influence the rate of cyst development due 
to germline mutations. By applying these methods, we found that at least half of the 
patients harbored abnormalities outside of known cyst regions.  
 
2.) What are the characteristics of cultured cyst and normal biliary cells as measured by 
RNA expression? Are any specific pathways dysregulated in liver cyst cells as compared to 
normal biliary cells? (chapter 6) 
In chapter 5 we use RNA sequencing to determine the gene expression pattern of eight liver 
cyst cell cultures and compare that with four normal biliary cell cultures. Despite discovery 
of a genetic interaction network between kidney and liver cyst genes in 2011, it remains 
unclear which pathway becomes dysregulated upon loss of polycystin-1 expression. The 
possibility of growing stem cells of liver cysts has opened up a new opportunity to study the 
mechanism of disease in cystogenesis. We hypothesize that differentially expressed 
pathways occur between cyst cells and normal biliary cells. We explore whether biliary cells 
cluster based on genetic background and LOH status, and find evidence in agreement with 
this hypothesis.  
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3.) What is the ADPLD-associated protein interactome? (chapter 5) 
To discover clues on disrupted pathways in ADPLD, we used tandem affinity purification to 
isolate ADPLD protein complexes, and analyzed them using mass spectrometry. GIIB, SEC63p 
and LRP5 are used as bait proteins to uncover interacting proteins in an unbiased way. We 
hypothesize that novel interaction partners may point the way towards new ADPLD genes 
and explain more parts of ADPLD pathophysiology. We explore whether GIIB, SEC63p and 
GIIA interact with components of Wnt signaling, cilium formation or other pro-cystogenic 
pathways. Reversely, the relation of LRP5 to other cyst-related proteins is researched. We 
detected many known interactors of GIIB and SEC63p, and several new ones that might 
point the way towards a cyst interactome. 
 
4.) What is the effect of mutation of genes underlying ADPLD on primary cilia and Wnt 
signaling? (chapter 5) 
In chapter 4 we use CRISPR-Cas9 to induce mutations in the genes underlying ADPLD to 
study two hypothesized mechanisms of disease. A frequent observance in cyst formation is 
abnormal or low numbers of primary cilia. LRP5 is the strongest suggestion for an important 
role of Wnt signaling in cyst development thus far. We hypothesize that loss of PRKCSH or 
SEC63 leads to reduced ciliogenesis and impaired Wnt signaling. The effect of loss of the 
genes on LRP5 expression is explored with regard to n-glycosylation and protein maturation. 
We show here that loss of PRKCSH and SEC63 leads to formation of a lower number of cilia 
in two cell lines.  
 
5.) Do stem cells occur in liver cysts and what are their characteristics? (chapter 6) 
We extracted cells from cyst fluid and epithelium and placed them under conditions suitable 
for the expansion of adult liver stem cells. Based on data from biliary tracts, we hypothesize 
that cyst epithelium possesses stem cells capable of in vitro proliferation. This fits with the 
theory of cyst development, which states that a single stem cell acquires a second-hit 
mutation to cause cyst development. Bipotent cyst stem cells developed, and displayed 
characteristics of ADPLD, including LOH, expression of ciliary genes, and response to 
somatostatin analogues. 
 
6.) Can zebrafish model polycystic liver disease? (chapter 7) 
CRISPR-Cas9 technology is again applied to induce mutation in the genes underlying ADPLD, 
but this time in zebrafish. Currently, no accurate models of ADPLD exist, only mice with post-
natal disruption of pro-cystogenic genes. As new genes for the disease are discovered, their 
effects can be validated in test animals. Given the need for new therapeutics, models should 
be developed that allow drug screens to be conducted without problem. Zebrafish have the 
advantage of rapid development and translucent embryos. These favorable conditions allow 
study of the effect of ADPLD mutations on liver development in an organism. We 
hypothesize that disruption of PRKCSH, SEC63, LRP5 or all three genes leads to formation of 
liver cysts in zebrafish. In chapter 7, we compare the phenotype of the mutated fish to those 
of morpholino knockdown fish (expression of genes is only partially disrupted in morpholino 
knockdown), and find large discrepancies.  
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Abstract 
Polycystic livers are found in autosomal dominant polycystic kidney disease 
(ADPKD), caused by PKD1 and PKD2 mutations in virtually all cases, and in 
isolated polycystic liver disease (PCLD), caused by known PRKCSH and SEC63 
mutations in only ~20% of cases together. Loss-of-heterozygosity in single 
hepatoblasts leads to underlying cystogenic ductal plate malformations. 
Crucially, actual components driving this development remain elusive. Recent 
advances have unraveled the roles of TGF-β, Notch and Wnt signaling, 
transcriptional regulators like HNF6 and HNF1β, as well as cilium function in 
hepatobiliary organogenesis. In polycystic liver disease, mutation or defective 
cotranslational processing of key elements required for primary cilium 
formation have been implicated. This review recapitulates liver patterning 
factors in hepatobiliary development and extracts molecular players in hepatic 
cystogenesis. 
Lay summary 
Liver cysts, abnormal fluid-filled sacs, are caused by complete loss of genes like 
PKD1, PKD2, PRKCSH and SEC63 in the body. This review summarizes the 
subsequent effects on the molecules responsible for development of the liver and 
bile ducts, to determine what goes erroneously to cause cysts. 
Keywords 
polycystic liver disease, loss-of-heterozygosity, hepatobiliary organogenesis, 
ductal plate malformation, hepatic cystogenesis, primary cilium 
 
Brief introduction into polycystic liver disorders 
Liver cysts are a relatively common finding on routine abdominal imaging, being present in 
approximately 2.5-18.0% of the population [1]. Polycystic livers are defined by the presence 
of >20 cysts and are estimated to be present in 0.05-0.53% of the population [2]. Polycystic 
liver disease (PLD) is part of the phenotype of two inherited disorders: autosomal dominant 
polycystic kidney disease (ADPKD); and polycystic liver disease (PCLD). PCLD is distinguished 
from ADPKD by the absence of polycystic kidneys. Cystic livers, together with hepatic 
fibrosis, may also be found in the spectrum of diseases that have dysfunction of the primary 
cilium (Box 1).  
ADPKD, caused by mutations in polycystic kidney disease (PKD)1 and PKD2, is the most 
common cause for end-stage kidney disease, and is seen in approximately 0.10-0.25% of the 
population [3]. PKD1 encodes the transmembrane protein polycystin-1, and is seen in 85% of 
ADPKD cases. PKD2 encodes the transmembrane protein polycystin-2, which is responsible 
for 15% of ADPKD cases. Although polycystic kidneys are the primary presentation, liver 
cysts occur in 83-94% of patients as an extrarenal manifestation [4, 5]. PCLD is rare and is 
estimated to be present in about 0.03% of the population [6]. There is considerable genetic 
heterogeneity as Protein kinase C substrate 80K-H (PRKCSH) and SEC63 mutations have been 
identified only in about 20% of the cases [7], leaving over 80% of cases currently without a 
genetic diagnosis.  
Cyst development is driven by somatic second hit mutations, which affect wild-type alleles of 
biliary type cells during early hepatic organogenesis [8, 9]. This process, termed loss-of-
heterozygosity (LOH), occurs in most cysts associated with PRKCSH, PKD1 or PKD2 mutations, 
and at a lower proportion in SEC63 mutated cysts [10]. The key processes that lead to 
development of cysts start early in life. In PCLD it is thought that subsets of cells behave 
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abnormally during maturation of the ductal plate [11]. Unlike normal biliary plate 
hepatoblasts, these cyst initiator cells do not undergo regression after disconnection from 
the biliary tree but continue to proliferate.  
The molecular disease mechanism leading from focal LOH to a defective response during 
ductal plate remodeling represents a key event for cystogenesis, but actual components that 
drive the development remain elusive. In normal hepatobiliary development, the important 
roles of Notch, transforming growth factor (TGF)-β and Wnt signaling have recently been 
unraveled and have afforded better insight into transcriptional regulation by the involved 
transcription factors (i.e. hepatocyte nuclear factor (HNF)6 and HNF1β). The common 
denominator in cystogenesis is the mutation of individual genes that are part of these signal 
transduction routes, and the disruption of many of these encoded proteins affects the 
primary cilium. This review aims to recapitulate molecular players in cystogenesis by 
focusing on known liver patterning factors in hepatobiliary development. 
Box 1. Additional cholangiociliopathies  
Hepatic cysts and fibrosis frequently occur as part of the phenotype of multiple ciliopathies, 
which have therefore also been termed cholangiociliopathies [37]. 
Autosomal recessive polycystic kidney disease (ARPKD) 
ARPKD always causes liver disease involving Caroli disease and syndrome, with a prevalence 
of 0.005% [2]. Caroli disease is defined as ectasia or segmental dilatation of the larger 
intrahepatic bile ducts (IHBDs), whereas Caroli syndrome is defined as ectasia of small 
IHBDs and congenital hepatic fibrosis in addition to Caroli disease. It is caused by mutations 
in PKHD1. Common features are enlarged kidneys with cysts, pulmonary hypoplasia, 
characteristic facies, and contracted limbs with clubfeet.  
Meckel–Gruber syndrome (MKS) 
MKS has a prevalence of 1:135 000 and frequently presents with liver cysts [46]. It is a 
recessive disease caused by mutations in MKS1, MKS2, and MKS3, and in genes also 
associated with NPHP such as NPHP3, NPHP6, and NPHP8. Renal cystogenesis, polydactyly, 
and occipital encephalocele are part of the MKS phenotype. 
Oral-facial-digital syndrome 1 (OFD1) 
OFD1, an X-linked disease caused by mutations in OFD1, presents with fibrocystic liver 
disease in ~40% of cases [57]. Prevalence estimates vary from 1:50 000 to 1:250 000 [58]. 
Renal cystogenesis, brain abnormalities, and malformations of teeth, jaw, facial bones, 
hands, and feet are often seen in OFD1 [36,58].  
Tuberous sclerosis (TSc) 
TSc presents with hepatic cysts in ~13% of cases [59] and has a prevalence of 1:10 000 to 
1:25 000 [60]. Loss of TSC1 or TSC2 leads to hamartomatous lesions in multiple organ 
systems. Renal cysts and angiomyolipomas are frequently present. 
Cranioectodermal dysplasia (CED) 
Three patients with CED, also known as Sensenbrenner syndrome, have been described 
with liver cysts as part of the phenotype [40,41]. CED is caused by mutations in genes 
encoding IFT-A proteins IFT122/CED1, IFT121/CED2, IFT43/CED3, and IFT144/CED4. 
Symptoms include kidney cysts, skeletal abnormalities, ectodermal defects, and 
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characteristic facies. 
Von Hippel–Lindau (VHL) disease 
VHL is an autosomal dominant disease, caused by VHL mutations [36], which may present 
with liver cysts [61]. VHL occurs at a frequency of 1:36 000 live births [62]. It is characterized 
by the development of hemangioblastomas of the central nervous system and retina, 
neuroendocrine tumors, and renal cysts [36]. 
Nephronophthisis, Bardet–Biedl, Joubert, and Jeune syndromes 
Ciliopathies NPHP, Bardet–Biedl, Joubert, and Jeune syndromes frequently present with 
isolated congenital hepatic fibrosis due to ductal plate malformation [37]. 
 
 Normal hepatobiliary development 
An overview of the process of normal hepatobiliary development and the roles of liver 
patterning factors therein is critical to understand the molecular mechanisms of hepatic cyst 
development. Hepatic organogenesis starts at week four (or embryonic day (E) 8.5 in mice 
[12]), when the liver bud arises from the cephalic part of the primitive foregut near the yolk 
sac [11] At that point the pars hepatica, one of two liver bud divisions, initiates liver 
precursor cells to grow into the mesenchymal separation between the pericardial and 
peritoneal cavities. These cells start to occupy endothelium-lined spaces of the septum 
transversum. In this manner, the basic architecture of the liver becomes established, with 
parenchymal cords and plates alternated by hepatic sinusoids. At week eight (or E10.5 in 
mice [13]) the first intrahepatic bile duct (IHBD) precursors develop.  Cytokeratin (CK)8, CK18 
and CK19 positive hepatoblasts start organizing in a ductal plate [11], enveloping the portal 
mesenchyme. This ductal plate induction is tightly controlled by a signalling environment 
involving several key signalling pathways [12].  
TGF-β, Notch and Wnt signalling pathways 
 
One of the signalling pathways that drives ductal plate development is TGF-β [13]. A 
signalling gradient of increased TGF-β/activin near the portal vein is implicated in ductal 
plate development at mouse E12.5. The TGF-β antagonist chordin is present in liver 
parenchyma at E16.5, while the presence of TGF-β transcription factor SMAD5 is limited to 
portal hepatoblasts [14]. The TGF-β gradient occurs in combination with HNF6 induced 
repression of the TGF-β receptor II (TGF-RII) in the liver parenchyma. TGF-βRII positive 
prebiliary cells shape a primary layer near the portal vein, a process that is associated with 
subsequent loss of TGF-βRII expression. Subsequently, a second layer of TGF-βRII positive 
hepatoblasts is created at the parenchymal side of the primary layer [13]. This allows 
development of a lumen between the asymmetric layers. Maturation of these layers 
expands in a wave starting at the largest portal veins of the liver hilum propelling towards 
the periphery, inducing the prebiliary hepatoblasts of the second layer to become 
cholangiocytes. 
Notch signalling is required for the processes of differentiation and tubulogenesis, as well as 
bile duct density [12, 15]. Notch receptors are activated by ligands such as Jagged1 and 
Notch2 from the periportal mesenchyme and biliary cells, which signal through 
(Recombining binding protein suppressor of hairless) Rbpj and hairy and enhancer of split-1 
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(Hes)/ Hairy/enhancer-of-split related with YRPW motif (Hey) family members. Both TGF-β 
and Notch signalling have consistently been implicated in in vitro murine biliary fate 
specification of bipotent adult liver stem cells [16].  
Similarly, a gradient of canonical Wnt signalling appears to regulate the ductal plate [17]. 
Effects of Wnt signalling are time- and context-dependent during liver development. In the 
ductal plate of wild type mice, the Wnt signal transducer β-catenin is strongly present at the 
membrane, while hepatoblasts elsewhere have a much weaker membranous β-catenin 
staining. This stabilization of β-catenin is transiently induced at mouse E15.5, reaching a 
peak membranous intensity on E17.5 up to adulthood. It is therefore hypothesized that Wnt, 
generated by the portal vein or mesenchyme, may help induce ductal plate formation. This 
concept is supported by in vitro studies that show that early embryonic liver cultures lack 
CK19+ biliary cells following β-catenin silencing [18], whereas culture in Wnt3a conditioned 
media leads to biliary differentiation [19]. Fibroblast growth factor (FGF) and bone 
morphogenetic protein (BMP) signalling pathways, together with extracellular matrix (ECM) 
components complete the extracellular factors involved in specifying biliary cell fate [20]. 
Biliary fate specification depends on a network of transcription factors 
 
Wnt, TGF-β and Notch signalling pathways function in concert with a network of intracellular 
transcription factors [21]. Biliary fate specification of hepatoblasts relies on 
hematopoietically expressed homeobox (Hhex), onecut domain family member (OC) 2, 
HNF6/OC1, SRY-box (Sox)9, and HNF1β. It also depends on absence of hepatocyte fate 
transcription factors such as T-box transcription factor (TBX)3, HNF1α, HNF4α, 
CCAAT/enhancer binding protein (C/EBP)α, Forkhead box protein A(FoxA)1 and 2. These 
intracellular transcription factors are not only regulated by the extracellular Wnt, TGF-β and 
Notch signalling pathways, but also function reciprocally. For example, HNF6 and Sox9 are 
vital to maintaining the TGF-β signalling gradient [13, 22]. Modulation of the regulatory 
factors acts in a timing and context dependent manner, and is required for regulation of 
hepatobiliary development. The cholangiocyte transcription factor machinery finally leads to 
expression of specific ciliary genes such as polycystic kidney and hepatic disease 1 (PKHD1) 
and cystin-1, but biliary differentiation itself may also be regulated by the primary cilium or 
its components (see below). 
Pathophysiology of hepatic cystogenesis 
Hepatic cystogenesis is thought to occur by defective remodeling of the ductal plate, and is 
considered a process of ductal plate malformation (DPM) [22]. Normally, when primitive 
ductular structures mature to bile ducts, ductal plate cells not involved in tubulogenesis 
involute or become periportal hepatocytes [23]. In PCLD, somatic second-hits in wild-type 
alleles are hypothesized to underlie the failure of single cells to undergo correct remodeling 
[8]. Studies of Hnf6, Hnf1β and cystin-1 mouse knockout models has allowed for a 
classification of cystogenic remodeling, which is found to occur by at least three distinct 
origins of DPM (Figure 1) [22], respectively: (i) DPM 1, disturbed differentiation of biliary 
precursor cells; (ii) DPM 2, impaired maturation of radially asymmetric primitive ductular 
structures; and (iii) DPM 3, abnormal duct expansion. Additional origins of cystogenic DPM 
potentially occur, and are described below.  
HNF6 and HNF1β have been shown to be downstream regulatory factors that are disrupted 
in multiple models, and a recurrent phenotype is poorly differentiated or hybrid 
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hepatobiliary cells with a tendency to develop cysts. These observations have also been 
made in conditional gene ablation mouse models of hepatocyte transcription factors C/EBPα 
and Hhex during early stages of biliary development [24, 25], as well as in a mouse line in 
which aberrant Wnt signaling is induced by loss of the gene encoding adenomatosis 
polyposis coli (APC) [17]. In the whole liver, disrupted hepatocyte development occurs in 
addition to cyst development in the three models. Postnatally, embryonic differentiation 
defects resolve in Hnf6-/- and Hnf1β-/- models [22], but DPM and defects of primary cilia 
persist.  In Hnf1β-/- mice dysplastic ducts additionally persist. C/EBPα-/- and Hhex-/- mice may 
develop adult polycystic liver disease, which has not been investigated for APC-/- mice. 
In Foxa1 and Foxa2 knockout mice bile duct hyperplasia occurs [26], which is reminiscent of 
DPM 3. A fourth DPM pattern may be found in models that overexpress the intracellular 
domain of Notch2 and knockout of Wnt5a, because this gives rise to aberrant remnants of 
ductal plate cholangiocytes [15, 27]. In these mice, Notch overactivation promotes 
cholangiocyte survival, biliary differentiation and increased periportal bile duct density. 
Xylosyltransferase (Xylt)2-/- mice also develop polycystic liver and kidney disease [28], but 
Xylt2 deficiency causes reduced glycosaminoglycan synthesis rather than hepatic morphogen 
signaling defects. Although increased β-catenin expression is observed and may be a 
downstream mechanism, Xylt2-/- mice implicate proteoglycan/ECM abnormalities as an 
additional mechanism to cystogenesis. Together these data suggest that cystogenic DPM can 
occur through multiple, distinct mechanisms depending on the genetic background.  
To date, it is not yet known which of these embryologic mechanisms cause PCLD following 
somatic loss of the wild-type alleles. Monoclonal proliferation and dilatation of single 
initiating cells are thought to cause the biliary hamartomas and cysts observed in adult PCLD 
patients. Recent discoveries in the function of hepatocystin and SEC63p have identified 
important clues to the cause of DPM in PCLD, and are discussed in the subsequent 
paragraphs. 
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Figure 1. Schematic representation of ductal plate remodelling and malformation. Ductal plate 
remodelling (DPR) depends on transforming growth factor (TGF)-b, Notch and Wnt signalling 
gradients, and cellular responsiveness to the respective ligands. Further modulation comes from cell–
cell and cell–environment interactions mediated by the extracellular matrix (ECM) and primary cilia. 
(A) Legend. (B) Left: normal DPR: (i) prebiliary cells shape a primary layer near the portal vein. (ii) 
Following maturation of the primary layer, a second layer of prebiliary cells allows a lumen to form. 
(iii) Biliary tracts are formed when the secondary layer matures to cholangiocytes. Right: ductal plate 
malformation (DPM) 1, 2, and 3 indicated by white numbers and a biliary hamartoma in the liver 
parenchyma designated by a black 4.  
DPM 1, disturbed differentiation of biliary precursor cells; DPM 2, impaired maturation of radially 
asymmetric primitive ductular structures; and DPM 3, abnormal duct expansion.  
PRKCSH, SEC63 loss of heterozygosity, and co-translational protein processing  
PRKCSH, located on chromosome 19p13.2, encodes for an 80 kDa protein that has been 
named hepatocystin [29].  It serves as the noncatalytic β-subunit of glucosidase (G)II, which 
requires hepatocystin for its endoplasmic reticulum (ER) retention. Cysts of PRKCSH mutated 
patients contain secondary somatic mutations in >76% of epithelia [8], indicating recessivity 
at the cellular level.  
SEC63, located on chromosome 6q21, encodes SEC63p, an 88 kDa protein involved in 
cotranslational protein translocation of secreted or membrane-inserted proteins into the ER. 
It associates in stoichiometric amounts with Sec61p, where it functions in the Sec61 
complex. Together with its luminal counterpart binding immunoglobulin protein, SEC63p is 
required for translocation and membrane insertion of a subset of ER-translocated proteins. 
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SEC63 mutation carriers only display LOH in 1 of 14 cyst epithelia [10]. Cyst development due 
to SEC63 variants therefore seems to depend upon another stochastic process.  
Cotranslational protein processing 
 
Protein transport into the ER is dependent upon N-terminal signal peptides, C-terminal tail 
peptides and signal recognition peptide anchors and occurs co- as well as post-
translationally. Signal-peptide containing proteins are transported in three stages: (i) 
targeting; (ii) membrane insertion at the Sec61 complex; and (iii) completion of membrane 
translocation. SEC63p is especially important for membrane insertion of proteins with 
multiple transmembrane regions. SEC63p-dependent ER transport relies on the sequence of 
signal peptides [30], and loss of SEC63p leads to reduced glycosylation as well as decreased 
ER membrane insertion of SEC63p-necessitating proteins. Interestingly, although loss of 
plasma membrane protein aquaporin (AQP)-2 is found in both Sec63-/- and Prkcsh-/- renal 
tubular cells, the proteins mediate this effect at different stages of protein biogenesis [30]. 
Transport of AQP-2 into the ER is unimpaired in Prkcsh-/- cells, indicating that protein loss 
occurs at a later stage.  
Hepatocystin assists in glycan processing by cleaving two glucose residues in the ER. This 
allows quality control enzymes calnexin/calreticulin to bind and assist in protein folding. 
Proteins that are folded correctly undergo cleavage of a final glucose residue by glucosidase 
II. In case of improper folding, re-glycosylation and additional cycles of glucose cleavage 
occur, until folding is completed or the protein becomes bound for ER associated 
degradation (ERAD). ERAD requires retranslocation out of the ER, also involving SEC63p. 
Although additional functions have been suggested (Box 2), hepatocystin and SEC63p 
function in closely related, but distinct stages of protein biogenesis.  
Table 1. Cystogenic genes, related protein product pathways and DPM malformationa 
Gene Pathway DPM DPM 
type
b
 
Additional 
remark 
Ref 
Apc  Wnt (canonical) Cystogenic  1 - [17] 
Wnt5a Wnt (noncanonical) Bile duct 
hyperplasia 
3 - [27] 
Notch2ICD  Notch Bile duct 
hyperplasia, 
ductal plate 
remnants 
3 Overexpressed [15] 
Hnf6α  Transcription factor Cystogenic 1 - [22, 57] 
OC-2 Transcription factor Cystogenic - - [57] 
Hnf1β Transcription factor Cystogenic, 
bile duct 
paucity 
2 - [22] 
 Polycystic liver disease: ductal plate malformation and the primary cilium | 41  
 
Foxa1 / 
Foxa2  
Transcription factor Bile duct 
hyperplasia 
3 Genes redundant, 
double knockout 
[26] 
Hhex  Transcription factor Cystogenic 1 - [25] 
C/ebpα  Transcription factor Cystogenic 1 - [24] 
Xylt2  Glycosaminoglycan 
synthesis 
Cystogenic - - [28] 
ALG8  N-glycan processing 
(CDG-Ih) 
Cystogenic, 
Caroli disease 
- - [31] 
PRKCSH N-glycan processing Cystogenic 3 Somatic LOH [29] 
SEC63  Protein quality 
control & membrane 
insertion 
Cystogenic 3 - [29] 
PKD1  Cilium Cystogenic 3 Somatic LOH [9] 
PKD2  Cilium Cystogenic 3 Somatic LOH [9] 
Pkhd1  Cilium Cystogenic 3 - [56] 
Cystin-1  Cilium Cystogenic 3 - [22] 
IFT88  Cilium (IFT-B) Cystogenic 1/2 - [45] 
MKS genes  Ciliary axoneme / 
basal body 
Cystogenic, 
Caroli 
syndrome 
1/2 - [46] 
OFD1  Cilium / basal body Cystogenic, 
Caroli 
syndrome 
- - [58] 
CED genes Cilium (IFT-A) Cystogenic, 
Caroli 
syndrome 
- - [40, 41] 
TSC1, TSC2  TSc complex / basal 
body 
Cystogenic - - [59] 
VHL  Von Hippel-Lindau / 
ciliary axoneme 
Cystogenic - - [60] 
a Abbreviations: DPM, ductal plate malformation; LOH, loss of heterozygosity. 
b DPM 1: differentiation defect described, DPM 2: defect of PDS maturation described, DPM 3: 
abnormal duct expansion described, -: unknown mechanism; Italics: DPM type not classified by 
referenced studies.  
42 |  Chapter 2 
 
Effects of defective co-translational protein processing on hepatic signaling  
Around 30% of proteins undergo ER translocation, and are subject to folding and quality 
control by PRKCSH and SEC63p. Defective processing of a key regulator of biliary cell growth 
is a likely cause of PCLD [29]. This is thought to be the mechanism that underlies DPM-
associated disorders in the context of PRKCSH and SEC63 mutations, as well as those 
observed in several congenital disorders of glycosylation (CDG) [31]. Patients with type I CDG 
have defects in synthesis and transfer of glycans, whereas type II CDG patients have 
defective glycan processing. Many CDG patients have hepatomegaly as part of their clinical 
phenotypes, and bile duct dilatation has been reported in CDG-Ib, CDG-Id, CDG-Ih and CDG-
IIb. Liver cysts have been observed in CDG-Ih. Unsurprisingly, the biochemical defect of at 
least two of these subtypes (CDG-Ih and CDG-IIb) shows considerable overlap with the 
protein translocation and folding defects seen in PCLD. Several biliary growth related 
transmembrane proteins are sensitive to defects in cotranslational processing, and 
polycystin-1 has recently been strongly implicated in relation to the known PCLD genes [32].  
 
Box 2: Postulated roles of hepatocystin and SEC63p beyond cotranslational 
processing 
Hepatocystin 
Knockdown of either hepatocystin or glucosidase II induces autophagy, as found by a 
significant increase in LC3 positive autophagic structures [64]. This did not occur through 
the unfolded protein response pathway, but rather through inhibition of mammalian target 
of rapamycin (mTOR) signaling. Although these findings indicate an additional role for 
hepatocystin in autophagy, they do not preclude an effect of its deficiency on the cilium. 
Interestingly, a pair of papers recently showed an interdependency of autophagosome 
induction and cilium formation [43, 65]. Another proposed function of hepatocystin is that 
of Inositol 1,4,5-Trisphosphate receptor (IP3R) induced regulation of calcium release activity 
[66].  
SEC63p 
SEC63p has been shown to interact with nucleoredoxin (NRX) in a yeast two hybrid assay 
[67]. This establishes an indirect link of SEC63p to Disheveled 1 (Dvl1), which is also an NRX 
binding partner. Intriguingly, Dvl1 has been shown to be important in Wnt signaling and 
planar cell polarity [68]. 
 
 
Cotranslational processing and defects in hepatic signaling routes 
 
Prkcsh and Sec63 function in a genetic interaction network with Pkd1, Pkd2 and Pkhd1 [32]. 
Polycystin-1 dosage is the final effector for severity of cyst development within this network. 
Loss of Prkcsh or Sec63 in combination with Pkd1 haploinsufficiency significantly worsens 
cyst development in comparison to loss of individual PLD proteins. Conversely, 
overexpression of polycystin-1 rescues the phenotype of the PCLD orthologous mice. 
Importantly, polycystin-1 expression, and that of selected membrane proteins such as Na/K 
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adenosine 5’-triphosphatase (ATP)ase, decreases significantly following homozygous 
deletion of either PCLD gene. A likely cause is the requirement of proteins such as Na/K 
ATPase β2-subunit to undergo multiple n-glycosylation dependent courses of folding and 
quality control [33].  
In the study by Fedeles’ group, cyst development follows loss of Prkcsh or Sec63 induced at 
mouse post-natal day 28 [32]. Cysts derived from bile ducts possibly also occur during 
patients’ adult life, but this mechanism does not have to be distinct from embryonic DPM, as 
bipotent liver progenitors persist in the adult biliary tract [16, 23], and differentiation 
depends on the same signaling factors found in ductal plate remodeling. Also, abnormal duct 
expansion of DPM 3 may occur in already differentiated cholangiocytes.  
TGF-β and Wnt hepatic signaling routes are sensitive to the n-glycosylation state of receptors 
TGF-βRII and low density lipoprotein receptor-related protein (LRP)6 [34, 35]. Membrane 
expression of TGF-βRII decreases following n-glycosylation defects of tunamycin-treated 
cells, an effect even stronger for TGF-βRII mutants lacking n-glycosylated asparagine sites. N-
glycosylation defects of TGF-βRII lead to 2.5-5-fold decreases in signaling and 
phosphorylated SMAD2 levels. Similarly, n-glycosylation of LRP6 is important for maturation, 
membrane localization and signaling. When n-glycosylation increases due to the loss of Mest 
protein, levels of active, phosphorylated LRP6 and β-catenin increase [35]. The levels of 
downstream Wnt-regulated transcription factors such as C/EBPα then decrease, indicating 
the importance of LRP6 glycosylation.  
Summarizing these studies, the strongest case has currently been made for the pivotal role 
of loss of polycystins as a cause for cystogenesis in PRKCSH and SEC63 deficient tissues. 
Defective Wnt or TGF-β signaling may be an alternative route to cystogenesis following 
impaired n-glycosylation, but other routes have also been postulated, involving primary 
cilium proteins. 
Polycystins and polycystic liver disease as a ciliopathy 
Primary cilia have been identified as key organelles in the pathogenesis of ADPKD and 
related cystic diseases [36]. In the liver parenchyma, only cholangiocytes possess a primary 
cilium. Primary cilia are solitary, non-motile organelles on the apical cell membrane surface 
of most mammalian cells (Figure 2). They are regarded as the cell’s antennas, involved in 
mechano-, osmo- and chemoreception of, for example, bile flow [37-39]. A cilium is 
assembled from a basal body that itself originates from the older of two centrioles in 
quiescent cells [36]. Non-motile cilia have a characteristic 9+0 microtubule arrangement. The 
ciliary compartment and ciliary membrane have a dedicated protein and lipid composition 
that separate this organelle from rest of the cell. This composition is assembled and 
maintained by active intraflagellar transport complexes A (IFT-A) and B (IFT-B), along 
axonemal microtubule tracks, and active protein and vesicle shuttling across different 
barriers at the ciliary base.  
Cilia have been implicated in planar cell polarity, cell cycle control, and numerous essential 
signalling pathways. Canonical Wnt, mammalian target of rapamycin (mTOR), cyclic 
adenosine monophosphate (cAMP), G protein-coupled receptors, cystic fibrosis 
transmembrane receptor, epidermal growth factor receptor, mitogen-activated protein 
kinase/extra cellular signal-regulated kinase and cellular calcium ion (Ca2+) signalling all 
locate to the cilium. The ciliary compartment is also the active site of the protein products of 
hepatocystic disease genes PKD1, PKD2, PKHD1, cystin-1, intraflagellar transport protein 88 
homolog (IFT)-88 and four cranioectodermal dysplasia (CED) genes that are part of IFT-A [36, 
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40, 41]. Meckel syndrome (MKS)-associated proteins are found in the transition zone, as well 
as the basal body [42], where tuberous sclerosis (TSC)1 and TSC2 protein products are also 
located. Oro-facial-digital syndrome 1 protein (OFD)1 is localized at or near the basal body 
[43], while the VHL protein product is associated with the cilium, but not located in it [36]. 
Noncystic DPM is also frequently observed in ciliopathies such as nephronophthisis (NPHP), 
Joubert syndrome and Bardet-Biedl syndrome [37]. Consequently, biliary ductal 
development and cilium expression are intimately linked. Ciliopathies frequently lead to 
DPM and, vice versa, genes causing DPM often lead to ciliopathy. 
 
 
Figure 2. Localization of cystogenic genes in and around the cilium. The ciliary compartment is the 
active site of the protein products of hepatocystic disease genes PKD1, PKD2, PKHD1, cystin-1, IFT88, 
and four CED genes that encode IFT-A proteins. MKS-associated proteins are found in the transition 
zone, as well as the basal body, where TSC1 and TSC2 protein products are also located. OFD1 is 
localized at or near the basal body, whereas the VHL protein product is associated with the cilium, 
but not located in it (not shown). In the ER, co-translational processing by hepatocystin and Sec63p is 
essential for the dosage of polycystin-1 and polycystin-2. Gray arrow: transport from ER through the 
Golgi to the cilium. Black arrows: intraflagellar transport from ciliary base to ciliary tip and vice versa. 
Dashed line indicates cross-section of non-motile cilium showing its characteristic ‘9+0’ microtubule 
arrangement. Abbreviations: GIIb, hepatocystin; Sec63p, Sec63 protein; PKD1, polycystin-1; PKD2, 
polycystin-2; PKHD1, polycystic kidney and hepatic disease 1; CYS1, cystin-1; IFT88, intraflagellar 
transport protein 88 homolog; OFD1, oral-facial-digital syndrome 1 protein; MKS, Meckel–Gruber 
syndrome; TSC1, tuberous sclerosis protein 1; TSC2, tuberous sclerosis protein 2; IFT, intraflagellar 
transport; ER, endoplasmic reticulum. 
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Cystogenic ciliopathies and ductal plate malformations 
 
Although ciliopathies are associated with DPM, ciliopathy genes may confer different types 
of DPM (Table 1). DPM 1 and 2-associated transcription factors HNF6 and HNF1β are main 
players in the differentiation of biliary hepatoblasts, and loss of these genes leads to ciliary 
impairment in mice, and paucity of cilia has been observed in human HNF1β heterozygotic 
mutants [22]. Mutant cholangiocytes display reduction of cystin-1 concurrently with loss of 
cilia. It is not yet known which of the ciliary genes causes the DPM of HNF1β and HNF6 
mutants. The ciliopathy of cystin-1 mutants is not linked to a cholangiocyte differentiation or 
duct maturation defect (DPM 1 or 2), but to aberrant bile duct expansion (DPM 3).  
At least two ciliopathy associated genes do show differentiation defects. Mutations of IFT-88 
lead to defective ciliary assembly and DPM in mice [44] and man [45]. Cells in the portal area 
of the mice show differentiation defects as determined by the expression of 
alphafetoprotein and biliary lectins. Similarly, five out of six human Meckel syndrome 
foetuses possess hybrid cells co-expressing ductal (CK19) and hepatocyte (HNF4α, Albumin) 
markers in DPM-associated cysts [46]. Half of these foetuses have a reduction in, or 
complete absence of, cilia. The study authors suggest that defective differentiation may have 
been the initial cause.  
Given that ciliopathies cause different DPM categories, dependent on the genetic 
background, it is not directly clear to which DPM category PCLD and APDKD belong. Cystic 
expansion of bile ducts occurs following post-natal loss of Pkd1, 2, Prkcsh or Sec63 [32] and 
this implicates DPM 3 as a likely option. Consistent with this hypothesis, cilium-independent 
cystogenicity of the polycystins has recently been excluded [47].  
Loss of polycystins causes severe cystogenesis through cilia  
 
Polycystin loss without loss of cilia is the likely cause of the severe phenotype of ADPKD 
livers [47] and likely that of PRKCSH and SEC63 livers as well [32].  Loss of cilia by either a 
mutation of the gene encoding the kinesin-like protein (Kif3a) or by Ift20 mutation causes 
milder cystic disease compared to cystogenesis induced by polycystin loss, and polycystin 
dosage variation following cilium loss does not affect cyst severity. Conversely, if cilia are lost 
after polycystins, cyst severity increases with time as long as cilia persist, and slows after 
cilium loss. These findings exclude a cystogenic contribution of polycystins without cilium 
activity. Polycystins therefore inhibit a cilia-dependent cyst growth signal, which becomes 
constitutively active upon polycystin loss (Figure 3). Loss of cilia results in slower cyst 
growth, which is likely regulated by activation of a polycystin-independent basal ciliary cyst 
growth signal. In summary, the normal role of polycystins appears to be functional ductule 
adaptation to chemo- or mechanosensation, only allowing derepression of the cilia-
dependent growth signal when necessary.  
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Figure 3. Loss of polycystins causes cystogenic growth through cilia.  
(1) Modulation of a ciliary growth signal by polycystins (PKD) under normal conditions. This probably 
depends on functional ductule adaptation for chemo- or mechanosensation, only allowing 
derepression of the cilia-dependent growth signal when necessary (red arrow demarcated by dashed 
line).  
(2) Loss of polycystins leads to constitutive activity of a cilia-dependent cyst growth signal (red arrow 
demarcated by unbroken line).  
(3) Loss of cilia leads to a polycystin-independent basal ciliary cyst growth signal (red arrow 
demarcated by unbroken line). Flow: fluid flow such as that induced by bile, depicted by blue arrows. 
Abbreviations: PKD1, polycystin-1; PKD2, polycystin-2.  
Treatment perspectives: cAMP, somatostatin analogues and ciliopathies 
The cAMP signaling pathway is one of many disturbed in PLD, but it is important as the 
pathway inhibited by somatostatin analogues (SAs) [48, 49]. SAs such as lanreotide, 
octreotide and pasireotide show limited, but universal effectiveness in curtailing cyst growth 
[50]. Laboratory work has shown that SAs have beneficial effects on further fibrocystic 
ciliopathies like PKHD and NPHP [51, 52]. Contrarily, a randomized clinical trial with mTOR 
inhibitor and SA combination therapy did not show added benefits in comparison to SA 
monotherapy in PLD [53]. cAMP regulation in cholangiocytes is not only orchestrated by 
somatostatin receptors (SSTRs), but also by secretin receptors, adenylyl cyclases and 
phosphodiesterases [51]. In addition, bile components may regulate cAMP levels through 
cilium-associated chemoreceptors TGR5, a G protein-coupled bile acid receptor, and 
purinergic G protein-coupled receptor (P2Y)12 [38, 39]. cAMP levels modulate cholangiocyte 
proliferation, apoptosis and fluid secretion, and thereby influence hepatic cyst expansion.  
Another mechanism involving cAMP and cilia has recently been discovered [54], and this 
mechanism may help explain cAMP abnormalities and SA effectivity in ciliopathies. It has 
been found that cAMP levels and ciliary length are reciprocally regulated. Following fluid 
shear-mediated polycystin activation, Ca2+ signaling decreases cAMP, whose lower level in 
turn downregulates ciliary length by impairing delivery flux of cilium components. Dynamic 
regulation of ciliary length may thus be compromised in human cystic diseases involving 
perturbed polycystin function, while cAMP levels may remain improperly modulated 
following ciliary disruption.  
The Pkhd1-/- rat model has ciliary disturbances in addition to renal and hepatic cysts [51]. 
Ca2+ signaling is curtailed, while cAMP levels are elevated in cystic cholangiocytes. Elevated 
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cAMP levels are also found cystic cells of multiple polycystic kidney disease animal models, 
including jck mice (Nek8jck), PCK rats (Pkhd1pck), Pkd2WS25/− mice and pcy mice (Nphp3pcy) 
[55]. Cholangiocyte primary cilia of the PKHD-/- rats are at least two times shorter compared 
to those of control rats. Octreotide can suppress cAMP levels through SSTR 2, 3 and 5 
induction in these rats, causing decreased cell proliferation and increased apoptosis. 
Pasireotide enhances these effects, as the molecule binds more strongly to diverse SSTRs 
and has a longer half-life [56]. In inner medullary collecting duct cells with NPHP gene 
knockdown, octreotide prevents defects in spheroid formation [52]. It is therefore plausible 
that SAs are effective in a larger group of fibrocystic diseases than in PLD. 
Concluding remarks 
In the past several years, our understanding of the intricacies of signal and transcriptional 
networks in normal and cystogenic biliary development has expanded tremendously. 
Initiation of cysts occurs by LOH in single cells, leading to defects in biliary signaling and 
environmental sensing, with monoclonal proliferation as a consequence. Many studies find 
ciliary dysfunction precedes cyst development, and this seems to be the common path to 
hepatic cystic disease. In case of polycystin related PLD, residual ciliary activity is important 
for the severe cystogenesis phenotype.  
Several questions remain, however (see Box ´Outstanding questions´). Most importantly, 
genetic diagnosis currently eludes up to eighty percent of PCLD cases in the clinical setting. 
In addition, PLD treatment remains suboptimal. Normal pathways of hepatobiliary 
development, as well as genes of cyst disease models may yield clues to the actual 
pathogenesis. A better understanding of cilium-induced growth signals and subsequent DPM 
in PLD will open up new avenues for therapeutic intervention. 
Outstanding questions 
- Which are the genes responsible for the 80% of PCLD cases that currently remain 
unexplained? 
- What is the primary pathway that becomes disrupted following loss of polycystins? 
- What is the mechanism of DPM following loss of polycystins? 
- Is only LOH capable of causing random subsets of biliary cells to develop into cysts 
following germ line mutations? Or does another chance-based mechanism exist for Sec63 
mutations that cause cysts to occur? 
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Glossary 
Adenomatosis polyposis coli (APC): is a member of the destruction complex of the canonical 
Wnt signaling pathway. Loss of APC leads to constitutive Wnt pathway activation. 
Autophagy/autophagosome: catabolic mechanism involving breakdown of unnecessary 
protein components in lysosome organelles of cells, following transport by autophagosomes. 
Autophagosome induction and cilium formation have recently been found to be 
interdependent processes.  
Autosomal dominant polycystic kidney disease (ADPKD): a common genetic nephropathy, 
in which PLD is found in 83–94% of patients.  
Canonical Wnt signaling: is involved in cellular differentiation and proliferation in embryonic 
and adult tissues. Following activation by Wnt ligands, Frizzled and LRP5/6 receptors initiate 
signaling through the β-catenin transcription factor by induction of a destruction complex. 
Cholangiocytes/biliary cells: epithelial cells that line the biliary tract.  
Ciliopathy: genetic disease caused by dysfunction of the cilium or cilium-anchoring 
structures. Examples include ADPKD, ARPKD, MKS, and, most probably, PCLD. Ciliopathies 
are as phenotypically diverse as the cells and tissues on which primary cilia are present; 
cystic kidneys, fibrocystic liver disease, diabetes, retinal degeneration, anosmia, situs 
inversus, skeletal involvement, mental retardation, obesity, and infertility are all part of the 
ciliopathy phenotype spectrum.  
Congenital disorders of glycosylation (CDG): type I CDG has defects in synthesis and transfer 
of glycans, whereas type II CDG has defective glycan processing. CDG often presents with 
ductal plate malformation. cyclic AMP (cAMP): a second messenger important in many 
biological processes. The cAMP signaling pathway is one of many disturbed in PLD but is 
important as the pathway is inhibited by SAs.  
Cytokeratins (CKs): are protein markers commonly used to identify cell types. For example, 
CK19 marks biliary cells.  
Ductal plate: layer of hepatoblasts enveloping the portal vein/mesenchyme, bound to 
become biliary tract cholangiocytes and periportal hepatocytes during hepatobiliary 
development.  
Ductal plate malformation (DPM): defects in remodeling of the ductal plate during biliary 
tract development.  
Extracellular matrix (ECM): includes the interstitial matrix and basement membrane of 
multicellular tissues. It functions in cell adhesion, cell-to-cell communication, and cellular 
differentiation. Hepatoblast: bipotent cell that may differentiate towards biliary or 
hepatocyte cells. Normally present during embryology, but bipotent liver progenitors persist 
in the biliary tract during adulthood.  
Hepatocyte: main epithelial cell of the liver parenchyma.  
Notch signaling: notch signaling is involved in cellular differentiation and proliferation in 
embryonic and adult tissues. Following activation by Notch or Jagged ligands, Notch 
receptors initiate signaling through Rbpj and Hes/Hey transcription factor families.  
Polycystic kidney disease (PKD): polycystic kidneys are the primary presentation of PKD, but 
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polycystic livers are found in most patients. PKD1 and PKD2 are the genes responsible for 
ADPKD in 85% and 15% of cases, respectively. PKHD1 is the gene responsible for virtually all 
incidences of ARPKD.  
Polycystic liver disease (PLD): PLDs are defined as presence of >20 cysts in the liver.  
Polycystic liver disease (PCLD): a rare form of PLD, which presents without polycystic 
kidneys. Primary cilia: solitary, non-motile organelles on the apical cell membrane surface of 
most mammalian cells involved in mechano-, osmo-, and chemoreception. In addition, 
primary cilia are implicated in planar cell polarity, cell cycle control, and numerous essential 
signaling pathways.  
Protein kinase C substrate 80KH (PRKCSH): is one of two genes known to cause PCLD, and 
PRKCSH mutation is found in more than 10% of cases. It encodes the protein hepatocystin 
that serves as the non-catalytic β-subunit of GII and is involved in n-glycan processing.  
SEC63: is one of two genes known to cause PCLD. SEC63 mutation is found in more than 5% 
of cases. It encodes the Sec63p protein, which is part of the Sec61 complex involved in co 
and posttranslational protein transport.  
Somatostatin analogs (SAs): include lanreotide, octreotide, and pasireotide. cAMP 
regulation can be orchestrated by SAs through SSTRs. Lanreotide, octreotide, and 
pasireotide have different binding affinities for SSTR subtypes as well as different half-lives, 
which affects clinical effectivity. Transforming growth factor (TGF)-β signaling: is involved in 
cellular differentiation and proliferation in embryonic and adult tissues. Following activation 
by TGF-β ligands, TGF-β receptors initiate signaling through SMAD complex transcription 
factors. 
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Abstract 
Autosomal dominant polycystic liver disease (ADPLD) is caused by variants in 
PRKCSH, SEC63, and LRP5, while autosomal dominant polycystic kidney disease 
(ADPKD) is caused by variants in PKD1, and PKD2. Liver cyst development in 
these disorders is explained by somatic loss-of-heterozygosity (LOH) of the wild 
type allele in the developing cyst. We hypothesize that we can use this mechanism 
to identify novel disease genes that reside in LOH regions. In this study, we aim to 
map abnormal genomic regions using high-density SNP microarrays to find novel 
polycystic liver disease genes.  
We collected 46 cysts from 23 patients with polycystic or sporadic hepatic cysts, 
and analyzed DNA from those cysts using high-resolution microarray (n=24) or 
Sanger sequencing (n=22).  We here focused on regions of homozygosity on the 
autosomes (>3.0Mb), and large CNVs (>1.0Mb). 
We found frequent LOH in PRKCSH (22/29), and PKD1/PKD2 (2/3) cysts of 
patients with known heterozygous germline variants in the respective genes. In 
the total cohort, 12/23 patients harbored abnormalities outside of familiar areas. 
In individual ADPLD cases, we identified germline events: a 2q13 complex 
rearrangement resulting in BUB1 haploinsufficiency, a 47XXX karyotype, 
chromosome 9q copy number loss, and LOH on chromosome 3p. The latter region 
was overlapping with an LOH region identified in two other cysts. 
Unique germline and somatic abnormalities occur frequently in and outside of 
known genes underlying cysts. Each liver cyst has a unique genetic makeup. LOH 
driver gene BUB1 may imply germline causes of genetic instability in PLD. 
Lay summary 
Liver cysts, abnormal fluid-filled sacs, are caused by complete loss of genes like 
PKD1, PKD2, PRKCSH, SEC63 and LRP5 in the body. The genetic makeup of 46 cysts 
of 23 patients is studied. Although sharing similarities in loss of known genes, 
cysts are found to be unique with regard to other genetic abnormalities. Genes 
outside of known genes are frequently affected, some of which may modify the 
risk of cyst development. 
Keywords 
polycystic liver disease, cholangiocytes, loss-of-heterozygosity, microarray, 
candidate genes 
 
Introduction 
Polycystic liver disease (PLD) is part of the phenotype of two inherited disorders; autosomal 
dominant polycystic liver disease (ADPLD), and autosomal dominant polycystic kidney 
disease (ADPKD). In 83-94% of ADPKD patients polycystic livers are seen.1,2 Variants in 
Protein Kinase C Substrate 80K-H (PRKCSH), SEC63 homolog (S. Cerevisiae) (SEC63), and Low-
density lipoprotein Receptor-related Protein 5 (LRP5) cause ADPLD, and are present in ~25% 
of cases,3,4 while variants in Polycystic Kidney Disease 1 (PKD1) and Polycystic Kidney Disease 
2 (PKD2) are responsible for ADPKD in virtually all cases.5 
Protein products of genes underlying PLD are located to the endoplasmic reticulum (ER) or 
primary cilium.6,7  Experimental data favor a genetic interaction network between ER-
localized protein products of PRKCSH and SEC63, and cilium-localized PKD1 and PKD2.7,8 The 
finding of LRP5 variants in PLD suggests that Wnt signaling may be disrupted downstream of 
this interaction network. Genes that underlie PLD thus function in distinct organelles and 
pathways, despite a final common cystogenic effect. Furthermore, ciliopathy-associated 
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genes act outside of the PKD1 / PKD2 genetic interaction network,7,9 and may also cause 
liver cysts. The search for new genes should therefore not be limited to currently known 
genomic sites.  
At a tissue level, PLD appears to be a recessive disease. Complete loss of cyst gene 
expression from diseased epithelium follows loss-of-heterozygosity (LOH),10-15 which may be 
related to cyst genetic instability.16,17 The proportion of somatic variants varies with the gene 
that is affected in the germline. Recent studies found that second, somatic variants or LOH 
occurred in 56/71 liver cysts (79%) from patients with PRKCSH variants,11 in 4/5 (80%) PKD2 
variant carriers,18 but only 1/14 cysts (7%) from a patient with a SEC63 variant.10 This 
indicates LOH incidence depends upon the genetic and phenotypic background.  
We hypothesize that a ‘two-hit model’ is a general principle for development of hepatic 
cysts. Therefore, somatic LOH regions in cyst epithelium may harbor novel candidate PLD 
causing genes that harbor heterozygous germline variants in the respective cases. 
Considering the genetic interaction network in PLD,7,8 digenic or transheterozygous variants 
at two genetic loci may also play a role. Transheterozygous PKD1 / PKD2 variants have been 
described in renal cysts,14,15 whereby a variant in one cyst gene is succeeded by a variant in a 
second cyst gene. Cysts with heterozygous variants in PRKCSH and SEC63 continue to express 
the relevant proteins.10,11 It is reasonable to hypothesize that transheterozygosity may be 
another mechanism in hepatic cyst formation. This study aims to determine novel genetic 
loci that are involved in cystogenesis both at germline and somatic level. To this end, we 
followed an unbiased approach and assessed copy-number variations (CNV) and LOH regions 
in PLD cyst epithelium using a genome-wide high resolution cytogenetic array analysis.  
 
Methods 
 
Patient material 
 
We obtained DNA from liver cyst cholangiocytes of 23 newly included patients who 
underwent either laparoscopic cyst fenestration or aspiration sclerotherapy from 2011-2014 
because of large cysts. All patients except one were female, and had single or multiple liver 
cysts. All patients had severe symptoms and the mean age was 54 (range 42-83) years. 
Seventeen patients had ADPLD, three had ADPKD, and three had solitary or sporadic cysts. 
Use of this tissue for research was reviewed and approved by the regional ethics review 
board “Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen”. 
 
Cyst work-up 
 
We isolated cholangiocytes by four methods (Figure S1; Table 1). First, as described from 23 
previously studied laparoscopy – derived liver cysts (6 patients) obtained from 2010 to 
2012,18 we collected cells from fresh tissue by ethylenediaminetetraacetic acid (EDTA) 
detachment. Keratin (KRT)-19 staining indicated the purity of each sample. Second, we 
collected cells from 30 laparoscopy – derived liver cysts of eight patients from 2012 to 2014. 
These cells expanded into adult liver organoids using conditions suitable for their 
expansion.19 Under these conditions, only stem cells with a cholangiocyte-like phenotype 
expressing KRT19 persisted. DNA from one cyst per patient was studied using high density 
SNP microarrays (Affymetrix Cytoscan HD). DNA from the remaining 22 cysts was used to 
assess somatic loss of the wildtype allele of heterozygous PRKCSH germline variants by 
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Sanger sequencing. 
Third, symptomatic cyst patients were referred to our hospital for aspiration sclerotherapy. 
We collected 68 cyst fluid aspirates from 50 patients in 2011 and 2012. We subjected all 
samples to centrifugation, KRT19 staining and fluorescent-activated cell sorting (FACS) of 
cholangiocytes (appendix). This yielded eight additional samples for single nucleotide variant 
(SNP) microarray studies. Fourth, we grew eight cultures from 30 aspiration sclerotherapy 
fluids collected from 2012 to 2014 using conditions suitable for the expansion of adult liver 
stem cells.19 We obtained cyst fluid and epithelium samples and stored them in the course of 
treatment following the Dutch Code for the proper secondary use of human tissue. Use of 
this tissue for research was reviewed and approved by the regional ethics review board 
“Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen”.  
 
DNA isolation from cyst cholangiocytes 
 
We isolated DNA from the cyst cholangiocytes using the QIAamp DNA Micro kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. For samples with low DNA 
yields (which included all FACS obtained samples), whole genome amplification (WGA) using 
the Qiagen REPLI-g Mini kit (Qiagen) was performed.  
 
Genetic analysis by microarray and genotyping 
 
We assessed copy-number variations, LOH regions and regions of homozygosity using 
genome-wide high resolution cytogenetic array analysis (CytoScan HD, Affymetrix, Santa 
Clara, CA, USA).  
We screened whole blood PLD patient DNA for germline variants in PKD1 (NG_008617.1, 
NM_001009944.2), PKD2 (NG_008604.1, NM_000297.3), PRKCSH (NG_009300.1, 
NM_002743.3), SEC63 (NG_008270.1, NM_007214.4), and LRP5 (NG_015835.1, 
NM_002335.3) using direct sequencing as described previously.11  Briefly, we isolated DNA 
from whole blood using the PureGene DNA isolation kit (Gentra Systems/Qiagen, 
Minneapolis, Minnesota, USA) or High Pure Polymerase chain reaction (PCR) template 
preparation kit (Roche, Mannheim, Germany), and stored it at 4°C. PCR amplified PKD2, 
PRKCSH, SEC63, and LRP5, exons and flanking intronic sequences with specific primers (Table 
S1). Screening for germline variants in PKD1 (NG_008617.1, NM_001009944.2) was done by 
a method adapted from Tan et al 20. In short, primer sequences (Table S1) for long range PCR 
were chosen on specific regions of the PKD1 gene preventing the amplification of the known 
duplications of the first 33 exons at the proximal side of the gene. PCR reactions were 
performed according the manufacturer’s manual using FastStart™ Taq DNA Polymerase 
System  supplemented with GC-RICH solution (Roche) for exon 1 or GeneAmp® High Fidelity 
PCR System (Life technologies, Carlsbad, USA) supplemented with 5% DMSO for all other 
fragments. Annealing temperatures during PCR were carefully selected for each amplicon in 
order to amplify the desired regions. After purification of PCR amplicons from gel using the 
QIAEXII Gel Extraction Kit (Qiagen) a total of 500 ng of equimolar amounts of the PCR 
amplicons of each sample were sequenced in a single run using Ion Torrent™ Next-
Generation Sequencing (Life Technologies).  
All cysts from patients with PRKCSH variants were analyzed for LOH using direct sequencing 
of this variant. We screened the entire coding region of BUB1 Mitotic Checkpoint 
Serine/Threonine Kinase (BUB1) (NG_012048.1, NM_004336.4) in a cohort of unrelated 
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patients with ADPLD (n=100) that met the Reynolds criteria.21,22 We performed high 
resolution melting curves (RotorGene-Q; Qiagen) to reveal differences in melting curve 
shape that correlate to BUB1 genotype variants and validated these findings by Sanger 
sequencing. Adenylate Cyclase 1 (ADCY1) (NG_034198.1, NM_021116.2), Insulin-Like Growth 
Factor Binding Protein (IGFBP) 1 (NC_000007.14, NM_000596.2), and IGBPF3 (NG_011508.1, 
NM_001013398.1) were analyzed in a patient with cyst chromosome 7 copy number loss. 
Exons and flanking intronic sequences were amplified using polymerase chain reaction with 
specific primers (Table S1). We purified PCR amplicons from gel using the QIAEXII Gel 
Extraction Kit (Qiagen) and sequenced them with the BigDye terminator kit and ABI3730, 
ABI310 or ABI3100 Genetic Analyzers (Applied Biosystems, Boston, MA, USA) or from 2014 
onwards Ion Torrent sequencing (Life Technologies Carlsbad, CA, USA).  
 
Data analysis 
 
We considered large regions of homozygosity on the autosomes (>3.0Mb) and large CNVs 
(>1.0Mb) for further analysis. For samples not derived by FACS/WGA, we placed no limits for 
size of LOH or copy number variants (CNV) around known cyst genes. We only assessed X 
chromosomes for whole chromosome abnormalities. For selected cases, we compared the 
array results derived from cyst cell DNA (somatic) and germline DNA (genomic) to ensure 
identification of somatic events. We selected cases for germline analysis based on 
FACS/WGA origin of cyst DNA or presence of non-mosaic >1.0 Mb CNVs. We used individual 
CytoScan HD data chromosome analysis suite (CHAS, Affymetrix) V2.1. For analysis involving 
multiple SNP array data, we used Nexus Copy Number (Biodiscovery, El Segundo, CA, USA) 
V6.0.  
SNP array data 
The data discussed in this publication have been deposited in NCBI's Gene Expression 
Omnibus (Wills et al., 2016) and are accessible through GEO Series accession number 
GSE78808 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kjipyeauhnwbzqv&acc=GSE78808). 
Described variants have also been deposited at NCBI’s database of genomic structural 
variations (Wills et al., 2016) and are accessible through dbVar 
(http://www.ncbi.nlm.nih.gov/dbvar) accession number nstd125. 
 
Table 1. Patient characteristics.  
Unknown germline variant indicates no variant in PRKCSH (NM_002743.3), SEC63 (NM_007214.4), or 
LRP5 (NM_002335.3) was found for ADPLD patients, and no variant in PKD1 (NM_001009944.2) or 
PKD2 (NM_000297.3) was found for ADPKD patients.   
CNV: copy number variation; chr.: chromosome; CNN: copy number neutral; ROH: region of 
homozygosity; LOH: loss-of-heterozygosity; Epith.: epithelium; Loss: copy number loss; Gain; copy 
number gain 
a Or abnormality in PKD1, PKD2, PRKCSH, SEC63, or LRP5 in case of sporadic cysts 
# 
Patient & 
age 
Sourc
e 
Disease, germline mutation 
& SNP array CNV 
Second hit 
mutationa 
Additional 
events 
1 
Male, 
Fluid 
ADPLD 
None detected None 
61 years Unknown 
  Loss chr 9q (2.9Mb) 
  CNN ROH chr. 3p (12.7 Mb) 
  CNN ROH chr. 13q (5.4Mb) 
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2 
Female, 58 
years 
Fluid 
ADPLD 
None detected 
CNN LOH chr. 5q 
(3.6Mb)  
Unknown 
3 
Female, 60 
years 
Fluid 
ADPLD 
None detected None detected 
Unknown 
4 
Female, 
Fluid 
ADPLD 
None detected None detected 
50 years Unknown 
5 
Female, 
Fluid 
ADPLD 
None detected None detected 
59 years Unknown 
6 
Female, 
Fluid 
ADPLD 
None detected None detected 
55 years Unknown 
7 
Female, 83 
years 
Fluid 
ADPKD 
CNN LOH chr. 16p 
(34.6 Mb) 
CNN LOH chr. 1p 
(6.9Mb) 
PKD1 hg38 
chr16:g.2090007T>G 
CNN LOH chr. 
12q (4.4Mb) 
8.
1 
Female, 
Fluid 
ADPLD 
CNN LOH chr. 19p 
(12.9 Mb) 
None detected 
44 years 
PRKCSH hg38 
chr19:g.11437972G>C 
  Gain chr 2q13 (1.3Mb) 
  Loss chr. 2q13 (1.7Mb; 
including Bub1)  
8.
2 
Female, 44 
years 
Epith. 
ADPLD 
CNN LOH chr. 19p 
(1.5Mb) 
Loss  chr 7p 
(1.7Mb) 
PRKCSH hg38 
chr19:g.11437972G>C 
Gain chr 2q13 (1.3Mb) 
Loss chr 2q13 (1.7Mb) 
9 
Female, 54 
years 
Epith. 
Sporadic cyst 
None 
CNN LOH chr. 2q 
(3.1Mb) 
- 
CNN LOH chr. 
12q (3.7Mb) 
10 
Female, 57 
years 
Fluid 
Sporadic cyst 
None None 
- 
11 
Female, 58 
years 
Epith. 
ADPLD 
CNN LOH chr. 19p 
(1.7Mb) 
Mosaic trisomy 
chr 7  
Unknown 
CNN LOH chr. 
12q (3.6Mb) 
12 
Female, 47 
years 
Epith. 
ADPLD 
CNN LOH chr. 19p 
(20Mb) 
CNN LOH chr. 6p 
(3.3Mb) PRKCSH hg38 
chr19:g.11449074A>G 
13 
Female, 70 
years 
Fluid 
ADPLD 
Del chr 4q (39kb) 
CNN LOH chr. 5q 
(5.4 Mb) 
Unknown 
14 
Female, 52 
years 
Epith. 
ADPLD 
None None 
Unknown 
15 
Female, 61 
years 
Epith. ADPLD None 
CNN LOH chr. 2q 
(3.2Mb) 
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Unknown 
CNN LOH chr. 5p 
(3.2Mb) 
16 
Female, 51 
years 
Fluid 
ADPLD 
Del chr 6q (42 Mb) None SEC63 hg38 chr6: 
g.107904719del 
17 
Female, 50 
years 
Epith. 
ADPLD 
None 
CNN LOH chr. 5q 
(3.1Mb) PRKCSH hg38 
chr19:g.11449074A>G 
18 
Female, 52 
years 
Fluid 
ADPKD PKD1 hg38 chr16 
g.[2135508G>A(;)20
90517_2090558deli
nsGGAC], 
c.[182C>T(;)12171_
12212delinsGTCC], 
p.[Pro61Leu(;)Ser40
57Argfs*87] 
CNN LOH chr. 3p 
(3.4Mb) CNN 
LOH chr. 19 
(1.2Mb) 
PKD1 hg38 chr16 
g.[2135508G>A(;)2090517_2
090558delinsGGAC], 
CNN LOH chr 11 
(1.3Mb) 
c.[182C>T(;)12171_12212deli
nsGTCC], 
p.[Pro61Leu(;)Ser4057Argfs*
87] 
  
19 
Female, 47 
years 
Epith. 
ADPLD 
CNN LOH chr 19 
(15.9Mb) 
Trisomy X 
(entire) 
PRKCSH hg38 
chr19:g.11437972G>C 
CNN LOH chr. 3p 
(6.1 Mb) 
47XXX   
20 
Female, 43 
years 
Fluid 
Sporadic cyst Gain CN 2.26 chr. 
16p (3.8Mb) 
CNN LOH chr. 1p 
(3.6Mb) 
- 
21 
Female, 61 
years 
Fluid 
ADPLD 
None None PRKCSH hg38 
chr19:g.11437972G>C 
22 
Female, 42 
years 
Fluid 
ADPLD 
CNN LOH chr 19 
(19.6 Mb) 
None 
PRKCSH hg38 
chr19:g.11437972G>C 
23 
Female, 51 
years 
Fluid 
ADPKD 
None None 
Unknown 
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Results 
 
Figure 1. Overview of abnormal regions found in this study by SNP array. 
 
Patient characteristics 
 
We included DNA from 24 liver cysts from 23 patients for Affymetrix CytoScan HD SNP array 
analysis in this study (Figure 1, Table 1; Figure S1 for inclusion flow chart), together with 23 
cysts from 6 previously described patients (Table S2; Figures S2, S3). In the new cohort, all 
patients except one were female, and had single or multiple liver cysts. All patients had 
severe symptoms and the mean age was 54 (range 42-83) years. Seventeen patients had 
ADPLD, three had ADPKD, and three had solitary or sporadic cysts. Six carried PRKCSH 
variants, one carried a variant in SEC63 and two had PKD1 variants.  
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Figure 2. Upper panel: 2q13 complex rearrangement present in genomic blood DNA of PRKCSH 
variant patient (#8). Lower panel: Presence of three X-chromosomes in genomic blood DNA of blood 
of another PRKCSH variant patient (#19). 
 
Germline variants 
 
In the total cohort, three patients displayed germline abnormalities detectable by our 
criteria outside of PRKCSH, SEC63, LRP5, PKD1, and PKD2 genomic regions. We found a 
heterozygous 3.0 Mb 2q13 complex rearrangement in germline and cyst DNA of a PRKCSH 
variant carrier (patient 8; Figure 2). This rearrangement constituted of a copy number gain as 
well as a copy number loss, and contained the genes BUB1, ACOXL, BCL2L1, ANAPC1, 
MERTK, TMEM87B, FBLN7, and ZC3H8* (Figure 3).  
Peripheral blood and cyst DNA of another patient (#1) displayed a large copy number loss 
(12.7 Mb) of chromosome 3p containing Wnt signaling effector Catenin (Cadherin-
Associated Protein), Beta 1 (CTNNB1), amongst others (Figure 4). We additionally identified a 
large copy number loss (2.9Mb) in patient #1, which contained the genes SYK, NFIL3, and 
ROR2** . This CNV in chromosome 9 occurs with low frequency in a normal, healthy 
cohort.  A third ADPLD patient carried a gain of the entire X-chromosome (Triple X) in her 
germline and somatic DNA (patient 18; Figure 2).  
* Acyl-CoA Oxidase-Like (ACOXL); BCL2-Like 1 (BCL2L1); Anaphase Promoting Complex 
Subunit 1 (ANAPC1); MER Proto-Oncogene, Tyrosine Kinase (MERTK); Transmembrane 
protein 87B (TMEM87B) 
Fibulin 7 (FBLN7); Zinc Finger CCCH-Type Containing 8 (ZC3H8) 
** Spleen Tyrosine Kinase (SYK); Nuclear Factor, Interleukin 3 Regulated (NFIL3); Receptor 
Tyrosine Kinase-Like Orphan Receptor 2 (ROR2) 
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Figure 3. BUB1 is present at the centromeric part of the 2q13 loss region. 
 
Germline BUB1 variants 
 
The 2q13 rearrangement pointed to the well-known mitotic checkpoint gene BUB1.23 In 
order to test whether this gene played a more general role in ADPLD, we studied the gene in 
genomic DNA from 100 severely affected ADPLD patients. Using high-resolution melt curves 
(HRM) and subsequent Sanger sequencing on abnormal melting curves, we identified one 
synonymous SNP (rs370559107: hg38 chr2:g.110672765C>G, silent variant) in these 100 
patients.  In addition, a single, nonsynonymous SNP (rs61730706; hg38 
chr2:g.110667649G>A, c.677C>T, p.(Ala226Val)) was present in the DNA of one patient of 
this cohort, which occurs with a minor allele frequency of 0.002-0.005 in the general 
population. Polyphen and SIFT showed conflicting effects (SIFT: 0.28, tolerated; Polyphen 
(HumDiv): possibly damaging 0.749; Polyphen (HumVar) benign 0.219; Variant taster variant 
(p=0.617). We did not consider this SNP as causative or disease-related, as it is normally 
present in the general population. 
 
LOH surrounding PRKCSH, SEC63, LRP5, PKD1 and PKD2 
 
To validate our approach, the SNP array cohort included seven cysts from six patients with 
known PRKCSH variants. The SNP arrays of five cysts of four patients revealed copy number 
neutral (CNN) LOH on chromosome 19 at the position where PRKCSH is located (Figure S4). 
Sanger sequencing of additional cyst DNA from patients (#12, 17, and 19) with known 
PRKCSH variants revealed somatic loss of the respective wildtype alleles in 17 out of 22 cysts 
(Table S3).  
DNA of a cyst of patient #7 contained a >30Mb homozygous region on chromosome 16p. 
Although initially classified as having isolated PLD with a single renal cortical cyst, a germline 
PKD1 variant was found (hg38 chr16:g.2090007T>G, c.12632A>C, p.(Glu4211Ala)). No CNN 
LOH was found in cyst DNA of the other two ADPKD patients by SNP array, and we 
proceeded by directly sequencing PKD1 and PKD2. Patient #18 had a germline PKD1 variant 
(hg38 chr16:g.2135508G>A, c.182C>T, p.(Pro61Leu)).  
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Figure 4. Left: CNN LOH on chromosome 3p of patient #18, 19 and 1, from above to below in that 
order. Right upper panel: Mosaic whole chromosome 7 gain in an ADPLD patient (#11) with 
unknown variant, chromosome 7p shown. Right lower panel: 1.7 Mb loss on chromosome 7p of a 
PRKCSH patient cyst (#8.2). 
 
In the cyst, the second allele was likely affected by a somatic deletion (hg38 chr16 
g.[2135508G>A(;)2090517_2090558delinsGGAC], c.[182C>T(;)12171_12212delinsGTCC], 
p.[Pro61Leu(;)Ser4057Argfs*87]). We detected no variants in germline or somatic DNA of 
the final ADPKD patient.  
LOH across ADPLD genes was a frequent occurrence in somatic DNA of our total cohort, 
regardless of variant status of germline DNA. Approximately 40% of 34 cysts with high-
quality SNP array data displayed LOH or allelic imbalance (AI) across PRKCSH, while more 
than 25% of cysts had PKD1 LOH or AI. PKD2, SEC63 and LRP5 both had lower percentages of 
LOH/AI, ~15%, ~15% and ~10% respectively. Copy number losses and gains in ADPLD 
occurred less frequently.  
 
Novel, digenic abnormalities in cysts 
 
As described above, patient #8 presented with two germline events. We identified a PRKCSH 
variant and a complex rearrangement resulting in BUB1 haploinsufficiency. DNA from her 
second cyst displayed multiple second hits when compared to peripheral blood. A 1.7 Mb 
copy number loss region on chromosome 7 was present as well as CNN LOH surrounding 
PRKCSH on chromosome 19 (Figure 4). The loss region includes the genes ADCY1, IGFBP1 
and IGFBP3, as well as the pseudogene Septin 7B2 (SEPT7B2). It was not detected in the SNP 
array profile of germline DNA, nor were germline variants detected in any of these genes 
using Sanger sequencing. Sanger sequencing also did not reveal variants in these genes in 
the cyst. Another PRKCSH mutant cyst displayed mosaic trisomy 7 (#11), although only 
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present in a subset of cells.  
Copy number neutral LOH of chromosome 19 (1.2 Mb), encompassing PRKCSH, and 
chromosome 11 (1.3 Mb), encompassing LRP5, was present in cyst DNA of an ADPKD patient 
(#18, germline PKD1 variant). In this patient, an additional copy number neutral LOH region 
was detected on chromosome 3p (hg19 chr3:g.49,735,745_53,133,526), partially 
overlapping with a region of a PRKCSH variant carrier (#19; hg19 
chr3:g.46,715,645_52,852,488). Notably, patient #1 with a larger copy number neutral LOH 
on chromosome 3p on germline and cyst DNA also had overlap (hg 19 chr. 
3:g.39,874,567_52,653,645). The minimal region of LOH contained >60 genes, containing 
multiple tumor suppressor genes (Table S4).  
 
Sporadic cysts 
 
Two sporadic cysts of the same patient showed novel chromosomal LOH (patient #28; Table 
S2). These cysts had been previously described without abnormalities encompassing the 
then known cyst genes PRKCSH, SEC63, PKD1, or PKD2. Copy number neutral LOH (2.0 Mb) 
was found around LRP5, a novel cyst gene (Figure S5). Germline DNA revealed no variant in 
LRP5, and the presence of two germline heterozygous LRP5 SNPs (hg38 
chr.11:g.68403545T>C, rs545382; hg38 chr.11:g.68425222G>A, rs556442) indicated that 
LOH was only present at a somatic level. Unfortunately, no cyst DNA remained, and it could 
not be confirmed whether this copy number neutral LOH led to loss of wild type alleles by 
variant.  
Finally, the sporadic cyst from patient 20 displayed a 3.8 Mb mosaic copy number gain at the 
telomeric part of chromosome 16p on cytoscan. The signal was relatively weak, yet may 
suggest presence of a cellular subpopulation of this cyst with PKD1 gain.   
 
Discussion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Here we show that germline and somatic abnormalities outside of known cyst genes 
frequently occur in PLD, and many cysts of PLD patients have a unique genetic signature. 
LOH in known regions was confirmed for PRKCSH (22/29), and PKD1/PKD2 (2/3) variants. In 
the SNP array cohort of 23 new patients (24 cysts), we detected 12 cysts with sizable copy 
number losses or LOH outside of earlier identified genomic regions. In 3 patients we found 
the presence of unique germline aberrations in PLD. Additionally, a patient with a primary 
liver phenotype had a germline PKD1 variant. Cyst DNA showed recurrent copy number loss 
on chromosome 3, with overlap between three patients. On chromosome 7, a 1.7 Mb copy 
number loss and a mosaic whole-chromosome gain were found. Sporadic cysts displayed 
LOH around LRP5 and a mosaic gain surrounding PKD1 at a somatic level.  
Although many genomic abnormalities were present beyond genomic regions known for 
second hits, most were unique. Chromosomal mapping suggests that each cyst follows an 
independent genetic pathway, similar to mosaicism observed in tissues of other somatic 
second hit disorders.24,25 This likely reflects significant heterogeneity that is at the genomic 
root of cyst development. It also reflects that general genomic instability presumably 
precedes cyst development.16,17 BUB1 haploinsufficiency is a known driver of chromosomal 
instability resulting in LOH and tumorigenesis,23,26 and a 2q13 microdeletion has previously 
been described.26,27 While we show that it is unlikely that this specific gene is generally 
involved in LOH in PLD, other drivers of genetic instability may be present in the disease.  
Wnt signaling abnormalities appear to be common in PLD. Wnt signaling abnormalities are 
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associated with tumorigenesis in the liver and kidney, and cause aberrant cyst development 
in mice.28,29CTNNB1 deletions and APC variants are also frequently found in 
hepatoblastoma.30,31 Variants in canonical Wnt signaling component LRP5 causes ADPLD in 
man,4 whereas the c-terminal tail of polycystin-1 might interact with beta-catenin.32 In the 
same vein, our finding of copy number neutral  LOH around CTNNB1 together with copy 
number loss of ROR233 in the germline of an ADPLD patient, together with copy number 
neutral  LOH around LRP5 in two sporadic cysts of another patient further implicates this 
pathway as a crucial for cystogenesis.  
Trisomy X, the final germline abnormality we found, is unlikely to be involved in 
cystogenesis. Although female gender is a risk factor for cyst development and 
complications,34 this is most likely due to sex hormones.35,36 Furthermore, gene expression 
of triple-X cells is largely limited to one copy by X-inactivation, excluding 5-10% of genes on 
the X-chromosome located in pseudoautosomal regions.37 We see this as a chance finding, 
considering its prevalence of 1 in 1000 females.  
On a somatic level, possible digenic or transheterozygous variants and a PKD1 gain were 
present on cysts. The 1.7 Mb chromosome 7 copy number loss of a PRKCSH variant carrier 
might point towards a novel transheterozygous modifier region. Haploinsufficiency of genes 
such as IGFBP1, IGFBP3 and ADCY1 might be relevant in cyst development, as these genes 
are related to the IGF and adenylyl cyclase pathway that the anti-cystogenic somatostatin 
analogues are involved in.38-41 Surprisingly, another cyst displayed a mosaic gain over the 
whole of chromosome 7, indicating that overexpression of these or other genes may also be 
relevant for cyst development. More difficult is the recurrent, overlapping LOH region on 
chromosome 3 (49,735,745-52,653,645). Although two cysts display clear LOH, the third may 
have had a partially normal cellular subpopulation. Over 60 genes are present at this 
location, none of which are known cyst-related genes. This 3p21.3 region does contain a 
cluster of tumor suppressor genes,42 such as tumor susceptibility gene Rassf1a.43 The cluster 
frequently undergoes LOH in early formation of different tumors,42 including 
hepatocarcinomas and cholangiocarcinomas.44 The mosaic gain of PKD1 in one cyst may be 
consistent with overexpression of Pkd1 in mice leading to cystogenesis.45 The mosaicism of 
this region was relatively low however, and may represent an artefact. Given the substantial 
investment that went into genotyping this cohort, we express our disappointment that we 
found no more specific leads to clarify the origination of multiple cysts in the liver.   
Concluding, our chromosomal mapping indicates significant genetic heterogeneity outside of 
known second-hit regions of liver cysts. We identified unique cystogenic regions, as well as 
characteristics of general genomic instability in hepatic cyst DNA. These findings may explain 
the large number of APDLD cases without a known variant, as well as phenotypic 
dissimilarities between similar cyst germline variants.  
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Abbreviations 
ADPKD  autosomal dominant polycystic kidney disease  
ADPLD  autosomal dominant polycystic liver disease 
AI  Allelic imbalance 
CNN  copy number neutral 
CNV  copy number variation 
Del  deletion 
ER  endoplasmic reticulum 
FACS  fluorescent-activated cell sorting 
LRP5  low density lipoprotein receptor-related protein 5 
LOH  loss of heterozygosity 
PCR  polymerase chain reaction 
PLD  polycystic liver diseases (ADPLD and ADPKD)  
PKD1  polycystic kidney disease 1 protein (polycystin-1) 
PKD2  polycystic kidney disease 2 protein (polycystin-2) 
PRKCSH  protein kinase C substrate 80K-H (80 kDa protein, heavy chain) 
SEC63  Saccharomyces cerevisiae homolog 63 
SNP  single nucleotide variant 
Wnt  wingless-type MMTV integration site family member 
WT  wildtype 
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Abstract 
Mutations in the PRKCSH, SEC63, and LRP5 genes cause autosomal dominant 
polycystic liver disease (ADPLD). The proteins products of PRKCSH (alias GIIB) 
and SEC63 function in protein quality control and processing in the endoplasmic 
reticulum (ER), while LRP5 is implicated in Wnt/β-catenin signaling. To identify 
common denominators in the PLD pathogenesis, we mapped the PLD interactome 
by affinity proteomics, employing both HEK293T cells and H69 cholangiocytes. 
Identification of known complex members, such as glucosidase IIA (GIIA) for 
PRKCSH, and SEC61A1 and SEC61B for SEC63, confirmed the specificity of the 
analysis. GANAB, encoding GIIA, was very recently identified as an ADPLD gene. 
The presence of GIIA in the LRP5 complex pinpoints a potential functional 
connection with PRKCSH. Interestingly, all three PLD-associated protein 
complexes included filamin A (FLNA), a multifunctional protein described to play 
a role in ciliogenesis as well as canonical Wnt signaling. As ciliary dysfunction 
may also contribute to hereditary liver cyst formation, we evaluated the 
requirement of PRKCSH and SEC63 for ciliogenesis and Wnt signaling. By CRISPR-
Cas9 induced knockdown of both ADPLD genes in HEK293T cells and H69 
cholangiocytes, we identified that their depletion results in defective ciliogenesis. 
However, only H69 knockouts displayed reduced Wnt3a activation. Our results 
suggest that loss of PRKCSH and SEC63 leads to general defects in ciliogenesis, 
while quenching of the Wnt signaling cascade is cholangiocyte-restricted. 
Interactions of all three PLD-associated protein complexes with FLNA may mark a 
common link between the ADPLD proteins and the cystogenic processes driving 
this disease. 
Lay summary 
Isolated liver cysts, fluid-filled sacs in the liver, are caused by loss of PRKCSH, 
SEC63, and LRP5 genes. Primary cilia, the cell’s antennas, are disturbed due to this 
loss. Wnt signaling, important in development of tissues and organs, is similarly 
impaired. Evidence of a connection between PRKCSH, SEC63, LRP5 and another 
protein, filamin A, may be the cause for these disturbances of cilia and Wnt 
signaling. 
Keywords 
polycystic liver disease, primary cilia, Wnt signaling, protein interactome, 
CRISPR-Cas9 
 
Introduction 
Polycystic liver disease (PLD) is part of the phenotype of two disorders; autosomal dominant 
polycystic liver disease (ADPLD), and autosomal dominant polycystic kidney disease (ADPKD). 
ADPLD is caused by mutations in PRKCSH, SEC63, and LRP5 in up to 25% of cases (1, 2), and 
PKD1 and PKD2 mutations cause ADPKD in virtually all cases (3). Recently, mutations in 
GANAB, encoding the glucosidase IIa (GIIA) subunit, were also found to cause ADPKD and 
ADPLD in a very small percentage of cases (4). GANAB, together with ALG8, encoding α-1,3-
glucosyltransferase, and SEC61B  were identified very recently as ADPLD genes in a large 
exome sequencing effort (5). Cysts frequently display loss-of-heterozygosity (LOH) (6-11). 
Wild-type alleles are completely lost by this process, which appears to be crucial for cyst 
development. 
PRKCSH, SEC63 and GIIA proteins are located in the endoplasmic reticulum (ER), LRP5 on 
plasma membranes, and polycystin-1 (PC1) and polycystin-2 (PC2), encoded by PKD1 and 
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PKD2 respectively, on the primary cilium (2, 12, 13). A study on a genetic interaction network 
between PRKCSH, SEC63, PKD1, and PKD2 implicated PKD1 as the rate limiting component of 
cyst formation (12-14). PRKCSH, also known as glucosidase IIb (GIIB), functions in n-glycan 
processing through its interaction with GIIA. PRKCSH maintains the complex in the ER 
through a localization signal (15). SEC63 is present on the ER membrane in the SEC61 protein 
translocon, where it facilitates protein translocation and transmembrane protein insertion. 
Both ER proteins are part of post-translational quality control and processing of PC1 and PC2 
(12-14), while GIIA was shown to be required for maturation of PC1, and subsequently for 
correct surface and ciliary localization of both polycystins (4). Although direct evidence of 
the suggested function of the polycystins in ciliary calcium trafficking has remained elusive 
(16, 17), much credence has been given to the hypothesis that they are important for ciliary 
function (18-20). Intact cilia are important drivers of cyst development (21). Primary cilia in 
biliary ducts act as mechano-, osmo-, and chemosensors (22), and structural ciliary 
abnormalities may be present in cysts (23, 24). Although it has become clear that 
PRKCSH/GIIB (and recently GIIA), and SEC63 protein loss leads to defective PC1 processing, 
resulting in a cilia-dependent cyst formation (4, 14), it remains unclear whether other 
aspects of cilium formation, cilium structure, or cilium-directed pathways are also affected. 
The polycystin complex has been implicated in MAPK/ERK, mTOR, and cAMP pathways (21), 
yet disturbance of these pathways is not sufficient to cause cilia-dependent cyst growth. 
Wnt/β-catenin signaling is another pathway essentially linked to primary cilia function. LRP5, 
the most recent identified ADPLD gene (2), implicates Wnt signaling in cystogenesis. Wnt 
signaling through LRP6, a close homologue of LRP5, is dependent upon n-glycosylation (25). 
Similarly, several experimental data link SEC63 to Wnt signaling by binding to nucleoredoxin 
(26), a protein that binds to Disheveled (27) and determines its levels (28), while the c-
terminal tail of polycystin-1 directly associates with beta-catenin, thus regulating canonical 
Wnt signaling (29). Finally, primary cilia may restrict the activity of the canonical Wnt 
pathway by spatial sequestering of beta-catenin to the cilium (30, 31). It remains to be 
identified if PRKCSH and SEC63 directly interact with Wnt signaling components, and/or if 
mutations directly affect the Wnt pathway. 
In this study we first aimed to unveil the associating functional protein modules and pinpoint 
the candidate common pathogenic denominators using affinity proteomics. Our results 
suggest that none of the three PLD-associated proteins (LRP5, PRKCSH and SEC63) plays a 
direct role in either Wnt signaling or cilium function, as none of the canonical players in 
these processes were found to interact. However, FLNA, a signaling scaffold protein 
previously shown to bind to polycystin-2 (PC-2), and to be involved in ciliogenesis as well as 
canonical Wnt signaling, was present in all three PLD-associated protein complexes. By 
CRISPR-Cas9 mediated knockdown of LRP5, PRKCSH and SEC63 in HEK293T cells and H69 
cholangiocytes, as well as evaluation of patient-derived cells, we determined the importance 
of these genes for correct ciliogenesis and Wnt signaling. 
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Materials and Methods 
CRISPR-Cas9 gene knockout 
For generation of PRKCSH, SEC63 and LRP5 mutant cell lines, we developed CRISPR-Cas9 
constructs based on the pSpCas9(BB)-2A-GFP plasmid. pSpCas9(BB)-2A-GFP (PX458) was a 
gift from Feng Zhang (Addgene, Cambridge, USA; plasmid # 48138) (52). This plasmid 
contains a mammalian-codon optimized Cas9 with nuclear targeting sequences, a gRNA 
backbone, and enhanced green fluorescent protein (eGFP) for selection. We designed oligo 
pairs of 20-nt on "http://tools.genome-engineering.org" (table 2), which provides a score 
from 0-100 based on the specificity of target sites. We annealed oligos and ligated them into 
PX458 plasmid, and subsequently transformed them into competent E. coli. We screened 
plasmids from two E. coli clones per construct using Sanger sequencing. Verified constructs 
were transfected into HEK293T and H69 cells in 6-wells plate using FuGene HD (Promega, 
Madison, USA).  
Table 1. Target sites and oligos used for CRISPR-Cas gene knockout. 
Scores indicate target site specificity on a scale from 1-100, higher scores are more specific. 
*Target site found in sequence following ATG/start codon 
Gene Exon Target site Oligo 1 (5'->3') Oligo 2 (5'->3') Score 
PRKCSH 2* ACCCATGTGCTGGGCCGTGGAGG CACCgACCCATGTGCTGGGCCGTGG AAACCCACGGCCCAGCACATGGGTc 67 
PRKCSH 3 GGATGGTGGCCGAACCGTCCAGG CACCgGGATGGTGGCCGAACCGTCC AAACGGACGGTTCGGCCACCATCCc 94 
SEC63 1* TCCCGGCGACATACTACCTCTGG CACCgTCCCGGCGACATACTACCTC AAACGAGGTAGTATGTCGCCGGGAc 94 
SEC63 2 GGTGTATGTGGTATCGTTTACGG CACCgGGTGTATGTGGTATCGTTTA AAACTAAACGATACCACATACACCc 88 
LRP5 1* GCTGGCGCTGTGCGGCTGCCCGG CACCgGCTGGCGCTGTGCGGCTGCC AAACGGCAGCCGCACAGCGCCAGCc 60 
LRP5 2 CAACCGCCGGGACGTACGGCTGG CACCgCAACCGCCGGGACGTACGGC AAACGCCGTACGTCCCGGCGGTTGc 99 
 
Selection of knockout cells 
We sorted single GFP+ cells into a 96 well’s plate using FACS on an Aria SORP sorter (BD 
Biosciences, San Jose, CA, USA). Remaining H69 cells were additionally seeded to a 6-well’s 
plate, and we used 50% filtered, conditioned medium from 70% confluent H69 cells to 
improve their growth rate. From the 6-well’s plate, we transferred clones individually onto a 
96-well’s plate after 2-3 weeks. We conducted Sanger sequencing for targeted regions, as 
well as western blot of protein products to confirm knockouts. 
For both cell lines, we screened 15 clones per construct for mutations at a DNA and protein 
level. For experiments, we selected two PRKCSH-/- or SEC63-/-clones per construct, and 
validated loss of protein expression on western blot in duplo. 
DNA isolation and genotyping 
We screened clones for mutations in PRKCSH, SEC63, and LRP5 using direct sequencing as 
described previously (7). Briefly, we isolated DNA from trypsin-detached cells using the 
PureGene DNA isolation kit (Gentra Systems/Qiagen, Minneapolis, USA) or High Pure PCR 
template preparation kit (Roche, Mannheim, Germany), and stored it at 4°C. Polymerase 
chain reaction (PCR) amplified PRKCSH, SEC63, and LRP5 exons with specific primers (table 
S3). 
 
 
Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling | 75  
 
DNA constructs 
We generated entry clones encoding full-length human PRKCSH, SEC63, and LRP5 from cDNA 
from liver tissue; 528, 760 and 1615 amino acids respectively [NCBI Reference Sequence: 
NM_002743.3 (PRKCSH); NP_001001329.1 (PRKCSH), NM_007214.4 (SEC63), NP_009145.1 
(SEC63); NM_002335.3 (LRP5); NP_001278831.1 (LRP5). We isolated total RNA from liver 
tissue using TRIzol Reagent (Life Technologies, Carlsbad, USA), and produced oligo dT cDNA 
by RT Transcriptor First Strand cDNA synthesis kit (Roche Applied Sciences, Mannheim, 
Germany). Full-length PCR fragments were obtained using the FastStart High Fidelity PCR 
System (Roche) using primers from table S4. Fragments were cloned into the Gateway entry 
vector pDONR201 (Life Technologies). LRP5 intracellular (ICD) fragment constructs, encoding 
the C-terminal amino acids 1409–1615 were generated using the LRP5 full-length entry clone 
as a template. LRP5ICD was added to the experiments to improve protein complex capture. 
Removing the transmembrane portion of proteins generally increases (water-soluble) 
protein yield. We made expression constructs from all entry clones using Gateway cloning 
procedures (Life Technologies) according to the manufacturer's protocol in N- and C-teminal 
TAP expression vectors. LRP5 mutant constructs were previously generated using the Quick 
Change-II-XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, USA) and a 
pcDNA3.1V5His WT-LRP5 as a template (table S2) (2). Sequences were confirmed by Sanger 
sequencing.  
Immunostaining and western blotting 
We transfected plasmids expressing cTAP-PRKCSH, nTAP-SEC63, nTAP-LRP5, and nTAP-
LRP5ICD in H69 and HEK293T cells with FuGene HD (Promega). We lysed cells using lysis 
buffer (50 mm Tris–HCl (pH7.5), 150 mm NaCl, 1% NP-40) on ice with complete protease 
inhibitor cocktail (Roche) 48 hours after transfection. Cells were spun down after 10 minutes 
incubation on ice and supernatant was collected. Sample Buffer (4x NuPAGE) was added to 
the supernatant and heated for 10 min at 70°C. Samples were run on NuPAGE Novex 4–12% 
Bis–Tris SDS–PAGE gels. We performed immunostains with anti-Flag, anti-PRKCSH, or anti-
SEC63 as well as with anti-alpha tubulin as primary antibodies (conditions shown in Table 
S5), and goat anti-rabbit IRDye800 and goat anti-mouse IRDye680c as a secondary 
antibodies (1 mg/ml, Molecular Probes, Waltham, USA). Washing steps used PBS-Tween 
(PBS with 0.2% Tween 20). We kept western blots in the dark and scanned them on an 
Odyssey infrared imaging system (Li-Cor, Lincoln, USA). Bands were detected and processed 
by ODYSSEY application software (Version 1.2, Li-Cor).  
Cell culture and DNA transfection 
HEK293T were cultured in high glucose DMEM AQmedia (Sigma Aldrich, St. Louis, USA), 
supplemented with 10% FCS, 1% penicillin/streptomycin, 1 mM sodium pyruvate, and 10mM 
HEPES. H69 cells were cultured in DMEM/F12, supplemented with 10% FCS, 1% 
penicillin/streptomycin, and 10mM HEPES. For DNA transfections, HEK293T and H69 cells 
were seeded, grown overnight, and then transfected using FuGene HD (Promega). 
Tandem affinity proteomics and mass spectrometry 
Cells transiently expressing the Streptavidin-FLAG (SF-TAP)-tagged PRKCSH (cTAP), SEC63 
(nTAP), and LRP5 (nTAP, ICD) fusion proteins were lysed on ice with complete protease 
inhibitor cocktail (Roche Diagnostics) in lysis buffer (50 mm Tris–HCl (pH7.5), 150 mm NaCl, 
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1% NP-40). The Streptavidin- and FLAG based tandem affinity purification steps were 
performed as previously described (53, 54). 5% of the final eluate was evaluated by SDS-
PAGE followed by silver staining, according to standard protocols, while the remaining 95% 
was subjected to protein precipitation with chloroform and methanol. Protein precipitates 
were subsequently subjected to mass spectrometry analysis and peptide identification as 
previously described (55). Proteins identified in SF-TAP control experiments (empty SF-TAP 
vector), or identified in more than 15% of the experiments from our in-house TAP-proteome 
data collection (33), were removed as nonspecific complex members. Protein interaction 
networks were visualized by Cytoscape software (56). 
Immunofluorescence and microscopy 
We cultured HEK293T and H69 cells on poly-L-lysine coated glass slides under standard cell 
culture conditions in Dulbecco's modified Eagle's medium (DMEM) or DMEM/Ham’s F12 
with 10% fetal calf serum (FCS). Serum-starved medium (H69: Opti-MEM1; HEK293T: 
DMEM/PBS 1:1) induced cilia for 72hr prior to staining. Subsequently, we fixated cells in 
3.8% paraformaldehyde in phosphate buffered saline (PBS) and permeabilized with 1% 
Triton-X-100 in PBS. We blocked cells with freshly made 2% bovine serum albumin (BSA) in 
PBS for 1 hour, followed by 1 hour incubation with primary antibodies (in 2% BSA in PBS) at 
room temperature. We washed cells with PBS, and added secondary antibodies at room 
temperature for 30 min. We used the following primary antibodies: anti-PRKCSH, anti-SEC63, 
anti-PDI, anti-ARL13B, anti-FLAG, anti-peroxisomal biogenesis factor 14, anti-alpha-tubulin, 
and anti-beta-actin (table S5). Secondary antibodies (all from Life Technologies) were: anti-
rabbit IgG Alexa Fluor 488, and anti-mouse IgG Alexa Fluor 568 (Table S6). We protected 
glass slides with stained cells with Vectashield (Vector Laboratories, Burlingame, CA) and 
placed them on a microscopic glass slide. We performed microscopy on an Axio Imager ZI 
fluorescence microscope (Zeiss, Sliedrecht, The Netherlands) with an ApoTome slider. We 
processed images using AxioVision (Zeiss) software, and we assessed three images per 
experiment. Percentages of ciliated cells are depicted as mean ± S.D.  
Cell cycle analysis 
Cell cycle analysis was performed with HEK293T wild type cells,  2 PRKCSH knock-out cell 
lines and a SEC63 knock-out cell line in log phase. Approximately 1× 106 cells were collected 
using trypsin and the cells were washed with PBS. The cells were fixed by adding 70% 
ethanol to the cell pellet while mixing and incubated for 1 hour at 4°C. The cells were then 
washed with PBS at 850 × g and 1 ml of Propidium Iodide working solution (40 µg/mL PI and 
100 µg/mL RNase A in PBS) was added to the cells. After an incubation of 30 minutes at 37°C 
cells were measured with the FC500 flowcytometer (Beckman-Coulter, Indianapolis, IN) with 
excitation at 488nm (15mW) and emission at 610nm longpass filter. The first peak 
represents the G1 phase, the second peak the G2 phase and in between the S phase. 
(De)glycosylation assay 
To check whether PRKCSH and SEC63 can influence the maturation and expression of LRP5, 
HEK293T wild type cells,  2 PRKCSH knock-out cell lines and a SEC63 knock-out cell line were 
transiently transfected with the pcDNA3.1V5His WT-LRP5 construct because of the low 
endogenous LRP5 expression in HEK293T cells. After 48 hours cells were lysed with lysis 
buffer (50 mm Tris–HCl (pH7.5), 150 mm NaCl, 1% NP-40, 0.1% SDS) on ice with complete 
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protease inhibitor cocktail (Roche). Total protein was subjected to Endoglycosidase H or N-
Glycosidase F (Roche) treatment according the manufacturers manual. 20 Micrograms of 
treated and non-treated total protein samples were subsequently analyzed using SDS-PAGE 
followed by western blotting. LRP5 was visualized by the Clarity ECL-kit (Bio-Rad 
Laboratories, Hercules, CA)  using the primary V5-antibody (Life Technologies) and the 
secondary rabbit anti-mouse-HRP antibody (Dako; Glostrup, Denmark).  
mRNA levels of the cell lines were analyzed by isolating RNA using TRIZOL (Life Technologies) 
according the manufacturers manual. cDNA was produced using iScript cDNA Synthesis Kit 
(Bio-Rad). Real time PCR was performed in triplicate with SybrGreen using primers LRP5  
forward (5’- GAGATCCTCCGTAGGTCCGT-3’) and reverse (5’- CCAAGCGAGCCTTTCTACAC-3’) 
or primers housekeeping gene B2M forward (5’- ATGAGTATGCCTGCCGTGTG-3’) and reverse 
(5’- CCAAATGCGGCATCTTCAAAC-3’). The protein and mRNA measurements were performed 
in duplicate. 
Wnt Luciferase Activity Assays 
We performed Wnt luciferase assays as described previously (2). For the activity assay, we 
seeded 5.0 × 103 HEK293T cells, or 5.0 × 103 human cholangiocyte 69 (H69) cells per well in a 
96-well plate in triplicate. After 24 h, we transiently transfected cells using FuGene HD 
(Promega) with 100 ng LRP5 construct or empty vector and 100 ng of TCF/LEF1 Reporter or 
100 ng negative control according to the manufacturers’ instructions (Cignal TCF/LEF1 
Reporter Assay Kit; Qiagen). Twenty-four hours after transfection, medium was replaced by 
medium with or without 50% Wnt3a conditioned medium to initiate Wnt signaling. We 
cultured cells for another 24 h, and detected luciferase activity using the Dual-Glo Luciferase 
Assay System (Promega) in an InfiniteM200-Pro plate reader (Tecan, Männedorf, 
Switzerland). Firefly luciferase activity was normalized to Renilla luciferase activity to correct 
for variations in transfection efficiencies. Values are reported as means ± S.E.M. Each 
experiment was conducted in triplicate.  
RNA isolation and RT-qPCR 
Total RNAs were isolated using TRIzol according to the manufacturer’s protocol. We reverse 
transcribed RNA into complimentary DNA (cDNA) using a iScript cDNA synthesis kit according 
to the protocol (Bio-Rad, Hercules, USA). 1 µl of resulting cDNA was used for RT-qPCR. 
Briefly, the RT-qPCR was carried out on an thermal cycler (CFX96, Bio-Rad), using the 2−ΔΔCt 
SYBR green protocol (57). We amplified axin 2 and beta-2-microglobulin (reference) in 40 
cycles. RT-qPCR data were analyzed using the CFX-Manager software, which validates primer 
quality by analyzing melting curves. All the RT-qPCRs were repeated three times with 
triplicates for each treatment. For RT-PCR, all values were represented as mean ± S.D. 
Statistical analysis 
For cilia measurements, luciferase assays, and RT-qPCR we used Mann-Whitney test to test 
for significance. A two-tailed P-value of <0.05 was considered significant.  
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Results 
 
Figure 1. PLD-associated protein interaction network. (A) The network is constructed using mass 
spectrometry data of the indicated tandem affinity purified PLD proteins PRKCSH, SEC63, LRP5 or the 
intracellular domain of LRP5 (in purple) as bait in HEK293T and H69 cells. Except for GANAB/GIIA and 
SEC61A1, proteins shown are either selected for their uniqueness in this dataset (the size of the node 
is proportional to the uniqueness) compared to a recently published large protein interaction dataset 
((32), bait count ≤10) or are identifed in the affinity purification data of at least two out the three 
different TAP-tagged bait proteins (LRP5, PRKCSH, SEC63), and identified in replicate experiments. 
Proteins highlighted in green are discussed in the results. (continued on next page)   
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(continued from last page) FLNA is a SYSCILIA gold standard protein ((56) (red border). The network 
was visualized using Cytoscape software (54). (B-G) SEC63 and LRP5 associate with FLNA in vitro. (B-
D) Western blot analysis of HEK293T cell co-immunoprecipitation containing either PRKCSH, SEC63 or 
LRP5 as bait protein. An antibody against FLAG showed the input of bait proteins PRKCSH, SEC63 or 
LRP5 respectively. (E) Following co-immunoprecipitation with PRKCSH as bait, an antibody against 
FLNA detected no co-precipitating protein at 280 kDa, corresponding to the expected size of FLNA on 
western blot. (F, G) Following co-immunoprecipitation with SEC63 (F) or LRP5 (G) as bait, an antibody 
against FLNA detected a specific co-precipitating protein of 280 kDa, corresponding to the expected 
size of FLNA on western blot. Arrow: Expected size of FLNA.  
Table 2A: Selected proteins captured with PRKCSH as bait 
Protein # out of 19 TAPs found Protein coverage (average) 
PRKCSH 19 51% 
α-subunit glucosidase (GIIA) 19 57% 
Peroxisomal biogenesis factor 14 
(PEX14) 
5 19% 
nucleoporin 210kDa (NUP210) 5 13% 
Filamin A (FLNA) 3 5% 
Myosin IB (MYO1B) 3 7% 
 
Table 2B: Selected proteins captured with SEC63 as bait 
Protein # out of 4 TAPs found Protein coverage (average) 
SEC63 4 57% 
SEC61B 4 38% 
SEC61A1 4 17% 
transducin (beta)-like 2 (TBL2) 4 45% 
Thymopoietin (TMPO) 4 35% 
ADP-ribosylation factor GTPase 
activating protein 1 (ARFGAP1) 
4 33% 
Methionyl-tRNA synthetase (MRS) 4 13% 
Dynein, axonemal, heavy chain 7 
(DNAH7) 
4 2% 
Metadherin (MTDH) 3 8% 
Filamin A (FLNA) 2 12% 
Peroxisomal biogenesis factor 19 
(PEX19) 
1 10% 
 
Tandem affinity proteomics determines the PLD-associated interactome 
We performed affinity proteomics to identify putative physical connections between the 
molecular machinery of PRKCSH, SEC63, and LRP5, and to find molecular clues for the 
observed abnormalities (Fig. 1). Tandem affinity purification followed by mass spectrometry 
was performed both in H69 cholangiocytes as well as in HEK293T cells. Recently, we and 
others demonstrated that HEK293T cells are very efficient in assessment of interacting 
protein complexes and networks, both of the entire cell (32) as well as of a specific organelle 
such as the cilium (33). In total, we performed 5 experiments with the full length LRP5 
protein, 6 experiments with the LRP5 intracellular domain (ICD), 7 experiments with SEC63, 
and 19 experiments with PRKCSH, resulting in 2357 TAP-MS identifications (Table S1, Fig. 1). 
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PRKCSH TAPs captured 233 proteins, and 94 remained after filtering. SEC63 bait caught 353 
prey proteins, 155 of which remained after filtering. LRP5 TAPs captured 371 proteins, and 
filtering left 119 proteins. Glucosidase IIA (GIIA), the main binding partner of PRKCSH/GIIB, 
was present in all 19 PRKCSH TAP experiments (Fig. 1). Five PRKCSH TAPs captured 
nucleoporin 210kDa and another five caught peroxisomal biogenesis factor (PEX) 14. SEC63 
captured interaction partners SEC61B and SEC61A1 in four of seven experiments, and one 
SEC63 TAP captured another peroxisomal biogenesis factor, PEX19. Since peroxisomes 
require the ER for their formation (34), we assessed peroxisome formation in our knockout 
cells. We found that peroxisome formation was uninhibited as determined by 
immunofluorescence for PEX14 (Fig. S1). LRP5 full-length protein did not localize to the 
primary cilium (Fig. S2). GIIA was identified to associate to the LRP5 ICD complex in two out 
of six experiments, without PRKCSH/GIIB being detected. Interestingly, Filamin A (FLNA) was 
found to interact with all three bait proteins (detected in 9/37 TAP experiments). Although 
immunofluorescence did not indicate co-localization of FLNA with the bait proteins (data not 
shown), co-immunoprecipitation confirmed the presence of small amounts of FLNA with 
SEC63 and LRP5ICD (Fig. 1B). GIIA was also present with co-immunoprecipitation. These 
results indicate that LRP5 protein might interact with GIIA, and that all proteins underlying 
ADPLD might have an interaction with FLNA in common.  
Table 2C: Selected proteins captured with LRP5 full-length protein as bait 
Protein # out of 4 TAPs found Protein coverage (average) 
LRP5 4 22% 
kinesin family member 11 (KIF11) 3 7% 
proteasome 26S subunit, non-
ATPase 12 (PSMD12) 
3 8% 
Filamin A (FLNA) 2 10% 
 
Table 2D: Selected proteins captured with LRP5-ICD as bait 
Protein # out of 6 TAPs found Protein coverage (average) 
LRP5 6 9% 
protein phosphatase 2, catalytic 
subunit, beta isozyme (PPP2CB) 
6 17% 
protein phosphatase 2, regulatory 
subunit B, alpha (PPP2CA) 
6 30% 
chromobox homolog 3 (CBX3) 5 18% 
phospholipase B domain containing 2 
(PLBD2) 
5 6% 
carboxypeptidase, vitellogenic-like 
(CPVL) 
3 10% 
Filamin A (FLNA) 2 2% 
α-subunit glucosidase (GIIA) 2 2% 
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Figure 2. PRKCSH and SEC63 localize to the ER of H69 cholangiocytes, without any presence in 
primary cilia. (A) PRKCSH (red) co-localizes with ER-marker PDI (green). (B) SEC63 (red) co-localizes 
with ER-marker PDI (green). (C) PRKCSH (red) does not co-localize with cilia-marker ARL13B (green). 
(D) SEC63 (red) does not co-localize with cilia-marker ARL13B. (A–D) DAPI (blue) stains the nuclei; 
size bars correspond to 20 µm. (E, F) PRKCSH and SEC63 localize to the ER of ciliated H69 
cholangiocytes, without any presence in primary cilia. (E) PRKCSH (red) does not co-localize with cilia-
marker ARL13B (green). Arrows indicate cilia. (F) SEC63 (red) does not co-localize with cilia-marker 
ARL13B. Arrows indicate cilia. (E, F) DAPI (blue) stains the nuclei; size bars correspond to 10 µm. 
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PRKCSH and SEC63 TAPs captured mainly ER localized proteins, most of which are implicated 
in ER protein synthesis, including many ribosomal proteins (Table 1; Table S1). 
Immunofluorescence staining co-localized PRKCSH and SEC63 protein products with protein 
disulfide isomerase (PDI), a resident enzyme of the ER, without any detectable signal at 
primary cilia (Fig. 2), which was in line with our affinity proteomics results. 
CRISPR-Cas9 induced knockdown of PRKCSH and SEC63 disrupts ciliogenesis 
In order to study the effect of PRKCSH, SEC63, and LRP5 mutations, the genes were knocked 
out in H69 cholangiocyte and HEK293T cells using CRISPR-Cas9 technology to introduce 
deletions resulting in loss of protein. All constructs were effective in inducing mutations, 
albeit with different efficiencies (Fig. S4 and S5). We subsequently assessed PRKCSH and 
SEC63 clones expected to have bi-allelic deletions for loss of protein on western blots (Fig. 
S6). Two knockout clones per gene were selected for HEK293T cells and H69 cholangiocytes, 
which all completely disrupted the cognate protein production. 
Cilium formation of PRKCSH and SEC63 knockout cells was clearly diminished when 
compared to controls, for both H69 and HEK293T cells (Fig. 3A-D; Fig. S7). Both stress-free 
proliferative as well as serum-starved ciliogenic conditions displayed decreased ciliogenesis 
of knockout cells. Wildtype (WT) H69 cholangiocytes had cilia on 33.1%  5.7% of cells, 
PRKCSH-/- H69 on 10.3%  3.43% (p<0.0001) of cells and SEC63-/- H69 on 8.7%  1.9% 
(p<0.0001) of cells. WT HEK293T showed cilia on 9.0%  3.7% of cells, whereas PRKCSH-/- and 
SEC63-/- HEK293T displayed cilia on 2.3%  1.3% (p=0.0002), and 4.2%  1.9% (p=0.004) of 
cells respectively. Evaluation of the cell cycle progression by flow cytometry did not reveal 
major differences (Fig. 3E, Fig. S8), although a small shift could be observed of the 
population of cells in G1 (slightly decreased) to G2 (slightly increased) upon SEC63 knockout, 
while the percentage of cells in S phase is the same as in WT cells (Fig. 3E). No significant 
differences in any cell cycle phase could be observed upon PRKCSH depletion. These data 
indicate that mutations in the genes underlying ADPLD significantly reduce ciliogenesis. 
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Figure 3. Depletion of PRKCSH or SEC63 in cholangiocytes disrupts ciliogenesis. (A) H69 
cholangiocytes form cilia upon serum depletion. Cilia are marked by the ciliary GTPase ARL13B 
(green). (B) CRISPR-Cas9 mediated knock-down of PRKCSH significantly reduces the frequency of cilia. 
(C). CRISPR-Cas9 mediated depletion of SEC63 renders a similar reduction of ciliogenesis. (A–C) DAPI 
(blue) stains the nuclei; size bars correspond to 20 µm. (D) Graphical representation of the significant 
reduction of the number of cells that carry cilia (shown in (A–C)) in cells depleted of PRKCSH (69% 
reduction) or SEC63 (74% reduction) compared to wildtype cells in three independent experiments. 
*: p < 0.05 (E) Graphical representation of cell cycle distribution in WT versus PRKCSH or SEC63 KO 
HEK293 cells, determined by flow cytometric analysis of cell cycle with propidium iodide DNA 
staining (plots included in online Supplementary Material, Fig. S7). Results are expressed as % of 
counted cells in each phase of the cell cycle. Two independent experiments; means ± standard 
deviations are presented. *: p = 0.0005. 
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Knockdown of PRKCSH and SEC63 reduce Wnt signaling in H69 cholangiocytes 
Since Wnt signaling is disrupted by LRP5 mutations of ADPLD, and can be affected by 
mutation of ciliary genes, we assessed Wnt signaling in PRKCSH and SEC63 knockouts using a 
TCF/LEF1 luciferase reporter assay. Wnt signaling was significantly decreased due to loss of 
PRKCSH and SEC63 in H69 cholangiocytes in three independent experiments (Fig. 4). Wnt3a-
treated WT H69 cells showed a significantly higher luciferase activity (2,2  0,1; 1,3  0.02) in 
both ciliated and non-ciliated conditions in comparison to PRKCSH-/- (1,0  0,07, p=0,0056; 
0.83  0.03, p=0,0019) and SEC63-/- cells (1,0  0,05, p=0,0019; 0.64  0.01, p<0,0001).  
 
Figure 4. Depletion of PRKCSH and SEC63 in cholangiocytes and loss of LRP5 impairs Wnt signaling.  
(A) TCF/LEF1 luciferase assays to measure levels of activated β-catenin, and hence canonical Wnt 
signaling following transfection of indicated cell line by reporter constructs. Knockout H69 
cholangiocytes with cilia induced by serum starvation (‘cilia+’) display significantly decreased Wnt 
signaling in comparison to controls. (B) TCF/LEF luciferase assays as in (A). Knockout H69 
cholangiocytes in normal conditions that induce no extra cilia (‘cilia-’) also display significantly 
decreased Wnt signaling in comparison to controls. (C) TCF/LEF luciferase assays as in (A). Depletion 
of Wnt co-receptor LRP5 in HEK293T cells leads to reduced Wnt signaling under conditions as in (B).  
(D) Co-transfection of luciferase assay as in (A) together with LRP5 constructs as indicated. We used 
LRP5 mutant constructs that contained recently identified ADPLD mutations (2), which demonstrated 
decreased Wnt signaling. Three out of eight mutant LRP5 constructs showed impaired Wnt signaling. 
Constructs are numbered as in table S2 (1. LRP5 c.1360G>A, p.Val454Met, 2. LRP5 c.1680G>T, 
p.Trp560Cys, 3. LRP5 c.3562C>T, p.Arg1188Trp, 4. LRP5 c.4587G>C, p.Arg1529Ser, 5. LRP5 
c.4651G>A, p.Asp1551Asn, 6. LRP5 c.3468G>C, p.Gln1156His, 7. LRP5 c.3403C>T, p.Arg1135Cys, 8. 
LRP5 c.3107G>A, p.Arg1036Gln.). (A-D): *: p<0.01, Mann-Whitney U-test.  
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Additional testing confirmed this pattern. Two different H69 knockout clones with knockout 
of PRKCSH or SEC63 displayed similarly decreased Wnt signaling (Fig. S9A), while tests using 
axin2 mRNA expression as Wnt readout showed consistent results (Fig. S9B). In contrast, in 
HEK293T cells Wnt signaling was not affected by loss of PRKCSH and inconsistently affected 
by loss of SEC63 (Fig. S9C, D). For SEC63-/- HEK293T cells effects on Wnt signaling appeared 
to be clone rather than mutation specific. 
LRP5 glycosylation is not dependent on PRKCSH and SEC63 
As a disrupted function of the glucosidase PRKCSH/GIIB (and also GANAB/GIIA that was 
identified in our TAP dataset) is expected to induce N-glycosylation defects, we evaluated if 
LRP5 was a substrate affected by CRISPR-Cas9 mediated PRKCSH knockout, and if possibly 
SEC63 also plays a role in this. Our glycosylation assay showed that LRP5 is similarly 
glycosylated between WT, PRKCSH-/- and  
SEC63-/- HEK293T cells (Fig. 5A). Endo F and Endo H treatment similarly removed N-
glycosylation of LRP5 between the types of cells, as indicated by the reduced molecular 
weight of the protein on western blot (Fig. 5A). Interestingly, the LRP5 signal intensities 
seemed to be decreased in the knockout cells. This was confirmed by evaluation of LRP5 
protein expression levels in relation to β-actin (Fig. 5B). To evaluate if the reduced levels 
were caused by a transcriptional downregulation, we assessed the LRP5 mRNA levels in the 
knockout cells, which were not reduced and even slightly increased (Fig. 5C).  
 
Figure 5. ADPLD knockouts show reduced expression of LRP5, without an abnormal protein 
glycosylation pattern. (A) Both WT and ADPLD knockout cell lines only display glycosylated LRP5. N-
glycosylation can be removed by Endo F and Endo H treatment, resulting in a smaller protein and 
molecular weight. (B) LRP5 expression is reduced in ADPLD knockout cells in comparison to wildtype 
cells, without a comparative loss in β-actin expression, indicating that the reduction is induce by loss 
of PRKCSH or SEC63. (C) Relative LRP5 mRNA expression is slightly increased in PRKCSH and SEC63 
knockout cells in comparison to WT cells. PRKCSH1-/-= PRKCSH-/- clone 1; PRKCSH2-/-= PRKCSH-/- 
clone 2. 
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Effects of patient LRP5 mutations on Wnt signaling in LRP5-/- HEK293T 
HEK293T cells without LRP5 displayed significantly impaired Wnt signaling in comparison to 
wild-type cells (Fig. 4C). Transfection of these cells allowed assessment of Wnt signaling 
abnormalities without presence of endogenous LRP5. We used LRP5 mutant constructs that 
contained recently identified ADPLD mutations (2) that demonstrated decreased Wnt 
signaling (Table S2). Three out of eight mutant LRP5 constructs showed impaired Wnt 
signaling (Fig. 4D). Specifically, construct 1 (c.1360G>A, p.Val454Met), construct 2 
(c.1680G>T, p.Trp560Cys), and construct 3 (c.3562C>T, p.Arg1188Trp) significantly decreased 
Wnt signaling, while construct 5 (c.4651G>A, p.Asp1551Asn) decreased it all three times 
without reaching significance. The remaining mutant constructs were either similar to or 
higher than the wild-type construct in luciferase intensity.  
Discussion 
Here we show that cyst genes and proteins involved in liver cyst development play an 
important role in Wnt signaling and cilium formation. CRISPR-Cas9 induced knockout of 
PRKCSH and SEC63 in HEK293T and H69 cells leads to a significant decrease in cilium 
formation, without affecting cell proliferation. Independent of cilium number, Wnt signaling 
is decreased in H69 PRKCSH-/- and SEC63-/- cells. By contrast, HEK293T KO cells show clone-
dependent effects on Wnt signaling. Finally, patient’s LRP5 mutant constructs show reduced 
Wnt signaling compared to wildtype LRP5 in LRP5-/- HEK293T cells. 
Affinity purification experiments confirm known interactor GIIA for PRKCSH, and SEC61 
complex proteins for SEC63, validating the current approach. It shows that PRKCSH and 
SEC63 interact with PEX14 and PEX19 respectively. The identification of these peroxisomal 
proteins confirms previous studies. Peroxisomes form in the ER, where they bud off in foci to 
form mature peroxisomes (34). PEX14 is localized in the ER near SEC63 when newly formed 
(35), and combined SEC62/SEC63 loss impairs peroxisome biogenesis. Although liver cysts 
may be found in peroxisome biogenesis disorders (36), our findings indicate no further link 
to ADPLD development. Single loss of PRKCSH or SEC63 did not affect PEX14 presence or 
localization in our cell lines.  
We were able to discover novel PRKCSH interacting partners, such as NUP210, FLNA, and 
MYO1B, while SEC63 complex interactors include TBL2, TMPO, ARFGAP1, MRS, DNAH7, 
MTDH, and FLNA. No Wnt signaling interactors are present for LRP5 full-length protein or 
intracellular domain, but LRP5 was found in a complex with KIF11, PSMD12, FLNA, PPP2CA, 
PPP2CB, CBX3, PLBD2, CPVL, and GIIA.  
Several of our findings do further implicate Wnt signaling in hepatic cystogenesis, which 
pathway has previously been found to cause cyst development (2, 29, 37, 38). First, the 
interaction of LRP5-ICD with GIIA points towards n-glycan processing of this part of LRP5. 
Second, loss of ADPLD genes PRKCSH and SEC63 in H69 cells leads to a small decrease in Wnt 
signaling, and, third, this small Wnt signaling decrease is similar to that observed for LRP5 
mutations present in ADPLD families ((2) and this study). An explanation may be that n-
glycosylation of LRP6 is necessary for its maturation and plasma membrane localization (25). 
LRP5 processing may be similarly n-glycosylation dependent, which protein displays 
approximately 71% homology (39) and contains at least four predicted n-glycosylation sites 
((40-42), (http://www.cbs.dtu.dk/services/NetNGlyc/). It is unknown whether LRP5 
maturation and membrane translocation also requires SEC63 and the SEC61 complex, like 
many transmembrane proteins (43, 44), but SEC63 has been linked previously to Wnt 
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signaling through nucleoredoxin (26). Interestingly, GANAB, the gene encoding GIIA, is the 
most recently identified ADPKD and ADPLD gene (4), and required for maturation of PC1. 
The N-glycosylation of LRP5 however, that we could observe in HEK293T cells (Fig. 5) was not 
diminished by depletion of either PRKCSH/GIIB or SEC63, which suggests that LRP5 is not a 
substrate of glucosidase II and SEC63 is not involved in the regulation of LRP5 N-
glycosylation. Our findings together strengthen the case for Wnt signaling abnormalities as a 
common contributing factor in hepatic liver cyst development. If this is unrelated to 
maturation and trafficking of polycystin-1 remains to be identified. The fact that we 
determined that knock out of either PRKCSH or SEC63 led to reduced levels of LRP5, while 
the transcript levels were slightly elevated, suggests connectivity of the ADPLD-associated 
pathways downstream of gene transcription. 
The cell-line dependent effect of PRKCSH and SEC63 loss on Wnt signaling is a surprising 
finding. This is either a limitation to the applicability of our findings, especially regarding the 
use of HEK293T cells   to evaluate this as in contrast to the H69 cholangiocytes, this cell line 
shows variability between different knock out clones. However, it may also point towards a 
tissue-specific effect of loss of ADPLD genes. In man, PRKCSH and SEC63 mutation only leads 
to significant cyst development in the liver, and little to no cyst development in the kidney 
(45). Another limitation is that ciliary formation did not affect Wnt signaling impairment. 
Wnt signaling is putatively inhibited by primary cilia (30, 31), but Wnt signaling was impaired 
in both proliferative (low cilia formation) and serum-starved (high cilia formation) 
conditions. Cilium-independent mechanisms, such as those described above, are therefore 
most likely the cause of the observed Wnt defect. 
Filamin A may provide a link between the PLD proteins, ciliogenesis and Wnt signaling. 
Although with the available reagents no co-localization could be identified with PRKCSH, 
SEC63 and LRP5, co-immunoprecipitation indicates the protein might link to SEC63 and LRP5. 
Filamin A is a molecular scaffold protein involved in cell motility and signaling, and interacts 
with a large number of proteins (46). The protein is part of the SYSCILIA gold standard 
protein list of known ciliary components (47). Filamins crosslink cortical actin filaments into a 
dynamic 3D structure, and are thought to function as a signaling scaffold for a variety of 
cellular processes. Filamin A has been shown to be important for stability of meckelin and 
polycystin-2 (48, 49), and FLNA loss leads to basal body positioning and ciliogenesis defects 
(48). The meckelin-filamin A interaction may additionally be required to maintain correct 
levels of Wnt signaling. 
Ciliogenesis is also defective in PLD in comparison to healthy tissues. Normal biliary ducts 
have solitary, cylindrical primary cilia on virtually all cells, with a length >4µm. In medium-
sized hepatic cysts (1-3cm diameter) cilia are short (1.25 ± 0.29 μm) and rare (1/200 cells), 
and the organelles are absent from larger cysts (>3cm diameter) (50, 51). Our findings 
indicate that loss of PRKCSH and SEC63 may lie at the root of these ciliary abnormalities. 
Both H69 and HEK293T cells with loss of these genes display a significant decrease in cilium 
formation under proliferative and serum-starvation conditions. This implicates structural 
ciliary abnormality in addition to previously found functional abnormality (12-14) in ADPLD 
cells.  
In conclusion, our results suggest that loss of PRKCSH and SEC63 leads to general defects in 
ciliogenesis, while quenching of the Wnt signaling cascade is cholangiocyte-restricted. 
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Interactions of all three PLD-associated protein complexes with FLNA may mark a common 
link between the ADPLD proteins and the cystogenic processes driving this disease. 
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Abstract 
Backgrounds & aims: Polycystic liver disease (PLD) is an autosomal dominantly 
inherited disorder caused by mutations in genes such as PRKCSH and SEC63. It 
has been thought that cysts develop from biliary progenitor cells due to loss-of-
heterozygosity (LOH), leading to aberrant proliferation or defects in 
differentiation. Cyst expansion can be suppressed by somatostatin analogues 
such as lanreotide. There is no human in vitro model available that truly 
recapitulates polycystic liver disease. We hypothesize that PLD progenitors can 
form bipotent liver organoids that carry key features of cyst development.  
Methods: Cells from normal biliary duct (n=6), cyst biliary epithelium (n=60) and 
cyst fluid (n=31) were isolated and placed under conditions suitable for 
expansion of human adult liver stem cells. We analyzed genetic LOH, gene 
expression, differentiation capacity, response to lanreotide and cilium formation 
of these organoids.  
Results:  Cholangiocytes from cyst biliary epithelium (47/60) and cyst fluid 
(9/31) proved capable of expanding as bipotent liver organoids. Multiple cyst 
organoids displayed LOH surrounding PRKCSH or SEC63 regions. Organoids 
formed cilia when proliferation was inhibited. Neither expansion nor 
differentiation of PLD organoids was impaired. RNAseq revealed differential gene 
expression depended on organoid genetic background. Lanreotide significantly 
decreased expansion of liver organoids in comparison to negative control (197% 
 46% versus 547%  28%; p: 0.038).  
Conclusions: Biliary progenitor cells from patient cyst epithelium and fluid 
expand into liver organoids. They recapitulate key characteristics of PLD, and are 
a promising human in vitro model for research, diagnostics and treatment of 
polycystic liver diseases and cholangiociliopathies.  
Lay summary 
Self-renewing cells of liver cysts, abnormal fluid-filled sacs, can be grown outside 
of the body. Grown in this manner, they are a promising development for 
research, diagnosis and treatment of various diseases of the liver.  
Keywords 
Liver disease, Cholangiocytes, Disease model, RNAseq, Drug test 
  
Introduction 
Polycystic liver disease (PLD) is a phenotypical expression of isolated polycystic liver disease 
(ADPLD), and of autosomal dominant polycystic kidney disease (ADPKD)(1). PLD is caused by 
germline mutations in PRKCSH, SEC63, LRP5, PKD1, and PKD2 (1, 2). ADPKD is the most 
prevalent (~1:1,000) (genetic) cause of end-stage renal disease. By contrast, ADPLD is 
infrequent and seen in ~1/158,000 of the general population. Patients with ADPKD have an 
increased total liver volume, and a recent study found that 81% of female ADPKD patients 
have severe hepatomegaly (3). An important feature of PLD is increased cholangiocyte 
proliferation and fluid secretion, causing symptoms related to abdominal distension. This 
can be suppressed by somatostatin analogues such as lanreotide (4-6).  
A common event that underlies these autosomal dominant disorders is complete loss of cyst 
gene expression from diseased epithelium (7-12). This is the result of the presence of a 
germline mutation that is accompanied by somatic inactivation of the second allele of a PLD 
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gene (second hit). The target cell of this genetic process is likely to be the cholangiocyte that 
carries stem-cell like capacities. Although this is an attractive concept, experimental data 
that demonstrated expansion from mutated cholangiocytes into a cyst are lacking.  
Cyst development is thought to be dependent upon ductal plate malformation (DPM) (1, 13) 
caused by disturbed differentiation of biliary precursors, impaired maturation of bile ducts, 
or abnormal duct expansion. Experiments in animal models have shown that the specific 
mechanism is dependent on the genetic background (1, 13).  Progress in studies on of the 
mechanism of cystogenesis in presence of PLD mutations has been hampered because 
models that rely on  biliary differentiation of human induced pluripotent stem, embryonic, 
or HepaRG cells are incomplete. These cells are derived from non-cystic tissues that do not 
have the same genetic make-up, including second hit mutations, as human cysts (14, 15). 
Thus far, no human 3D cyst model that possesses second hits, and that is capable of 
differentiation has been available.  
Recent studies have indicated that there are novel treatment options for PLD (16, 17), but at 
the same time highlight limitations of current models. There is poor access to primary 
human biliary tissue, which limits the scale of experiments. This illustrates the need for a 
more reliable human in vitro cyst model allowing large-scale pharmacological screens. 
The discovery of a method that allows unlimited expansion of liver derived bipotent stem 
cells opens avenues for development of a novel model (18-20).  We hypothesize that PLD 
cholangiocyte-like stem cells can develop into bipotent liver organoids with cyst like 
features. Here, we describe the isolation of cholangiocytes from human cyst biliary 
epithelium and cyst fluid, their expansion into bipotent liver organoids, and their stem cell, 
cholangiocyte and PLD-associated phenotype. We compare PLD-associated and normal stem 
cells by gene expression profiling, and assess their capacity to differentiate into hepatocytes 
and biliary cells. Finally, we demonstrate the translational value of liver organoids by 
evaluating the response to lanreotide on their expansion, and the presence of the molecular 
machinery required to respond to somatostatin analogues.  
Methods 
 
Patient material 
We obtained cyst epithelial cells from 40 patients with 91 PLD or with sporadic cysts. From 
this input material, 56 cysts from 17 patients could be included for this study. All included 
patients were female and had a median age of 54 years (43-70). Written informed consent 
was obtained for the use of secondary tissue, and samples were collected under appropriate 
ethics approval (“Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen”).  
Cholangiocyte isolation 
Primary human cyst epithelial cells were derived from surgical biopsies obtained through 
laparoscopic cyst fenestration, or isolated from cyst fluid that was acquired during aspiration 
sclerotherapy. Whole blood was collected from these patients. We obtained biopsies from 
healthy liver from clean resection margins of colorectal cancer liver metastasis surgery. 
Cholangiocytes were isolated from normal biliary ducts as described earlier (21), without 
enrichment for liver progenitors. Briefly, 0.5-1cm3 tissue was rinsed with DMEM (GIBCO by 
Invitrogen, Carlsbad, CA, USA) with penicillin/streptomycin, and minced using preparative 
scissors. Minced tissue was then incubated for 1 hour at 37 degrees C in digestion solution 
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(2.5 mg/ml collagenase B (Roche, Mannheim, Germany), 0.1mg/ml DNase I (Sigma, St. Louis, 
MO, USA) in HBSS containing Ca2+ and Mg2+ (GIBCO)) while slowly mixing on a magnetic 
stirrer (MR2002; Heidolph, Schwabach Germany). Digestion was stopped by adding DMEM 
with 1% FCS (GIBCO).  
Cells were isolated from cyst epithelium by incubation of the luminal side of epithelia on 500 
µL 50mM EDTA for 30 minutes at room temperature. Remaining tissue was further prepared 
as tissue from normal biliary ducts, with elongation of the collagenase digestion step to 2-3 
hours. Isolated cells from this second isolation were frozen in stocks. Organoid cultures were 
preferentially started from the EDTA isolation to maximize presence of cyst lumen derived 
cells. If this was unsuccessful, frozen stocks of collagenase isolated cells were used.  
Cells from cyst fluid of aspiration sclerotherapies were spun down by centrifugation. To 
maximize live cell numbers, 10 µL of spun-down cells were seeded along with 25 µL Matrigel. 
Any remaining cells were frozen as stocks. In case of organoid growth, cells were passaged 
until a stable culture was established. If growth-arrest occurred, additional cells from the 
frozen stock were subsequently seeded and passaged until a culture was founded.  
Human adult bipotent liver stem cell expansion medium 
Expansion medium (EM) consisted of AdDMEM/F12 (Invitrogen) with 1% N2, B27 (minus 
vitamin A) supplements (both from GIBCO), 1,25mM N-Acetylcysteine (Sigma),  10mM 
nicotinamide (Sigma), 50ng/ml EGF (Peprotech), 1ug/ml Rspo1 (Peprotech), 10nM gastrin 
(Sigma), 25 ng/ml HGF (Peprotech , Offenbach, Germany), 100ng/ml FGF-10 (Peprotech), 5 
µM A83.01 TGF-β inhibitor (Tocris, Ellisville, MO, USA), and 10 µM forskolin (Tocris). The first 
3-4 days after seeding cells, 50% Wnt CM (homemade prepared as described in (22, 23), and 
10 µM Y27632 Rho-kinase inhibitor (Sigma) were added. Cells (~10,000) were seeded in 25 
µL growth factor-reduced Matrigel (BD Biosciences, San Jose, CA, USA) in non-attaching 48-
wells plates (BD Biosciences). EM was replaced every 2-4 days. After 10-14 days, organoids 
were removed from Matrigel, mechanically dissociated and seeded in fresh Matrigel. Cells 
were subsequently passaged every 7-14 days with a 1:3 to 1:8 ratio, depending on the 
number of organoids.  
Long-term organoid storage 
Frozen stocks were prepared from dissociated organoids mixed with AdDMEM/F12 
(Invitrogen) with 10% DMSO, then placed overnight in -80 degrees C, followed by -180 
degrees C nitrogen storage.  
Hepatocyte and biliary differentiation medium 
For hepatocyte differentiation, 25ng/ml BMP7 (Peprotech) was added to the EM 7-10 days 
prior to splitting. Following 2-4 days of culture with EM + BMP7, hepatocyte differentiation 
medium (hDM) was added. hDM consisted of AdDMEM/F12 with 1% N2, B27 (minus vitamin 
A) supplements, 50ng/ml EGF, 10nM gastrin, 25ng/ml HGF, 500nM A83.01 TGF-β inhibitor, 
as well as 10uM DAPT (Abcam, Cambridge, MA, USA), 30uM dexamethasone (Sigma) and 
100ng/ml FGF19 (Peprotech). Biliary differentiation medium consisted of EM without Rspo1, 
nicotinamide, A83.01 TGF-β inhibitor, and forskolin. Organoids were cultured in biliary 
differentiation medium (bDM) for seven days before experiments.  
For induction of cilia, cells were cultured for seven days in normal expansion medium, and 
100nM nocodazole (Sigma) was added 2 hours before fixation (24).  
 Bipotent adult stem cells derived from cyst epithelium expand into organoids | 97 
retaining key characteristics of polycystic liver disease   
 
 
DNA isolation  
Organoids were removed from medium and mechanically dissociated before DNA isolation. 
Only organoids with less than 5 passages were used for DNA isolation.  DNA from organoids 
was isolated using the QIAamp DNA Micro kit (Qiagen) according to the manufacturer’s 
protocol, and stored at 4°C. For samples with low DNA yields, whole genome amplification 
using the Qiagen REPLI-g Mini kit (Qiagen) was performed. DNA was isolated from whole 
blood using the high pure PCR template preparation kit (Roche) according to the 
manufacturer’s protocol, and stored at 4°C.  
RNA isolation from organoids 
Organoids were removed from medium, mechanically dissociated before RNA isolation. For 
gene expression tests, RNA was isolated using Trizol (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. For RNA sequencing, RNA from organoids was 
isolated using the NucleoSpin® RNA kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturer’s protocol. Organoids used in RNA sequencing had been passaged less than 10 
times, and had been cultured under the same circumstances for two weeks prior to RNA 
isolation. 
Genotyping 
Whole blood patient DNA was screened for germline mutations in PRKCSH, SEC63, and LRP5 
using direct sequencing as described previously (8). Exons and flanking intronic sequences 
were amplified using polymerase chain reaction with specific primers (Supplementary Table 
1). The amplified fragments were purified (QIAEXII Gel Extraction Kit; Qiagen, Hilden, 
Germany) and sequenced with the BigDye Terminator Kit and ABI3730 capillary sequencer 
(Perkin-Elmer Applied Biosystems, Boston, MA).  
Cytogenic array analysis 
Copy-number variations and loss of heterozygosity (LOH) regions were assessed using 
genome-wide high resolution cytogenetic array analysis (CytoScan HD, Affymetrix, Santa 
Clara, CA, USA). For analysis of individual cytoscan HD data chromosome analysis suite 
(ChAS, Affymetrix) V2.1 was used.  
(reverse-transcriptase) Polymerase chain reaction 
Isolated RNA was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad, Veenendaal, 
the Netherlands). Targets were amplified for 40 cycles using gene-specific primers and Sybr-
Green (Life Technologies) in a thermal cycler (C1000 / CFX96, Bio-Rad). Primers used are 
listed in supplementary table 2. For RT-PCR, all values were represented as mean ± S.D. 
Mann-Whitney nonparametric test was used for statistical analysis, p < 0.05 was considered 
statistically significant. 
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Immunofluorescence  
Organoids were washed once and fixed whole-mount for 20 minutes using 
paraformaldehyde (PFA; 3.8%) at room temperature. Samples were subsequently 
permeabilized with PBS 0.5% Triton-x100 with 1% bovine serum albumin, and incubated 
overnight with primary antibodies. Following three washes with PBS 0.3% Triton-x100, 
samples were incubated 2 hours with secondary antibodies. Images were obtained using 
confocal microscopy (Olympus FV1000, Shinjuku, Tokyo, Japan). Antibodies used are listed in 
supplementary table 3 and 4.  
Scanning electron microscopy 
For cilium expression, organoids were grown in regular expansion medium on 8-well 
chambered cover slips (Ibidi, Martinsried, Germany). Matrigel containing organoids was cut 
open using a razor. Cells were washed once with PBS and fixed with 2% glutaraldehyde in 0.1 
M sodium cacodylate buffer for 1 h. After washing cells twice with sodium cacodylate buffer, 
cells were stored in this buffer at 4 °C until further fixation with 1% OsO4 (osmium tetroxide) 
for 30 min. Coverslips were then washed with 0.1 M sodium cacodylate buffer and 
dehydrated in a graded series of alcohol washes for 10 min each. Finally, coverslips were 
critical point dried, mounted on stubs, sputter coated with gold and viewed in a JEOL 
SEM6340F field emission scanning electron microscope.  
Library preparation 
RNA-seq libraries were prepared with the Illumina TruSeq mRNA Sample Preparation kit 
(Illumina Inc.; San Diego, CA, USA) according to the manufacturer’s protocol. Libraries were 
validated on an Agilent Bioanalyzer 2100. The standard protocol from Illumina for the 
preparation of RNA-SEQ libraries from total RNA includes a step in which polyA mRNA 
selection results in the removal of the bulk rRNA from the sample. This results in the removal 
of background signal. Synthesis of first and second strand cDNA was followed by end repair 
and addition of “A” to the ends and ligations of the adapters for sample multiplexing. 
Enrichment of the samples was carried out by PCR. The amplified libraries were size selected 
and libraries were quantified by PicoGreen assay (Life Technologies). We used TruSeqTM SR 
Cluster Kits v3 (Illumina) for cluster generation in an Illumina cBOT instrument following the 
manufacturer’s protocol. Six indexed libraries were loaded into each lane of flow cells. 
Sequencing was performed on an Illumina HiSeq 2500 instrument (Illumina) by the 
manufacturer’s protocol. Multiplexed two lanes of single-read runs were carried out with a 
total of 150 cycles per run (including 7 cycles for the index sequences). Custom programs 
were used to demultiplex individual samples using their unique index. Each sample had 25 
million reads on average. We used CLC Genomics Workbench 7 for RNAseq alignment and 
statistical analysis of the data. Human HG19 was used as reference sequence.  
Transcript Profiling 
The data discussed in this publication have been deposited in NCBI's Gene Expression 
Omnibus (Wills et al., 2015) and are accessible through GEO Series accession number 
GSE73579 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73579). 
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Gene expression analysis 
To calculate gene expression intensity, read counts were normalized to reads. Methods for 
data normalization and analysis are based on the use of “internal standards” (25) that 
characterize some aspects of the system’s behavior, such as technical variability, as 
presented elsewhere (26, 27). The comparison of these methods with some other 
normalization and analysis procedures was presented in (28). Created initially for the 
analysis of microarray data they were slightly modified to the needs of RNAseq data analysis.  
The two-step normalization procedure and the Associative analysis functions are 
implemented in MatLab (Mathworks; MA, USA) and available from authors upon request. 
These algorithms are also obtainable from an R package diffGeneAnalysis, available as a part 
of Bioconductor packages 
(http://www.bioconductor.org/packages/2.5/bioc/html/diffGeneAnalysis.html).  
Heatmaps were generated with the Spotfire Decision Site 9 (TIBCO; Palo Alto, CA, USA) with 
gene subsets created from the list of significant genes. Functional analysis of identified genes 
was performed with Ingenuity Pathway Analysis (Ingenuity® Systems; Redwood City, CA, 
USA, http://www.ingenuity.com).  Principal components analysis (PCA) was performed on 
log2-transformed normalized data to visualize variations between the samples of the 
different groups using R (version 3.1.11). 
Lanreotide and expansion experiments 
In three independent experiments, control (0.1 M acetic acid) or lanreotide (10−7M in 0.1M 
acetic acid) was added twice a day, at 12-hour intervals for seven days. Organoid 
development was followed by light microscopy and circumferential areas were quantified by 
Image J software (NIH). Data were expressed by percentage change in circumferential area 
(mean  SEM) on day 7 in comparison to day 1. Statistical analysis was performed by 
Student’s t-test.  
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Table 1. List of organoids and origin used in experiments. All cyst epithelium came from laparoscopic 
cyst fenestration, and all cyst fluids came from aspiration sclerotherapy. 
*: Limited to experiments shown in this article. We used only 1 line per experiment when multiple cyst 
lines from the same patient were available. p: passage 
Name Patient Origin Disease Mutation Passage 
time 
Organoid 
studies*  
PLD1 Female, 
45 years 
Epithelium ADPLD PRKCSH 
292+1G>C 
1 week - 
PLD2 Female, 
54 years 
Epithelium Solitary 
cyst 
- 1 week  IF, gene 
expression & 
differentiation, 
RNAseq (p6) 
PLD4 Female, 
55 years 
Fluid (300mL; 
turbid, orange) 
ADPKD Undetermined 2 weeks - 
PLD5 Female, 
55 years 
Fluid (2,5L; clear, 
yellow) 
Solitary 
cyst 
- 2 weeks - 
PLD7 Male, 59 
years 
Fluid (300mL; 
clear, yellow) 
ADPLD Unknown 2 weeks - 
PLD8.1-
8.10 
Female, 
56 years 
10 Epithelia ADPLD Unknown 1 week IF, gene 
expression & 
differentiation, 
RNAseq (p6) 
PLD9.1-
9.13 
Female, 
47 years 
13 Epithelia ADPLD PRKCSH 1362-
2A>G 
1 week Cytoscan, IF, 
RNAseq (p6) 
PLD10 Female, 
70 years 
Fluid (500mL; 
clear, yellow) 
ADPLD Unknown 2 weeks gene 
expression & 
differentiation, 
RNAseq (p4) 
PLD11 Female, 
52 years 
Epithelium ADPLD Unknown 1 week - 
PLD12.1-
12.4 
Female, 
61 years 
4 Epithelia ADPLD Unknown 1 week RNAseq (p5) 
PLD13 Female, 
51 years 
Fluid (970mL; 
clear, yellow) 
ADPLD SEC63 c.964del 1 week Cytoscan, IF 
PLD14.1-
14.16 
Female, 
50 years 
16 Epithelia ADPLD PRKCSH 1362-
2A>G 
2 weeks - 
PLD15 Female, 
52 years 
Fluid (100mL; 
clear, yellow) 
ADPKD PKD1 
c.182C>T 
1 week RNAseq (p6) 
PLD16.1-
16.14 
Female, 
47 years 
14 Epithelia ADPLD PRKCSH 
c.292+1G>C 
1 week Cytoscan, 
RNAseq (p6) 
PLD17 Female, 
43 years 
Fluid (200mL; 
clear, yellow) 
Solitary 
cyst 
- 1 week RNAseq (p6) 
PLD18 Female, 
55 years 
Fluid (1L; clear, 
yellow) 
ADPLD Unknown 2 weeks - 
PLD19 Female, 
61 years 
Fluid (400ml; 
clear, yellow) 
ADPLD PRKCSH 
292+1G>C 
1 week - 
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Results 
 
Figure 1. Organoids grown from cyst-fluid derived cells. 
A: Organoids derived from cyst cells. Left: PLD10, 2 week culture, no passage; right: PLD4, 5 week 
culture, passage 3. Images of a well, digitally reconstituted from multiple partial images.   
B: A single organoid from a cyst fluid cell over the course of 23 days, same magnification. 
Biliary progenitors form organoids from cyst epithelium and fluid 
We were able to expand and maintain cholangiocytes derived from epithelium of liver cysts 
(figure 1, table 1). This is consistent with the presence of a pool of biliary progenitor cells or 
precursors thereof in cyst epithelium. Under these conditions, we maintained cultures of 
organoids deriving for >4 months, or >20 passages. Cultures expanded from virtually all cyst 
epithelia obtained by laparoscopic fenestration. In total, 47 of 60 cyst epithelia from 8 
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patients successfully grew organoids (table 1).  
Since cyst fluid is routinely available from aspiration sclerotherapy of dominant liver cysts, 
we aimed to isolate and expand biliary progenitors from this fluid. By placing cyst fluid 
derived cells in conditions suitable for human adult liver stem cell expansion, we could often 
observe growth. Up to thirty organoids from individual stem cells grew from all cells isolated 
from cyst fluid. 9 out of 31 seeded cyst fluids established long-term cultures. Clear, yellow 
cyst fluids had the highest efficiency for culture establishment (~36% / 8 of 21), while darker, 
more turbid fluids yielded less long-term cultures (~10% / 1 of 10). Many cyst fluid derived 
organoids could be passaged like epithelium derived organoids (every 7 days), but some fluid 
derived cultures survived only with 14-day passaging intervals. We presume this difference 
may be related to the smaller original population of fluid-derived cells, in which more 
quiescent stem cells occur. No differences in gene expression were observed (see below). 
We could freeze and thaw all cultures according to the described protocol.  
 
 
Figure 2. Loss-of-heterozygosity in cyst – derived organoids. Comparison to control organoid derived 
from healthy liver from clean resection margins of colorectal cancer liver metastasis surgery. 
A: Loss of PRKCSH protein expression induced by loss-of-heterozygosity in multiple cyst – epithelium 
derived organoids from a 47 year old ADPLD patient with a PRKCSH c.1362-2A>G mutation. 
1. Cytoscan HD displaying copy number neutral loss-of-heterozygosity surrounding PRKCSH on 
chromosome 19 (i.e. loss/sparsity of blue dots at 0 (heterozygous state) in comparison to blue dots at 
-1 and 1 (homozygous states)). Location of PRKCSH on chromosome 19 indicated by dotted line. 
2. Chromatograms depicting the PRKCSH c.1362-2A>G mutation in germline and cyst – derived 
organoid DNA (mutation located in black dotted box). All three cysts display loss-of-heterozygosity of 
the PRKCSH c.1362-2A>G mutation. (continued on next page) 
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(continued from last page) 
3. Immunofluorescence indicated loss of PRKCSH protein (red) expression had occurred, immunoblot 
confirmed this loss of PRKCSH protein (green) in comparison to alpha-tubulin control protein (red). 
Immunofluorescent image: PDI (green): ER marker; DAPI (blue): nuclei marker. 
B: Loss of SEC63 protein expression induced by loss-of-heterozygosity in a single cyst – fluid derived 
organoid from a 51 year old ADPLD patient with a SEC63 c.964del mutation. Comparison to control 
organoid derived from healthy liver from clean resection margins of colorectal cancer liver metastasis 
surgery. 
1. Cytoscan HD displaying loss-of-heterozygosity induced by allelic loss surrounding SEC63 on 
chromosome 6 (i.e. loss/sparsity of purple dots at 0 (heterozygous state) in comparison to purple 
dots at -1 and 1 (homozygous states), inward shift of -1 and 1 channels in combination with 
downward shift of most upper channel indicates allelic loss). Location of SEC63 on chromosome 6 
indicated by dotted line. 
2. Chromatograms depicting the SEC63 c.964del mutation in germline and cyst – derived organoid 
DNA (mutation located in black dotted box). The cyst displays loss-of-heterozygosity of the SEC63 
c.964del mutation. 
3. Immunofluorescence indicated loss of SEC63 protein (red) expression had occurred, immunoblot 
confirmed this loss of SEC63 protein (green) in comparison to alpha-tubulin control protein (red). 
Immunofluorescent image: PDI (green): ER marker; DAPI (blue): nuclei marker. PDI (green): ER 
marker; DAPI (blue): nuclei marker. Organoids recapitulate cyst epithelium genetic background 
In contrast to the majority of PLD patient cells from healthy tissue, cysts are believed to 
develop due to monoclonal expansion of cells with somatic second hits or LOH. To confirm 
the presence of LOH, as well as recapitulation of patient germline abnormalities, we 
employed genome-wide high resolution cytogenetic array analysis on DNA derived from cyst 
organoids.  
Organoids possessed germline mutations, and also harbored additional mutations consistent 
with a second-hit hypothesis of cystogenesis (figure 2). In a cyst organoid line of a PRKCSH 
patient, chromosome analysis found a 13 megabase CNN LOH region on chromosome 19. 
Mutation analysis of multiple cyst epithelium organoid lines of this patient led to 
identification of recurrent PRKCSH LOH (c.1362-2A>G). Immunofluorescence of one of these 
lines indicated loss of PRKCSH protein expression. Genetic analysis of cyst fluid derived 
organoids led to identification of a 42 megabase chromosome 6 deletion encompassing 
SEC63. Subsequent analysis of germline DNA revealed a SEC63 mutation (c.964del), which 
led to a frameshift (p.Gln322Serfs*5). There was complete loss of wildtype SEC63 in cyst 
organoid DNA. Immunofluorescence indicated lower fluorescent signal for cyst organoids in 
the SEC63 band. On western blot, no PRKCSH or SEC63 protein was present in mutated 
organoids (supplementary figure 1).  
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Figure 3. Proliferation and differentiation of cyst and normal liver organoids (also see 20  for further 
characterization of normal liver organoids). 
A: Expression of a panel of hepatobiliary genes expressed in normal (NL) and cyst (PLD) organoids in 
comparison to normal liver tissue. Stem cell (LGR5, SOX), cholangiocyte (KRT7, KRT19, TGF-βR2) as 
indicated. For AFP, and LGR5 cDNA from fetal instead of adult liver was used as a positive control. In 
EM, both organoid types expressed stem cell markers SOX9 and LGR5, and expressed cholangiocyte 
markers KRT7, KRT19, and TGF-βR2. LGR5 expression was lost with hepatocyte differentiation. 
Transcription factors FOXA1, FOXA2, FOXA3, OC2, HHEX, HNF1α, HNF1β, HNF4α, and TBX3 were 
expressed. Albumin and CYP3A4 expression increased in both normal and cyst organoids following 
hepatocyte differentiation. Expression of HHEX, HNF1α, HNF1β, FOXA3, HNF4α, and TBX3 decreased 
under hDM conditions. No AFP expression was present under any condition. 
B: No significant differences in proliferative or differentiation capacity could be observed between 3 
normal (NL) and 3 liver cyst (PLD) organoid lines in three independent experiments, as determined by 
Mann-Whitney U non parametric testing. Proliferation measured by change in organoid 
circumferential area on day 7 in comparison to day 1. Differentiation capacity measured by KRT19, 
KRT7, CYP3A4 and LGR5 expression after 7 days in indicated condition (i.e. EM, hDM, bDM). Gene 
expression in proliferating and differentiating conditions. 
LGR5+ liver organoids are normally constituted of bipotent biliary stem cells (20), and it has 
been hypothesized that cysts might develop due to abnormal differentiation of biliary 
precursors (1, 13). We set out to characterize and compare normal liver and cyst organoid 
gene expression in expanding and differentiating conditions (figure 3). In EM, both organoid 
types expressed stem cell markers SOX9 and LGR5, and expressed cholangiocyte markers 
KRT7, KRT19, and TGF-βR2. Transcription factors FOXA1, FOXA2, FOXA3, OC2, HHEX, HNF1α, 
HNF1β, HNF4α, and TBX3 were expressed.  
The hDM condition allows differentiation to both hepatocyte and cholangiocyte lineages 
with concomitant loss of progenitor marker LGR5 (20). As bipotency was extensively tested 
in this previous study, we only set out to confirm this in our organoids by RT-PCR. Albumin 
and TTR expression was exclusive to the hDM condition in both normal and cyst organoids, 
while CYP3A4 expression increased in comparison to EM. LGR5 expression was lost with 
differentiation. Expression of HHEX, HNF1α, HNF1β, FOXA3, HNF4α, and TBX3 decreased 
under hDM conditions. No AFP expression was present under any condition. Expression of 
hepatocyte and cholangiocyte markers in the hDM condition confirmed the presence of both 
these cell types in the organoids.  
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Figure 4. Primary cilia are sporadically present on liver organoids. 
A: Scanning electron microscopy image of liver organoids in EM. A putative primary cilium of ~2µm is 
visible on a cell. 
B: Polycystic liver organoids express few, but clear primary cilia when grown in medium aimed at 
stem cell proliferation.  Shown is PLD organoid line 2 from solitary liver cyst epithelium of a 54-year 
old female patient with (also see table 1).  
DAPI: blue; β-catenin: green; GT335: red. 
C: Polycystic liver organoids express primary cilia when grown in conditions suitable for biliary 
differentiation. Shown is a normal liver organoid derived from healthy liver from clean resection 
margins of colorectal cancer liver metastasis surgery. 
DAPI: blue; ARL13B: green; KRT19: red. 
D: Polycystic liver organoids express primary cilia when treated with nocodazole, a pharmacological 
stimulant of cilia, 2 hours before fixation. Shown is PLD organoid line 8.1 from cyst epithelium of a 
56-year old female ADPLD patient (also see table 1).  
DAPI: blue; ARL13B: green; KRT19: red. 
Organoid expansion and differentiation capacity 
Using EM, bDM and hDM conditions, we compared expansion and differentiation capacity of 
cyst bipotent biliary progenitors (n=3) to that of normal bipotent biliary progenitors (n=3) in 
3 independent experiments (figure 3). Gene expression was similar among both types of 
organoids. All in all, we could exclude a differentiation defect.  
Since LRP5 mutations have recently implicated abnormal Wnt signaling in cystogenesis, we 
additionally cultured 3 normal and 3 cyst liver organoids without Wnt agonist Rspo1. Both 
culture types simultaneously arrested growth within two weeks of culture in three 
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experiments (data not shown). This indicates that Wnt/Rspo1 signaling is not disturbed in 
cyst organoids.  
Organoid primary cilia and polarization 
Besides differentiation problems, primary cilia dysfunction is crucial to cyst development, 
and we assessed their presence on organoids. Under EM conditions, primary cilia were 
present, but on relatively few cells (figure 4). On whole mounts stains with DAPI and GT335 
or ARL13B, we observed a small number of cells with cilia (figure 4; supplementary figure 2). 
Cells cultured without proliferative growth factors Rspo1, nicotinamide, A83.01 TGF-β 
inhibitor, and forskolin (bDM) for 7 days expressed more cilia, as did those cultured with 
100nM nocodazole 2 hours prior to fixation. Cells lining organoids with lumens had 
predominantly basolateral β-catenin, and only rarely were cilia observed on the external 
surface of organoids (depicted with PLD8.1). 
 
Figure 5. Gene expression of organoids. 
A: Expression of a panel of cyst-related genes expressed in organoids. PRKCSH, SEC63, LRP5, PKD1, 
PKD2, SSTR1-5, and ADCY1-10 as indicated. For ADCY8 cDNA from fetal instead of adult liver was 
used as a positive control. 
B: Principal component analysis of indicated liver organoid samples. 
C: Heatmap of differentially expressed genes. NL: Normal liver organoids; PLD: ADPLD/ADPKD 
organoids. Red: high expression; black: average expression; green: low expression. 
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RNA sequencing and pathway analysis 
We aimed to determine whether specific genes or pathways were present and / or disturbed 
in bipotent progenitors passaged 4-6 times (table 1; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73579). RNA sequencing of normal 
liver organoids (n=4)  and PLD organoids (n=8, including three PRKCSH mutants) was 
performed, which yielded ~25 million reads per sample. Organoids expressed cyst genes 
PRKCSH, SEC63, LRP5, PKD1, and PKD2 (figure 5). Many components of nonmotile primary 
cilia were clearly expressed in all organoids (supplementary table 5), as determined by the 
SYSCILIA gold standard list (syscilia.org). In addition, ciliopathy genes(1) involved in liver cyst 
development such as PKHD1, MKS1, OFD1, IFT88, and TSC1 were also expressed. Cellular 
components related to the lanreotide response were expressed such as somatostatin 
receptors 1, 2, 4, and 5, while SSTR3 was not. SSTR2 was expressed in only some lines of 
normal and liver cyst organoids (data not shown). Adenylyl cyclases 1, 4, 6, 7, and 9 were 
expressed, ADCY5, 8 and 10 were not expressed. 
Following normalization, principal component analysis, F-means clustering, and heat maps 
revealed different clustering of normal and PLD organoids (figure 5). Clustering was 
dependent upon mutation status. Two organoids with known PRKCSH mutations with LOH 
on chromosome 19 (PLD9 and PLD16) clustered together on principal component analysis 
(figure 5), but separately from other organoids. PLD15, from an ADPKD patient with a PKD1 
mutation background, also clustered separately from other organoids. F-means clustering 
revealed that these samples displayed significant co-expression of genes (supplementary 
figure 3). PLD9, PLD15, and PLD16 shared expression of a large set of genes, separating them 
from the other samples. As mentioned above, these organoids had a background of PRKCSH 
and PKD1 germline mutation and somatic LOH. Another set of genes was shared between 
these samples and PLD17, with an unknown mutation. PLD9 and PLD16 (both PRKCSH 
mutants) shared expression of a smaller subset of genes. PLD15, the only sample grown 
from a liver cyst of an ADPKD patient with PKD1 mutation, displayed a distinct expression 
pattern when compared to other PLD samples. We found no relation with culture origin 
(epithelium versus fluid) with PCA clustering, removing this as a source of bias. These data 
indicate that the mutational background of cysts are an important cause of differential gene 
expression. 
Genes such as KIF5C, PXDN, SEPT5, GBA3, PSCA, and FOLR1 were expressed many fold higher 
in the PLD group compared with the control (NL) group (supplementary table 6).  
Three out of four normal liver organoids shared a large set of genes (supplementary figure 
4). A small set of genes clustered differently between control and PLD organoids. PLD 
organoids displayed a heterogenous expression pattern within their group. Despite this 
heterogeneity, cyclic (c)AMP responsive element binding protein 1 (CREB1) was found to 
control many of the genes that were differentially expressed between normal and PLD liver 
organoids. No pathways were significantly dysregulated in the PLD organoid group. 
 
Lanreotide response 
Cholangiocytes from polycystic livers are known to respond to lanreotide by decreased 
growth, and we aimed to determine whether liver organoids would also be inhibited. Using 
normal EM in combination with 100nM lanreotide every 12 hours, no response could be 
observed (data not shown). We figured this may have had to do with competition by factors 
such as EGF and forskolin, which are known to have effects on cAMP signaling. We opted to 
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reduce all growth factors in the EM to 10%, except B27 and N2 supplements, and to add 
100nM lanreotide every 12 hours to the medium. Subsequently, a significant effect of 
lanreotide was observed in three independent experiments (figure 6). Lanreotide 
significantly decreased expansion of liver organoids in comparison to control (197%  46% 
versus 547%  28%; p: 0.038).  
 
Figure 6. Liver organoids respond to lanreotide by decreased growth. 
Lanreotide significantly decreased expansion of liver organoids in comparison to negative control 
(197%  46% versus 547%  28%; p: 0.038). 
Discussion 
Here we describe the methods to obtain patient-derived 3D cyst organoid lines from cyst 
epithelium and fluid, which recapitulate key features of polycystic liver disease. Crucial to 
polycystic liver development are presence of somatic second hits (e.g. in PRKCSH and SEC63), 
which we show here to be present in cyst derived organoids. Analysis of expression of LRP5, 
PKD1, and PKD2 cyst genes indicates that loss of these wild type alleles occurs in liver 
organoids. We found that SOX9, LGR5, KRT7, KRT19, and TGF-βRII expression is present in 
expanding organoids, indicating that biliary progenitors are responsible for proliferation. 
Differentiation capacity of cyst organoids was intact,  as measured by hepatocyte marker 
CYP3A4, and cholangiocyte markers KRT19 and KRT7. Using RNAseq we were able to show 
that clustering of organoids depended on their genetic background, as PRKCSH and PKD1 
mutant organoids shared gene expression. No significantly different pathways occurred in 
our PLD organoids, likely related to the heterogeneity of the organoids’ genetic background. 
Lastly, the response of the organoids to lanreotide indicates their translational value.  
An important finding is that bipotent cyst progenitors confirm the long-standing hypothesis 
that cysts develop from and are maintained by biliary stem cells (8). We found LOH in cyst 
derived organoids which is consistent with previous reports (7-12). For example, we 
discovered SEC63 LOH in our cell culture from a SEC63 mutant PLD patient. To our 
knowledge, this is only the second finding of a somatic second hit in SEC63 (7). Since neither 
expansion nor hepatoblast differentiation was dysregulated, we may exclude them as the 
mechanism of cyst formation under the tested circumstances (1, 13). In addition, human 
organoids expressed somatostatin receptors (including SSTR2 and 5) and adenylyl cyclases 
involved in lanreotide response and cyclic AMP signalling. These findings, along with 
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organoids’ response to the somatostatin analogue are in line with in vitro findings in 3D 
hepatic cysts from polycystic kidney disease rats (4, 6), and iPS-derived cholangiocytes (15). 
Interestingly, RSPO1, LGR5, and LRP5 cooperate, amongst others, in generating the Wnt 
signalling crucial to stem cell development and maintenance (29). Although beyond the 
scope of this study, this may implicate that LRP5 mutations found in PLD(2) may affect cystic 
stem cells.  
Our model has several advantages over previous models. PLD organoids could be grown 
from cells present in cyst fluid expanded in 3D, while retaining somatic second hits (which 
germline cells do not have (7-12)). This shows its advantages over use of cholangiocytes 
derived from HepaRG, embryonic  or induced pluripotent stem cells (14, 15). Additionally, 
cyst fluid – derived liver organoids denote bodily fluids as a novel source of primary bipotent 
liver cells. Other fluid-derived cells, such as metastasizing stem cells from hepatocellular 
carcinomas or cholangiocarcinomas in blood or bile fluid may also be cultured using these 
methods. RNAseq showed no separate clustering of organoids on the basis of epithelial or 
fluid origin, removing this as a source of differences between cultures. The response of the 
liver organoids to lanreotide shows their potential for use in (personalized) drug screens or 
other molecule screens. Similar screens have already been conducted with colorectal and 
prostate organoids (30, 31). As in these studies, further experiments may generate dose-
response curves for different organoid lines to exploit their specific sensitivies. 
Even though this study shows promising results, it has some limitations. First, some derived 
organoid lines may not reflect the whole cyst cell population, when cyst fluid organoids 
originated from few stem cells. Contaminating cells may also occur, such as normal biliary 
progenitors from the healthy side of cyst epithelium. It is therefore important to assess cell 
origins by assessing LOH and / or mosaicism regions. Second, under the tested conditions, 
relatively few cells expressed primary cilia. More cilia may be found in better differentiated 
biliary cells (14, 15). Conditions for biliary differentiation are expected to become more 
optimized, given extensive experiments. Third, as these reflect our first attempts at isolating 
and expanding cyst fluid progenitors, we anticipate that methods can be further improved. 
Efficient extraction of viable, biliary cells, e.g. through sorting EPCAM+ cells(21), or seeding 
all unsorted cells of larger cyst volumes might enhance culture establishment efficiency. A 
larger pool of initiating stem cells will improve the chances of obtaining stem cells with 
normal proliferation speed. Finally, we believe the heterogeneous gene expression of the 
organoids included for RNA sequencing to be a reflection of their heterogeneous genetic 
background, rather than a limitation of the technique. All organoids were cultured in the 
same conditions for at least two weeks, and variability of our treatment of the cells was at a 
minimum. Moreover, PRKCSH mutant organoids showed similar clustering on PCA, while 
PRKCSH and PKD1 mutant organoids shared a large set op genes that are differentially 
expressed from remaining samples. We believe this indicates the heterogeneity observed 
with RNAseq is dependent upon the genetic background of each organoid, rather than the 
culturing technique. 
In conclusion, we believe that the development of cyst-derived bipotent liver progenitor 
lines is an  important innovation for research, diagnostics, and treatment of various 
polycystic liver diseases as well as cholangiociliopathies.  
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ADPKD: autosomal dominant polycystic kidney disease 
ADPLD: autosomal dominant polycystic liver disease 
bDM: biliary differentiation medium 
EM: expansion medium 
DPM: ductal plate malformation 
hDM; hepatocyte differentiation medium 
LOH: loss of heterozygosity 
PLD: polycystic liver disease 
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Abstract 
Introduction: Autosomal dominant polycystic liver disease (ADPLD) is caused by 
PRKCSH, SEC63, and LRP5 mutations. Thus far, few animal models exist 
mimicking the human phenotype. Zebrafish can be used as a stable, scalable 
animal model, but the phenotype of most genetic knockouts for ADPLD is 
unknown. We aimed to establish zebrafish with induced mutations as an ADPLD 
model. 
Methods: We developed gRNAs targeting three genes underlying ADPLD. CRISPR-
Cas9 constructs were injected into embryos, and the embryonic phenotype was 
studied. 
Results:  gRNAs effectively targeted the genes, with high mutagenesis efficiencies 
(>75%) for Prkcsh and Sec63. Efficient bigenic editing was possible for these two 
genes. Any mutation in Prkcsh and Sec63 prevented larvae from reaching 
adulthood. Crispants did not display liver cysts. Only crispants with in-frame Lrp5 
mutations matured, which did not have obvious phenotypic abnormalities. 
Prkcsh- and Sec63-crispants presented with growth retardation. Sec63 and 
Prkcsh-/Sec63-double mutant larvae additionally failed to inflate swim bladders.  
Conclusion & discussion: Fully penetrant CRISPR-Cas9-based ADPLD gene 
knockdown in zebrafish causes death after the larval stage. Crispants do 
consistently show a phenotype of retarded growth and failure to inflate their 
swim bladder. These abnormalities may be used for future studies of underlying 
pathways or drug screens. Our described gRNAs might form a first step in 
developing liver-specific knockout fish to increase the cystogenic timeframe. 
Lay summary 
Genes involved in liver cyst development in humans, fluid-filled sacs in the liver, 
can be disrupted in zebrafish. In zebrafish larvae, loss of these genes do not cause 
cysts, but cause a failure to thrive and grow. For the Sec63 cyst gene,  
this could be associated with failure to inflate swim bladders, an organ important 
for zebrafish movement in the water.  
Keywords 
polycystic liver disease, zebrafish, CRISPr-Cas9, disease model 
 
Introduction 
Liver cysts occur in the context of autosomal dominant polycystic liver disease (ADPLD), 
autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic 
kidney disease (ARPKD). Renal cysts are the predominant feature of the latter two diseases. 
ADPLD has a prevalence of 1:158,0001, and is caused by mutations in the PRKCSH, SEC63, 
and LRP5 genes 2-5. ADPKD is caused by mutations in the polycystin genes PKD1 and PKD2, 
which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Recently, a large whole 
exome sequencing effort added four causative genes to this list: ALG8, GANAB, SEC61B, and 
PKHD1, together with the previously known explaining about 50% of the ADPLD cases 6. Liver 
cysts are the result of loss-of-heterozygosity (LOH) 7-12, in which process wild-type alleles are 
completely lost from diseased cells. It is experimentally shown that loss of ER-localized 
PRKCSH or SEC63p leads to impaired processing of crucial ciliary components, most 
prominently PC1 21. This was bolstered by the identification of ALG8, GANAB, and SEC61B 
that act in the same ER-based protein processing pathway as PRKCSH and SEC63, and 
showed reduced trafficking and maturation of PC1 6. However, as the function of PC1 is 
unknown, the relationship to cyst formation remains elusive. Mutations in LRP5 cause 
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ADPLD, which gene encodes a Wnt-signaling receptor. This mutation might implicate Wnt-
signaling as a process disrupted following loss of PC1 in the cystogenic process 13,14. Cyst 
growth can be curtailed, to some extent, by somatostatin analogues such as pasireotide 15-20.  
Recapitulating this pathological process in animal models has proven to be difficult. Prkcsh-/- 
and Sec63-/- mice are embryonically lethal 21. Liver-specific conditional Prkcsh-/- and Sec63-/- 
mice do allow post-natal cyst formation. Polycystic kidney (PCK) rats and Pkd2WS25/ - mice 
exist, but these are models for ARPKD and ADPKD respectively 16,22, rather than for ADPLD. In 
vitro models include human polycystic cholangiocytes and 3D polycystic kidney (PCK) rat 
cholangiocytes16, 17, but there is poor access to primary human biliary tissue and maintaining 
cells through passages is difficult 23.  For modeling purposes, animal models are still superior 
to in vitro cultures in many aspects.   
New ADPLD models are urgently required to gain more insight in the pathophysiology, 
validate pathogenicity of new candidate genes and variants, and develop new therapeutic 
approaches. Zebrafish have surfaced as valuable animal models for many diseases, especially 
for those where mice models proved to be inadequate 24-26. In an attempt to fulfil the need 
for new ADPLD models, zebrafish morpholino (MO) knockdown was previously performed 
for sec63, prkcsh and pkd1a27. Zebrafish morphants showed abnormal body curvature, liver 
cysts, and somatostatin analogue pasireotide inhibited cyst growth. Another study described 
sec63St67 mutant larvae, which displayed increased hepatic ER stress and liver steatosis, and 
failed to survive past 14dpf28. In contrast with the sec63 MO study, sec63 mutants do not 
display body axis curvatures and do not develop liver cysts. Although this does not resolve 
the discrepancies between the studies, the study authors suggested that the observed 
pathologies of sec63St67 mutants precede cyst formation28. Another cause might be aspecific 
toxic side effects of morpholinos.  
Here, we employed CRISPR-Cas9 to induce mutations in the ADPLD genes of zebrafish larvae. 
We aimed to generate mono- and oligogenic mutations of prkcsh, sec63, and lrp5 in 
zebrafish using CRISPR-Cas9 mutagenesis, to establish new models for APDLD and study liver 
cyst development. 
 Methods 
Fish keeping and husbandry 
We confirm that the experiments were carried out in accordance with European and 
institutional guidelines on animal welfare (2010/63/EU)). We bred Tupfel long fin (TLF) 
zebrafish and raised them under standard conditions 40. Adult zebrafish of the TLF strain 
were used to obtain embryos that were raised in E3 embryo medium (5 mM NaCl, 0.17 mM 
KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4) supplemented with 0.1% (w/v) methylene blue.  
CRISPR-Cas9 
 
We designed two gRNAs targeting different exons of each gene using ZiFiT (table 1; 
http://zifit.partners.org/ZiFiT/), and cloned these into pDR274 expression vector (Addgene 
#42250)30. gRNA constructs in pDR274 were linearized using DraI restriction enzyme, and 
RNA was synthesized using MAXIscript ® T7 in vitro Transcription kit (Ambion; 
cat#AM1312M) with the turboDNase step according to protocol. We synthesized capped 
Cas9n mRNA from XbaI-linearized pT3TS-nCas9n (Addgene #46757) with T3 polymerase 
using mMESSAGE mMACHINE Kit (Ambion; cat#AM1344) according to the manufacturer’s 
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protocol 31. This Cas9 nickase is a zebrafish codon optimized protein with a SV40 nuclear 
localization signal. The injection mixture contained 25ng/µL gRNA, 150ng/µL Cas9n mRNA, 
0.2M KCl, 0.05% phenol red diluted in twice demineralized water. We injected a volume of 1 
nL into the cell of 1-cell stage embryos with a Pneumatic PicoPump pv280 (World Precision 
Instruments), which was later raised to 5 nL for lrp5 exon 2 gRNA. To generate double and 
triple mutants, we mixed injection mixtures of prkcsh exon 4, sec63 exon 7, and lrp5 exon 2 
in a 1:1:2 ratio, and used 2 nL injection volumes. A minimum sample size of 50 larvae was 
used in each injection experiment.  
 
Table 1. CRISPr-Cas9 target sites and oligos used for gRNA cloning. 
Gene Exon Target site Oligo 1 Oligo 2 
prkcsh Exon3 
(R) 
GGCTTGTTCTCCTCATAAAA TAGGCTTGTTCTCCTCATAAAA AAACTTTTATGAGGAGAACAAG 
prkcsh Exon4 
(R) 
GGTGGGTTTGTAACCAGCAT TAGGTGGGTTTGTAACCAGCAT AAACATGCTGGTTACAAACCCA 
sec63 Exon7 GGTCTATGGGTTGGCATTTA TAGGTCTATGGGTTGGCATTTA AAACTAAATGCCAACCCATAGA 
sec63 Exon9 
(R) 
GGAACTTCAATGTTGTCTGT TAGGAACTTCAATGTTGTCTGT AAACACAGACAACATTGAAGTT 
lrp5 Exon2 GGTCAGTGATCTGGAGGACG TAGGTCAGTGATCTGGAGGACG AAACCGTCCTCCAGATCACTGA 
lrp5 Exon3 GGAGACAAACCGCATCGAAG TAGGAGACAAACCGCATCGAAG AAACCTTCGATGCGGTTTGTCT 
 
Genotyping 
We isolated DNA from embryos and larvae using a custom-made genotyping buffer (40mM 
NaOH, 0.2mM EDTA in sterilized water). For genotype-phenotype comparisons, we 
separated tail from head segments, taking care to avoid affecting the liver and abdominal 
organs. We placed single embryos, larvae or larval tails in an appropriate volume of 
genotyping buffer and heated it to 95°C for 20 minutes. Suspensions were vortexed until 
homogenous and diluted 1:10 as DNA input for PCR. For assessing the effect of CRISPR-Cas9 
injections, we amplified targeting sites using exon-specific primers (table 2). Mutagenesis 
was confirmed by screening for multiple sized products on a 4% agarose gel, followed by 
Sanger sequencing when determining gross morphology and liver phenotype. 
Table 2. Prkcsh, Sec63, Lrp5 sequencing primers. Nt: nucleotides 
Gene Exon Forward primer Reverse primer Product size 
(nt) 
prkcsh 3 ACCACGAGGAGTACCACTGT TCGTCTGAACCGTCTTTGCA 230 
prkcsh 4 TCTAGAATCTTCGGCCCAGA CACATTTGGCTCCACTGTTGT 308 
sec63 7 GCACCGTTTTGCCTGTGATT ACATAAGCAGCAATAGTGAGC
T 
304 
sec63 9 TCCTGATCAACACAACACAGC
T 
TTCCCAGCTCCCGAATCAAC 380 
lrp5 2 CCTTTGCTGCTTTTCGCCAA TCTGTTTGATGGCCTCCTCG 172 
lrp5 3 TTGCAGCTATGAAGGAGGCC AGGGGTTTAGTGCAATCGCT 220 
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Macroscopic phenotype, liver and pronephron histological analysis 
At desired stages, we made photographs of gross morphology of individual, live larvae under 
a Leica MZFLIII stereomicroscope (Leica Microsystems, Wetzlar, Germany). After tail removal 
for genotyping, we fixed larvae overnight in 4% formalin. We subsequently placed 10-40 
larvae or larval head regions on a 1% agarose mold intended for paraffin embedding 41. Sizes 
of wells in the agarose mold were adapted to 2.5 mm for larval head regions. Fish were 
dehydrated in a series of ethanol steps (50%, 75%, 85%, and 95%) and xylene and embedded 
in paraffin. Following paraffin embedding, we made sections and stained them using H&E. 
Slides were scanned using a Pannoramic scanner 250 (3D Histech, Budapest, Hungary) and 
independently assessed by the study authors ESW and SABH. 
Results 
 
Figure 1. Effective CRISPR-Cas9-based genome editing of ADPLD genes in zebrafish.   
A: Sequence traces of prkcsh surrounding the gRNA target site of DNA from a pool of embryos, 
mutagenized by a CRISPR-Cas9 construct targeting prkcsh exon 4. The chromatogram indicates 
different mutations occurring within the target site. 
Black circle: gRNA target site on forward Sanger sequence. 
B: Assessment of genome editing by prkcsh exon 4 gRNA in individual embryos as determined by 
heteroduplex analysis of PCR amplified DNA on electrophoresis gels. In case of a successful 
amplification, a high frequency of heteroduplex occurrence is seen (indicating successful 
mutagenesis). 
*: Incorporated mutation as detected by double/multiple bands upon agarose gel electrophoresis. 
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C: Sanger sequences of gRNA target site of DNA from pool of embryos, mutagenized by CRISPR-Cas9 
construct targeting sec63 exon 7. The chromatogram indicates different mutations occurring within 
the target site. 
Black circle: gRNA target site on forward Sanger sequence. 
D: Assessment of genome editing by sec63 exon 7 gRNA in individual embryos as determined by 
heteroduplex analysis of PCR amplified DNA on electrophoresis gels. In case of a successful 
amplification, a high frequency of heteroduplex occurrence is seen (indicating successful 
mutagenesis). 
*: Incorporated mutation as detected by double/multiple bands upon agarose gel electrophoresis. 
E: Sanger sequencing confirmed only infrequent mutations in lrp5 exon 2 in DNA from a pool of 
embryos injected with a high volume (5nl) of injection mixture. 
Efficient mutagenesis of ADPLD genes leads to lethality of zebrafish larvae 
 
To induce mutations in the genes underlying ADPLD, we set out to generate zebrafish 
mutants for prkcsh, sec63 and lrp5. We injected Cas9 mRNA along with gene specific gRNAs 
into 1-cell stage embryos. We designed two gRNAs per target gene, of which only the gRNAs 
targeting prkcsh exon 4 and sec63 exon 7 were able to generate indels with a high frequency 
(>75%), as determined by heteroduplex analysis of PCR amplified DNA on electrophoresis 
gels (Figure 1, Figure S1). For lrp5, we could not induce any mutations under normal 
injection conditions. As we initially set out to establish stable mutant lines, we increased the 
dose of CRISPR-Cas9 mixture from 1 nL to 5 nL, in an attempt to obtain larvae carrying lrp5 
mutations. This indeed resulted in larvae carrying mutation, but only sporadically.  
Only ~20% of prkcsh gRNA, ~23% of sec63 gRNA and ~12% lrp5 gRNA injected fish hatched 
independently, in comparison to ~53% for (uninjected) wildtype fish on average.  Only few of 
the prkcsh and sec63 gRNA injected larvae (total injected n=50-100 in two biological 
replicates) grew to adulthood. While mutations were frequently found in injected larvae, 
genetic analysis of DNA from tail fins did not reveal mutations in any of the surviving adults. 
Likely, mutations in these genes are not compatible with complete development. Indeed, 
mutations were commonly found in those larvae that died during development. For lrp5, 
only fish with mosaic in frame indels hatched and grew to maturity. We observed up to three 
different mutant alleles in the offspring of a single couple/fish, underlining the mosaic state 
of the injected generation. These recurrent in-frame mutations lead to replacement of an 
important peptide sequence (figure 2), but left the remaining protein intact. The region is 
conserved across species, indicating abnormalities are likely to have deleterious effects 
(figure 2). 
Remaining gRNA constructs proved ineffective in inducing mutations (Figure S1). For Lrp5 
exon 3 gRNA, an unexpected SNP was present at the target site (c.403A>G) that was not 
present in the zebrafish reference DNA, likely preventing mutagenesis. Mutagenesis was 
therefore possible with 3 out of 6 gRNAs, and 2 of these had high efficiency in biallelic 
disruption. 
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Figure 2. Three in frame deletions/insertions observed after injection of a Cas9-RNP mixture 
targeting lrp5 exon 2.  
inset: The in frame deletions/insertions lead to replacement of one, two or three amino acids in a 
region that is conserved across species. Red boxes indicate the deleted regions. 
 
Only ~20% of Prkcsh gRNA, ~23% of Sec63 gRNA and ~12% Lrp5 gRNA fish hatched, in 
comparison to ~53% for wildtype fish on average. Homozygous mutations in all three genes 
affected early development. Of 50-100 Prkcsh and Sec63 gRNA injected larvae in two 
experiments each, only fish without mutations grew to maturity. Mutations were only 
present in larvae that died before 14 days. For Lrp5 injections, only fish with mosaic in frame 
insertions/deletions hatched and grew to maturity to pass along germline mutagenized 
alleles. These recurrent in frame mutations lead to replacement of an important peptide 
sequence (figure 2), but left the remaining protein intact. The region is conserved across 
species, indicating abnormalities are likely to have deleterious effects (figure 2). 
The Lrp5 mutant fish were capable of germline transmission of affected alleles. By 
outcrossing, we observed both WT and heterozygous F1 fish as offspring. Offspring from a 
single couple inherited wild type alleles, and up to three different mutated alleles, which 
further indicated the mosaic state of mutant parents. Concluding, Prkcsh and Sec63 
mutations lead to larval lethality, and only in frame Lrp5 mutations are compatible with 
reaching adulthood. 
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Figure 3. Liver histology of CRISPr-Cas9 mutagenized zebrafish larvae. Depicted for each larva are a 
microscope image, a histologic section of the liver (outlined in red), and the chromatogram of the 
relevant target sequence. Depicted WT control larvae coincidentally had not yet inflated swim 
bladders. 
A: Mutations in prkcsh exon 4 did not cause liver cysts as determined by histological slides of 
Crispants. Both the wildtype larvae as well as the prkcsh crispants showed identical liver histology. 
B: Mutations in sec63 exon 7 did not cause liver cysts as determined by histological slides of 
Crispants. Both the wildtype larvae as well as the prkcsh crispants showed identical liver histology. 
Cas9-RNP injected somatic mutant larvae do not develop liver cysts 
 
Despite the embryonic lethality of single mutants, we investigated whether Cas9-RNP-
injected, somatic mutant larvae (Crispants) are valuable as a short-lived animal model. To 
assess the effect of mutations on the gross morphology and liver phenotype of these larvae 
(figure 3), we took microscopic images of whole, live larvae, and carefully removed tails for 
genotyping. Remaining upper body regions were embedded in paraffin for histology. As 
such, we could reliably determine both the genotype and phenotype of individual Cas9-RNP 
injected larvae. Injected larvae devoid of mutations in the tail fin served as controls.  
For prkcsh crispants, we observed no relation of somatic mutations with fish body curvature 
(figure 3; figure S2). We furthermore observed major organs such as the eyes, swim bladder 
and fins for abnormalities, but none displayed a phenotype correlating with the presence of 
somatic mutations. None of the prkcsh crispants showed liver cysts upon histological 
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investigation. 
Like the prkcsh crispants, sec63 crispants did not display defects in the body axis. There were 
also no gross morphological abnormities in any of the other major organs. However, 
mutations of sec63 almost completely correlated with failure to inflate swim bladders (figure 
S3), indicating high penetrance of this phenotype as assessed by microscopy. Histological 
investigation of the sec63 crispant showed that, like in prkcsh crispants, liver cysts were not 
present.  
The size of crispants was significantly decreased in comparison to wildtype fish and injected 
fish without detectable somatic mutations (figure 4).  We found a mean length of 3.046mm 
(95% c.i. 2.944-3.148mm) for prkcsh knockouts, 3.089mm (95% c.i. 3.028-3.150mm) for 
sec63 knockouts, in comparison to 3.212mm (95% c.i. 3.124-3.300mm) for wildtypes. Mean 
size of lrp5 exon 2 heterozygous mutant fish was not significantly different from WT fish 
from the same batch (figure S4). 
 
Figure 4. Length of zebrafish is decreased due to mutations in prkcsh and sec63. Prkcsh and sec63 
crispants showed decreased length in comparison to wildtype fish and unsuccessfully mutagenized 
fish injected by a Cas9-RNP mixture.  
Only straight fish were included for analysis.  
WT: uninjected WT fish; Prkcsh KO: crispants injected by prkcsh Cas9-RNP mixture with prkcsh 
mutations; prkcsh WT: larvae injected by prkcsh Cas9-RNP mixture without prkcsh mutations; Sec63 
KO: crispants injected by sec63 Cas9-RNP mixture with sec63 mutations; sec63 WT: larvae injected by 
sec63 Cas9-RNP mixture without sec63 mutations. *: p<0.05; **: p<0.01. 
Cas9-RNP injected somatic multiplex mutant larvae do not develop liver cysts 
 
To try to optimize conditions for liver cyst development we aimed to generate multiplex 
mutations and knock out two or more genes at the same time to develop a strong cystogenic 
genotype 30,31 . Previous experiments in mice showed a genetic interaction network exists 
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between the known ADPLD genes. Mutations or haploinsufficiency in more than on ADPLD 
gene will worsen the associated cystic phenotype 21. 
To this end, we injected 150 embryos with a Cas9-RNP mixture containing the gRNAs for 
prkcsh, sec63 and lrp5 gRNAs. The majority of the injected larvae (132) did not survive past 
5dpf. However, 14 out the 18 surviving larvae were found to carry mutations in both prkcsh 
exon 4, and sec63 exon 7 (figure S5). Moreover, one single larva of those 14 contained 
mutations in all three targeted genes. This larva showed a mosaic 6-nucleotide lrp5 deletion 
in the region described above. In this multiplex genome editing experiment, we never found 
larvae with mutations in only one of the three target genes.  
 
Figure 5. Liver histology of CRISPr-Cas9 mutagenized zebrafish larvae. Depicted for each indicated 
larva are a microscope image, a histologic section of the liver (outlined in red), and the 
chromatogram of the relevant target sequence. Combined mutations in prkcsh exon 4, sec63 exon 7 
(and Lrp5 exon 2) did not cause liver cysts.  
Since we have shown that multiplex genome editing is possible for the genes underlying 
ADPLD, we continued our investigations of the phenotypes of multiplex ADPLD crispants.  
The phenotype of prkcsh/sec63 double mutant fish was also normal with regard to body 
curvature. Similarly to sec63 single mutations, prkcsh/sec63 double mutations almost 
completely correlated with failure to inflate swim bladders (figure 5; figure S5). The double 
crispants did not display additional gross morphological abnormalities. Even the larva in 
which all three genes were successfully targeted presented no abnormal features other than 
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an uninflated swim bladder. Summarizing, introduction of multiplex somatic mutations in 
ADPLD genes did not result in the development of liver cysts.  
Discussion 
We set out to develop zebrafish models for ADPLD. Here we show introduction of prkcsh, 
sec63, and lrp5 mutations by CRISPR-Cas9 in zebrafish, and their associated phenotypes. 
Unfortunately, genetic knockout consistently caused death in our Cas9-RNP injected larvae 
in (late) larval stages (up to 14dpf). Here we show introduction of somatic prkcsh, sec63, and 
lrp5 mutations by Cas9-RNP injection in zebrafish embryos, and their resulting phenotypes.  
While mutagenesis of the first two genes was very efficient, and led to somatic mutations in 
the majority of injected embryos, lrp5 mutagenesis proved to be very inefficient for the two 
selected targets. Furthermore, prkcsh/sec63 double crispants could easily be generated 
within one generation. Of the three ADPLD genes investigated here, only larvae with in-
frame Lrp5 mutations developed into adults. Homozygous loss-of-function mutations in 
prkcsh, sec63 and lrp5 are apparently lethal during larval development.  The prkcsh fish did 
not reach maturity due to unknown reasons. As for the sec63 Cas9-RNP injected larvae, the 
failure to inflate their swim bladders is at least one major reason why these fish did not 
survive to adulthood. As lrp5 mutations in zebrafish were previously shown to results in 
severe developmental defects 32,33, the in-frame lrp5 mutations identified in adult Cas9-RNP 
inject fish likely do not result in complete loss of function. Alternatively, the mosaic nature of 
the introduced somatic mutations could also leave sufficient cells with intact lrp5 for normal 
development. Both prkcsh and sec63 fish displayed a failure to thrive as judged by total body 
length at 5dpf. Due to the aforementioned developmental problems of mutants, we adapted 
our approach to a gene-targeting assay, in which we directly analyzed the phenotype of 
larvae injected with highly efficient Cas9-RNP complexes targeting sec63 and prkcsh.  As 
mentioned before, these Cas9-NRP-injected, somatic mutant larvae are also known as 
crispants. Several studies have previously shown that this approach can result in sufficient 
cells with somatic mutations to mimic the effect of homozygous mutations 34-37. For this 
purpose, we established a reliable method to concurrently determine both the genotype and 
phenotype of individual crispants. 
With this strategy, prkcsh, sec63 and double crispants did not show polycystic livers on 
histologic sections. Likely, as larvae developed from Cas9-NRP-injected eggs, neither Prkcsh 
nor Sec63 protein seems to severely influence embryonic development. The proteins appear 
to have a detrimental effect on larval development (in case of sec63 crispants: such as swim-
bladder inflation).  
Our data are consistent with three of the four previously described experiments for ADPLD 
genes in zebrafish, as described below. The phenotype of our sec63 crispant larvae is in line 
with that previously reported for homozygous sec63st67/st67 mutation fish 28. St67 fish fail to 
inflate swim bladders and show decreased total body length, which we confirmed in our 
experiments. The st67 allele is the result of chemical mutagenesis. As such, sec63st67/st67 fish 
may carry additional mutations in the genome. The fact that we find a similar phenotype in 
sec63 crispants larvae indicates that the failure to inflate swim bladders is indeed the result 
of loss of Sec63 function.  It furthermore shows that our method of transient gene-targeting 
with CRISPR-Cas9 injection and subsequent phenotypic analysis of individual fish shortly 
after injection is reliable. Similar to the sec63st67/st67 larvae, our crispants did not show liver 
cysts during early larval development as a phenotypic consequence of the mutations.  
Our results are also consistent with experimental data that find MOs against lrp5 paralogue 
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lrp6 are lethal when knockdown is complete 32. Only careful titration of the MO to lead to 
incomplete knockdown resulted in live fish. 
Similarly, transient CRISPR-Cas9 mediated gene editing of lrp5 in zebrafish was also 
previously described to result in developmental defects of skeletal and neural tissue 33. The 
study authors did not determine mutagenesis frequency, type of mutations, or the presence 
of mutations in the fish whose phenotype they described.  They also did not describe the 
hepatic phenotype. Our approach is more reliable since we, in contrast to the 
aforementioned study, determined the presence of somatic mutations in individual larvae 
prior to phenotypic analysis.   
The lack of liver cysts in our experiments conflict with a morpholino (MO) knockdown study 
for the ADPLD genes prkcsh, sec63, and pkd1 27. This study finds abnormal body curvature 
and liver cysts in the morphants. Discrepancies between phenotypes of zebrafish knock-outs 
and MO knockdowns of the same gene could be the result of off-target effects and MO 
toxicity, but also from the knockdown of maternally contributed mRNA with translation 
blocking MOs. Several phenotypes, such as body axis curvature, pericardial edema and renal 
cyst formation can also result from off-target effects or MO toxicity. Although liver cysts 
have not been described before to result from off-target effects or MO toxicity, it has to the 
best of our knowledge never been investigated, as liver cyst formation can only be 
determined with histological analysis. As proper controls to establish knockdown specificity 
were not described in the aforementioned ADPLD study, it cannot be excluded that the liver 
cysts result from unwanted MO effects. Their finding that liver cyst formation can be 
attenuated by treatment with pasireotide; a drug prescribed to curtail cyst growth does 
support their description of liver cysts in these morphants however. Although differential 
effects of MOs and CRISPR-Cas9 knockdown due to different compensatory mechanisms 
cannot be excluded, it is likely that limitations in the experimental design underlie the 
observed differences in phenotype.  
It was previously shown in mouse models that knockout of multiple polycystic liver genes 
speeds up the development of liver cysts 21. In an attempt to create a genetic environment in 
favor of early liver cyst development, we performed multiplex genome editing, targeting 
prkcsh, sec63 and lrp5. The genetic results were similar to those previously described for 
multiplex genome editing 31. In the cited study, zebrafish with mutations in up to five genetic 
loci were developed. The generation of double mutants and even a triple mutant in our 
study further confirms their reported results.  
We considered the possibility that the genetic mosaicism observed in the crispants could 
confound results, yet found this to be unlikely due to the similarity of the sec63st67/st67 
mutant to our sec63 crispants 28. Additionally, several recent studies found a consistent 
phenotype of its crispants with data from other sources like morphants and disease-specific 
human cells 34-37.  
It remains difficult to explain the lack of cyst formation in zebrafish after mutagenesis of the 
genes underlying human liver cyst development. One probable cause might be that the cysts 
need more time to develop, as these fish all died before reaching adulthood. Another 
possible cause are potential differences underlying biliary tract development in humans and 
zebrafish 38, for example in ciliogenesis. This might need to be addressed in future studies.  
We suspect that more time is needed for cyst development in zebrafish with mutations in 
ADPLD genes. However, mutations in these genes effect survival of the fish, making it 
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impossible to study their effects on liver morphology and function. Therefore, we suggest 
liver-specific and / or conditional knockout fish should be the next step in this line of 
research. This approach has already been taken to develop liver cysts by conditional liver-
specific Prkcsh and Sec63 knockout in mice 21.  The gRNAs for sec63 and prkcsh, described in 
this paper, could be expressed in concordance with Cas9 under transcriptional control of a 
liver-specific promotor, such as fabp10 39. With this method, we can abolish the lethal 
effects that loss of function of the ADPLD genes has on other tissues than the liver. Such an 
elegant model can make a valuable contribution to our understanding of ADPLD 
pathophysiology, and might be relevant to more dominant disorders with loss-of-
heterozygosity as a mechanism of disease.  
Concluding, Cas9-RNP mediated mutagenesis of prkcsh, sec63 and lrp5 in zebrafish has a 
significant effect on zebrafish development. As a result, adult fish carrying nonsense 
mutations in these genes could not be obtained. Analyses of the Cas9-RNP injected larvae 
with somatic mutations in these genes revealed consistent absence of liver cysts. It appears 
that the genetic mechanism of ADPLD, loss of heterozygosity (LOH), cannot be modeled in 
zebrafish by means of conventional mutants, or the Cas9-RNP injected somatic mutants 
called crispants. Therefore, we recommend a more elegant approach, using e.g. tissue 
specific knockouts, for all genetic diseases that are the result LOH.  
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Much of our understanding of human diseases comes from the study of model systems such 
as cell lines. Cell lines derive from cells that have obtained the property to proliferate 
indefinitely, often by immortalization or isolation from cancerous tissue. They have the great 
advantage that they are easy to work with and can be kept in culture almost endlessly. The 
disadvantage is that they have lost the genetic signature of healthy primary cells, thwarting 
the interpretation of test results. This has led to the search for human cell systems that 
accurately recapitulate healthy or disease human primary tissues. Advances in stem cell 
technology have made it possible to create, maintain and expand induced or adult stem cells 
while they retain multi-lineage potential. This has led to the development of so-called 
organoids, which is defined as a 3D cellular cluster derived exclusively from primary tissue, 
embryonic stem cells or induced pluripotent stem cells (iPSCs). Organoids are capable of self-
renewal and self-organization into multiple types of differentiated cells, while maintaining 
the phenotype of the original tissue. In view of these advantageous properties organoids 
have been generated for many of the gastrointestinal tissues, particularly colon and liver but 
also stomach [1, 2]. Pancreatic organoids have gone through a long developmental phase, 
and have recently matured to their first practical application. Starting with the discovery that 
pinpointed the lack of insulin as a cause for diabetes in 1920s, scientists attempted to use 
artificial pancreatic tissue as a path towards a cure. As of 2005, scientists turned to iPSCs to 
develop in vitro pancreatic cells. Taking a long route from definite endoderm specification 
[3], towards foregut endoderm and pancreatic endoderm specification [4], and finally ending 
with development of pancreatic β-cells [5, 6], we can model pancreatic development from 
start to finish. One man’s particular crusade against the type I diabetes of his children, 
culminated in the production of artificial human glucose-sensitive, insulin-secreting beta 
cells in a petri dish [6]. Testament to this scientific tour-de-force is the addition of alpha and 
delta cells to the system. Despite this remarkable progress, development of iPSC-derived 
pancreatic cells of acinar and ductal lineage have long remained elusive. In 2015, scientists 
from the group of Hans Clevers in the Netherlands established conditions for the culture of 
human adult pancreatic stem cells [7], following their culturing recipe of human adult 
intestinal stem cells [1]. Subsequent experimentation led to the mastering of the conditions 
for 3D culture of pancreatic ductal and acinar cells from iPSCs, opening up a wealth of 
possibilities to model hereditary diseases of the (exocrine) pancreas [8].  One of the most 
common inherited diseases of the pancreas is cystic fibrosis (CF). An important phenotypical 
expression of CF is exocrine pancreatic failure which follows the more common pulmonary 
symptoms. CF is an autosomal recessive disease caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR). This gene encodes a chloride channel that is 
vital for electrolyte and fluid secretion of bronchiolar and ductal epithelia. Defective CFTR 
results in decreased secretion of chloride and increased reabsorption of sodium and water 
across epithelial cells. This increases viscosity and reduces clearance of secretions from the 
respiratory tract, pancreas, GI tract, and sweat glands.  The central pathology of CF is CFTR 
dysfunction and fortunately there are many CFTR modifiers in clinical development. These 
agents activate or correct CFTR channel function. In view of the large number and variable 
effects of underlying CFTR mutations, the prediction of a clinical response to new 
therapeutics in a particular patient represents a significant hurdle. This is where organoids 
can really make the difference. Organoids recapitulate the genotype and phenotype to the 
level that they are reminiscent of the tissue under study in both architecture and 
composition. Indeed, primary intestinal organoids from CF patients show strongly decreased 
swelling in comparison to those of healthy subjects when induced by forskolin. CFTR 
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chemical corrector VX-809 (lumacaftor) and potentiator VX-770 (ivacaftor) have been shown 
to restore function of these CF organoids [9]. On subsequent testing of rectum-derived 
organoids, in vitro drug responses did correlate with outcome data from clinical trials of 
these two drugs [10].  In this issue of Gut, Hohwieler and colleagues further advance the 
technology and now report a method to produce pancreatic exocrine cells from human 
pluripotent stem cells using a (mostly) small-molecule based protocol [11]. They use iPSC 
cells generated from cystic fibrosis patients to model a CFTR-like phenotype in organoids. 
This approach has the advantage that it better mirrors the phenotypical, ultrastructural and 
functional features of mature pancreatic tissue.  
The authors started out by achieving high yields of PDX1-positive pancreatic endoderm 
through stimulation of their set of small molecules. Several iPSC lines were then coaxed into 
PDX1/NKX6.1-positive pancreatic progenitors (PPs) using growth factors leading to sustained 
exocrine and ductal marker expression. Pancreatic maturation into cyst-like pancreatic 
organoids (POs) was aided by placement of these PPs in Matrigel facilitating 3-dimensional 
development. These POs expressed specific exocrine markers such as amylase, chymotrypsin 
C, SOX9 and keratin-19. In addition, organoids displayed carbonic anhydrase activity and 
CFTR expression, while ultrastructural analysis indicated presence of microvilli, tight 
junctions and secretory granula characteristic of the exocrine pancreas. The authors then 
moved on to disease modeling. By reprogramming keratinocytes derived from hair of two CF 
patients, the authors developed clonal iPSC lines carrying bonafide CF mutations that lead to 
loss of CFTR function. They convincingly show that POs with mutant CFTR developed 
similarly to those with wild type CFTR. Upon transplantation into mice, both type of POs 
developed into cells bearing markers of ductal, acinar and beta cells. The CF phenotype 
became apparent because CFTR channel activators forskolin and IBMX elicited luminal 
swelling of POs with wild-type CFTR but not with mutant CFTR channels. These iPSC-derived 
POs respond to forskolin and CFTR-correctors similarly to the rectal organoids developed by 
Clevers. CFTR gene supplementation through chemically modified RNA also led to 
phenotypic rescue.  
The apparent difference in organoid swelling may serve as a fine readout for the 
identification of CFTR enhancers. Indeed, this model can act as a humanized platform for 
(organ- and patient-specific) drug-screening and allow testing of a wealth of human 
therapeutic options, including gene therapy. As such it embodies true precision medicine, as 
we may expect that results from drug interventions from a patient-specific PO can be 
translated faithfully in that patient.  More importantly, their model is a significant step closer 
to the relevant target tissue, while their source materials, keratinocytes, have the advantage 
that they can be obtained non-invasively.  All in all this study adds a new model for the study 
of diseases of the exocrine pancreas, and provides clinicians with a non-invasively derived 
tool for individually predicting patient clinical response to new CF pharmaceuticals.  
The organoid revolution has expanded to areas outside the laboratory space and has begun 
to enter the arena of clinical gastroenterology.  The shrewd use of organoids by Hohwieler et 
al. to study pancreatic disease is just one example of the wealth of possibilities that are just 
around the corner. It is easy to predict that organoids will help us to navigate our way 
through drug development in a time efficient and cost-effective way.  
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Chapter 8 
Chapter discussion 
ADPLD is a disease with major parts of its pathophysiology unexplained, and its mechanisms 
of disease are currently under considerable scrutiny. For up to 80% of patients no genetic 
basis for the disease was previously found (1-3). Even with the most recently discovered 
genes, only 50% have a genetically pinpointed cause (4). Within families with similar 
mutations, large discrepancies in phenotype cannot be explained (3, 5-7). It remains unclear 
which pathway becomes disrupted after loss of central cystogenic component polycystin-1 
(8), although the cyst gene LRP5 might point towards Wnt signaling (2). Even where a 
consensus exists on primary cilia as the organelle causative of cyst development, this view is 
under debate. No animal model currently exists that accurately recapitulates ADPLD. 
Somatostatin analogues remain expensive and with only limited effects in curtailing cyst 
growth. Unsurprisingly, no pharmacological cure currently exists.  
In this chapter, the results of this thesis’ multipronged approach to tackle these issues by 
answering key research questions using studies at a genetic, RNA, protein, pathway, 
organelle, stem cell and organismal level, are recapitulated and critically discussed in view of 
the current knowledge of the field. In addition, an outlook to and perspectives for future 
research are proposed. Finally, an important overview is presented coining the opportunities 
for therapy, both available and under development.  
1.) Which underlying germline and somatic genomic abnormalities are present in ADPLD? 
(chapters 3, 4) 
We isolated DNA from biliary cells obtained from 46 cyst fluid and cyst epithelium samples 
from 23 patients, and analyzed these using high-density SNP arrays to detect LOH 
encompassing novel genes. In accordance with previous results, we found that in 76% 
(22/29) and 67% (2/3) of liver cysts of PRKCSH and PKD1 mutation patients respectively, LOH 
is present. We additionally found LOH in one cyst of a SEC63 mutation carrier. Abnormalities 
in novel regions outside of known regions underlying cyst formation were present in 12 of 23 
patients. Germline DNA of three individual patients contained aberrations at four regions. 
One patient with a known PRKCSH mutation harbored a complex rearrangement at 
chromosome 2q13, and this led to haploinsufficiency of the BUB1 gene. In the germline of 
another PRKCSH mutation patient trisomy X (47XXX) was present. The final germline 
abnormality was present in the DNA of a patient without germline mutations in any of the 
known genes underlying cyst development. Her DNA harbored copy number loss at 
chromosome 9q and an LOH region of chromosome 3p. The last 3p region overlapped with 
somatic LOH of another two patients. 
Literature comparison 
Our findings are consistent with previous studies by Janssen and colleagues that show 
somatic second hits leading to LOH as the main genetic mechanism in cystogenesis (9-11). 
When combining our data with these studies, we find that somatic second hits are present in 
79%, 13%, 100%, and 83% of liver cysts of patients with mutations in PRKCSH, SEC63, PKD1, 
and PKD2, respectively (figure 1). A small side-note should be made with regard to the 
occurrence of LOH in SEC63 mutant cysts; although Janssen’s study included 14 cysts, these 
came from only one patient. A second patient was included in our data, indicating that LOH 
was actually present in both analyzed patients that carry a SEC63 germline mutation. 
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Moreover, the predominant mechanism of LOH consistently appears to be telomeric CNN 
LOH in case of PRKCSH. Contrarily, PKD1, PKD2 and SEC63 LOH appears to occur by 
interstitial deletions.  
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Figure 1. Somatic second hits are present in PRKCSH, SEC63, PKD1, and PKD2 mutation cysts. 
Somatic second hits are defined as LOH or mutation of wild-type alleles. The numbers are calculated 
from data presented in chapter 3 Wills et al, Wills, Cnossen et al 2016, and historic data from Janssen 
et al, 2011; Janssen et al, 2012; Janssen et al 2015. 
*1 ADPKD patient with unknown germline mutation excluded 
One feature of ADPLD that remains unexplained is the low penetrance and mild phenotype 
in some family members with known mutations in genes underlying the disease (3, 5-7).  
Evidence of familial clustering of severe PLD suggests that genetic modifiers may play a role. 
An example is the hypothesis that incompletely penetrant heterozygous variants in LRP5 
may play a role in the penetrance of the PCLD phenotype of PKHD1 carriers, as the authors 
noted co-occurrence of variants in both genes (4). Secondary germline abnormalities found 
in PRKCSH mutation patients may provide further insight into the cause. Our data may 
provide such an example. The complex aberration on chromosome 2q13 leads to 
haploinsufficiency of the BUB1 gene. The protein product of this gene plays a crucial role in 
mitotic spindle assembly checkpoint and thereby chromosome congression (the process 
whereby chromosomes are properly aligned along the mitotic spindle) (12). Loss of the 
protein leads to aneuploidy and chromosomal instability. Loss of function or reduced 
expression of BUB1 is present in human tumors such as colon, esophageal, gastric, breast 
cancer and melanoma (13, 14). Consistently, mice with haploinsufficiency of BUB1 together 
with heterozygous mutations in genes such as APC and P53 present with increased colon 
tumorigenesis and thymic lymphomagenesis (15). Although dependent on the genetic 
background, these data show that BUB1 haploinsufficiency can drive tumor formation 
through tumor suppressor gene LOH. Indeed, in cysts from the patient we found CNN LOH 
encompassing PRKCSH on chromosome 19, and an interstitial chromosome 7p deletion.  
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Recurrent CNN LOH on chromosome 3p21.3 in germline (n=1) and somatic (n=2) DNA from 
ADPLD patients, may have implicated another tumor suppressor region in disease 
pathophysiology. The region contains a cluster of tumor suppressor genes. It is involved in 
early formation of tumors, including hepatocarcinomas and cholangiocarcinomas (16-18). 
Both BUB1 and the 3p21.3 tumorigenesis related regions may represent genetic modifiers 
involved in causing differences in disease penetrance in ADPLD families. 
Strengths and limitations 
A strong point of our approach is that our high-density SNP array can in principle detect 
larger LOH regions. However, although it did detect abnormalities for known genes PRKCSH 
and SEC63, novel regions were not definitively identified. Only recurrent LOH on 
chromosome 3p was found, the meaning of which is not directly clear. 
The main limitation of our approach to study germline and somatic genomic abnormalities 
lies in our methodology. Whereas medium to large chromosomal abnormalities are easily 
detected by our employed high-density SNP array, smaller mutations are likely missed. As 
we cross-sectionally linked genetic regions to disease, we cannot confer causality of the 
mutations we found to the phenotype we are studying.  
Outlook 
The new data is valuable, yet requires validation through additional studies as described 
hereafter. Causality may be proven by mutating the affected regions in animal models and 
determining the phenotypic outcome. This includes BUB1 and recurrent LOH on 
chromosome 3p. Adding BUB1 haploinsufficiency to a genetically susceptible animal model 
(e.g. Pkd2(WS25/-), Prkcsh(+/-) or Sec63(+/-) mice) could elucidate whether cystogenesis 
occurs earlier, more frequently, or more severely. The LOH region on chromosome 3p could 
be studied in a similar manner. 
Another main purpose of future genetic studies is to determine the genetic defects 
responsible for the remaining >50% of genetically unexplained APLD cases. Since family-
based linkage studies and SNP array LOH region studies have yielded no new genes in the 
past years, several alternative methods might be applied. In ADPLD cohorts, a large panel of 
hypothesized candidate-genes can be screened by molecular inversion probe analysis (19, 
20). Any commonly affected gene or mutation can be selected for further evaluation of its 
pathogenicity. Given the strongly reduced cost of whole-exome sequencing, the remaining 
cohort could be genetically mapped by this technique. This may unveil non-biased common 
genetic abnormalities that pinpoint a new disease gene. Whole-genome sequencing may 
next provide a final strategy to uncover new disease causing variants that were not 
identified by the other techniques. Non-coding regions of the genome have hardly been 
studied in ADPLD, and may contain explanative abnormalities. 
 
2.) What are the characteristics of cultured cyst and normal biliary cells as measured by 
RNA expression? Are any specific pathways dysregulated in liver cyst cells as compared to 
normal biliary cells? (chapter 6) 
In chapter 6 we used RNA sequencing to determine the gene expression pattern of eight 
liver cyst cell cultures and compared that with four normal biliary cell cultures. The cell 
cultures expressed all genes underlying cyst formation when mutated, and many genes 
considered important in the process. They expressed ciliary genes and genes of the cellular 
machinery involved in the somatostatin response (i.e. somatostatin receptors and adenylyl 
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cyclases). Although gene expression profiles were heterogeneous, with overlap between 
diseased and normal tissue, this appeared dependent on the genetic background. We found 
that two PRKCSH mutants clustered separately from the other normal and polycystic 
cultures on a principal components analysis (PCA), and that a PKD1 mutant also separates by 
PCA. No pathways were found to be regulated significantly different between liver cyst and 
control samples with gene set enrichment analysis. 
Literature comparison 
The heterogeneous expression pattern appears to indicate that variability of gene expression 
between humans exceeds any homogeneity induced by cyst gene mutations. It also fits 
genetic data that ADPLD is a heterogeneous disease, wherein >50% of cases go unexplained 
on a genetic basis (1, 2, 4). Two cysts with a similar PRKCSH LOH genetic background did 
cluster together, indicating that the pathways disturbed in these cell lines are similar. More 
cysts with a similar genetic background are required for further analysis. Pathways such as 
Wnt, Notch, BMP, pleiotropic growth factor/receptor tyrosine kinase may reveal relevant 
differential expression, as has been shown in ADPKD (21, 22). Downregulation of cilium-
associated genes such as HNF1B, PKHD1, IFT88 and CYS1 may be present in ADPKD (22), 
which is relevant to the current discussion on the role of primary cilia in cyst development. 
These genes were indeed expressed in the cultured liver stem cells, indicating the value of 
the cultures for further studies.  
Our findings highlight the importance of unraveling the consequences of loss of specific 
genes underlying liver cysts, rather than taking the cohort as a whole. The development of 
these liver cyst organoids allows this. As we obtain organoids from more patients and cysts, 
larger cohorts with specific genetic mutations might be compared to obtain gene- or patient-
specific abnormal expression patterns. 
Strengths and limitations 
RNAseq allows detection of a large number of RNA transcripts at a high coverage depth to 
unravel disturbed gene expression pathways. Several large disadvantages exist however. The 
genetic heterogeneity of PLD confounded detection of a specific dysregulated pathway. We 
found the clearest results by comparing the PRKCSH mutant samples to the remaining 
samples, which indicated disturbance of ER related pathways. Our samples did not include 
biological replicates. Although we attempted to apply a workaround by comparing the PLD 
group to normal liver cell group, a subsequent attempt might better use biological 
replicates, as few dysregulated pathways were present. This might yield more robust data 
for the analysis of each sample. Another confounder may be the culture conditions we 
applied. Under these circumstances, few to none differentially regulated pathways existed in 
the data. Although this could be related to genetic heterogeneity, this may also indicate that 
both normal and PLD cells adopt a similar expression pattern in our culture media. 
Alternatively, one normal liver sample displayed different gene expression in comparison to 
the other normal samples. Skewing by this sample of the gene expression of the normal 
sample group may be the cause of the low number of differentially expressed pathways 
between the normal and PLD samples groups.  
Summarizing, although relevant expression data was generated, subsequent studies may 
benefit from comparing larger groups with similar genetics, while preferably using biological 
replicates. 
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Outlook 
It proved very difficult to extract pathways involved in cystogenesis due to technical issues. 
Three methodological adjustments may resolve the underlying technical issues. First, 
studying the gene expression of many organoids with a similar genetic background may yield 
a novel disturbed pathway. The similar genetic background is essential, in our study only 
these cultures clustered together. This can be done in patient cells with the frequent PRKCSH 
mutation, but can also be performed in CRISPR-Cas9 generated knockout cell lines for rarer 
mutations.  
A second method entails growing different normal and patient stem cell cultures, and 
removing (or reducing) single growth factors. As the serum-less culture method contains 
only defined biological agents, removing each will likely uncover a pathway that is 
overactivated in cyst cultures in comparison to normal cells. Depending on the pathway, this 
may take some time; growth factors like EGF can be removed for many passages without 
effect on normal cell cultures. In this manner, researchers uncovered specific overactivated 
pathways like Wnt/APC in colon cell carcinomas (23). Later they experimentally confirmed 
the genetic basis of how these stem cells grow without their usual growth factors (24).  
Third, individual stem cell cultures can be screened with libraries of small molecules with a 
broad spectrum of pharmaceutical action (25, 26). Specific vulnerabilities or abnormal 
pathways may be uncovered and disrupted in this manner. 
Combining these approaches may increase the likelihood that one or several abnormal 
pathways in genetic subgroups of ADPLD will be uncovered. 
3.) What is the ADPLD-associated protein interactome? (chapter 5) 
To obtain clues about any disrupted pathways in ADPLD, we used a ‘guilt-by-association’ 
approach, employing tandem affinity purification (TAP) to isolate ADPLD protein complexes, 
and subsequently use mass spectrometry (MS) to identify their protein composition. 
We elucidated an interactome surrounding the known proteins underlying hepatic 
cystogenesis. The PRKCSH protein, also known as glucosidase 2 beta (GIIB), connected to 
glucosidase 2 alpha (GIIA, protein product of GANAB) in all 19 TAP-MS repeats. SEC63p 
captured SEC61A1 and SEC61B in 4 successful experiments. As these are all known 
interactions in the endoplasmic reticulum, this validated the specificity of our approach. 
Although the functional relationship with ADPLD requires further investigation, a number of 
exciting interactome members was unveiled in our experiments. The discovery of SEC61B as 
an ADPLD-causing gene validates the ‘guilt-by-association’ approach method as a gene-
discovery tool for hepatic cyst development. SEC61B was not known to cause ADPLD at the 
start of the study. We considered nucleoporin 210kDa (5/19 GIIB TAP-MS), peroxisomal 
biogenesis factor 14 (PEX14; 5/19 GIIB TAP-MS), and PEX19 (1/4 SEC63p TAP-MS) frequent 
interactors. We additionally found five more interacting proteins that were present in all 
SEC63p TAP-MS repeats: transducin (beta)-like 2 (TBL2), thymopoietin (TMPO), ADP-
ribosylation factor GTPase activating protein 1 (ARFGAP1), methionyl-tRNA synthetase 
(MRS), heavy chain 7 of axonemal dynein (DNAH7). 
Literature comparison 
The interactions with PEX14 and PEX19 confirmed the ER biogenesis of peroxisomal proteins 
(27), where especially the SEC61/SEC62/SEC63 complex appears to play a crucial role for the 
formation of peroxisomes. Even more interesting were interacting proteins that all three 
proteins underlying ADPLD had in common, potentially pointing towards the common 
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mechanism driving hepatic cystogenesis. Particularly frequent was filamin A, a scaffold 
protein that is important in cellular signaling. FLNA is a molecular scaffold involved in cell 
motility and signaling (28-30), and its loss leads to basal body positioning and ciliogenesis 
defects. We thus propose that the link of FLNA to the ADPLD proteins may (partially) explain 
impaired ciliogenesis observed in ADPLD gene knockouts. In summary, this interactome 
underlying cyst formation may provide a framework to explain direct abnormalities following 
loss of protein expression or disrupted protein function due to genetic mutation. 
Strengths and limitations 
The tandem affinity proteomics used in our study is a powerful technique (31, 32), and 
essential to the success of our guilt-by-association approach. Indicative of this is that the 
gene encoding GIIA, the protein most prominently associating to GIIB in our dataset, was 
recently indeed found to be mutated in ADPLD (3). Similarly, the gene encoding SEC61B, the 
protein associated to SEC63p in our dataset, was recently also found to be mutated in ADPLD 
(4). Similar to GIIB and SEC63p defects, loss of GIIA and SEC61B leads to reduced maturation 
and ciliary localization of PC1 and PC2. Loss of these latter proteins putatively leads to cyst 
development. Further extrapolating from the data, it is possible that SEC61A1 is also 
involved in cystogenesis. In comparison to SEC61B, this gene is more conserved and more 
essential to SEC61 complex function however (4, 33). These results indicate that at least a 
subset of the proteins in our ADPLD-associated interactome are encoded by candidate genes 
for the disease, and can be included in targeted gene sets for ADPLD diagnostics, e.g. 
employing MIPs. 
The main surprise of our affinity proteomics study to us is that it failed to detect any Wnt-
signaling related partners for LRP5, or its intracellular domain. There are multiple possible 
explanations. First, the cell lines studies may not be suitable to detect Wnt interaction 
partners due to lack of expression. This seems unlikely however; as Wnt has previously been 
studied in HEK293T cells and assays indicated clear Wnt activity (34). Second, our method 
may not be sufficiently suitable to detect Wnt signaling interactors, for example due to the 
transient a nature or low affinity of interactions between Wnt signaling components. 
Outlook 
In order to optimize the dissection of the LRP5-associated interactome to include the 
expected Wnt signaling components, two routes may be explored. First, a chemical cross-
linking step may be included in the affinity proteomics procedure to “freeze” the transient or 
weak interactions (35, 36). This will also allow a more structural investigation of the 
interaction interfaces of the identified (sub) complexes. Second, an alternative approach to 
the proteomics can be employed, such as yeast-two-hybrid screen of a relevant cDNA library 
(e.g. human cholangiocyte derived) to identify binary interaction partners for LRP5. 
Nonetheless, the novel interaction partner FLNA is a potentially central component of the 
PLD interactome, even for LRP5. One way to validate our data might be to further study the 
interactions by co-immunoprecipitation and co-localization on immunofluorescence. 
Interacting protein motifs may then be determined, mutated or removed to further assess 
the molecular interactions or effects of gene mutations. 
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4.) What is the effect of mutation of genes underlying ADPLD on primary cilia and Wnt 
signaling? (chapter 5) 
In chapter 4 we use CRISPR-Cas9 to induce mutations in the genes underlying ADPLD. We 
found that we can efficiently knock out PRKCSH, SEC63, and LRP5 in H69 cholangiocytes and 
HEK293T cells. In both of these cell lines, formation of primary cilia was significantly reduced 
by loss of PRKCSH or SEC63. In H69 cholangiocytes, Wnt signaling is additionally disrupted 
significantly as measured by luciferase assay and axin 2 mRNA expression. These findings 
indicate cilium formation requires normal PRKCSH and SEC63 expression, and that Wnt 
signaling may similarly be affected depending on the cell type.  
Literature comparison 
The reduced ciliation of PRKCSH and SEC63 knockout cells and the cell type-specific effects 
on Wnt signaling have several implications. Normal biliary ducts have cilia on virtually all 
cells, which organelles almost disappear in large sized liver cysts (1/200 cells) (37, 38). 
Functional ciliary abnormalities by loss of polycystins are therefore not the only 
consequence of PRKCSH and SEC63 loss. Whether the structural ciliary abnormalities follow 
functional ciliary abnormalities, or are a direct result of losing genes involved in cystogenesis 
remains unclear. Ca2+ and cAMP signaling may influence ciliary length (39), and polycystins 
influence these pathways. Diminished growth of primary cilia could be related to these 
processes.  
Reduced Wnt signaling following PRKCSH and SEC63 mutation in H69 cholangiocytes is 
similar to that observed with LRP5 mutations from patients (2). Surprisingly, out of the many 
functions contributed to GIIB and SEC63p, this is one of the first to be cell-type specific. 
HEK293T cells only showed inconsistent effects of loss of the genes. It might be a bridge too 
far to claim this underlies the tissue-specific outcomes of loss-of-heterozygosity, but it may 
point in that direction. 
The cause of the Wnt impairment is a second issue. Our data indicate GIIA as an interactor of 
the intracellular domain of LRP5. LRP5 contains at least 4 n-glycosylation sites that are 
known to be processed by glucosidase II. For LRP6, a homologue of LRP5, the n-glycosylation 
sites are necessary for normal maturation, plasma membrane localization and Wnt signaling 
(40). We believe that Wnt impairment following loss of PRKCSH may be LRP5-dependent. 
Whether SEC63 is important for LRP5 membrane localization is not known, but the protein 
may link to Wnt signaling through nucleoredoxin according to literature (41). 
The N-glycosylation of LRP5 however, that we could observe in HEK293T cells was not 
diminished by depletion of either PRKCSH/GIIB or SEC63, which suggests that LRP5 is not a 
substrate of glucosidase II and SEC63p is not involved in the regulation of LRP5 N-
glycosylation. Our findings together still strengthen the case for Wnt signaling abnormalities 
as a common contributing factor in hepatic liver cyst development. If this is unrelated to 
maturation and trafficking of polycystin-1 remains to be determined. It has been suggested 
that PC1 is a coreceptor for noncanonical Wnt (Ca2+) signaling, which may imply an indirect 
relationship between LRP5 and PC1 (4). 
The fact that we determined that knock out of either PRKCSH or SEC63 led to reduced levels 
of LRP5, while the transcript levels were slightly elevated, suggest connectivity of the ADPLD-
associated pathways downstream of gene transcription. 
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Strengths and limitations 
We managed to study primary cilia and Wnt signaling in ADPLD gene knockouts as expected. 
One problem of CRISPR-Cas9 may be aspecificity of induced double-stranded breaks. 
Obtained results may then be related to off-target mutations. Similarly, when growing out 
clones from single cells, a confounder effect may be clone-specific, rather than mutation-
specific. By using multiple clones for each experiment we likely circumvented this problem. 
Furthermore, effects on cilia and Wnt were not only observed in multiple clones, but also in 
both (PRKCSH and SEC63) genetic knockouts. This strengthens the validity of our 
observations and conclusions. 
Outlook 
Further studies on the effects of GANAB, ALG8, and SEC61B knockout on ciliogenesis and 
Wnt signaling are warranted, as are the studies on the effect of PRKCSH and SEC63 knockout. 
Some researchers suggest ciliary abnormalities are a bystander effect, rather than a 
causative effect in cyst development ((42, 43), see below).  A primary effect of PRKCSH and 
SEC63 knockout is reduced maturation and localization of PC1 and PC2 due to defective n-
glycosylation and quality control (8). This reduced polycystin expression is likely causative for 
cyst development, as increasing polycystin expression in PRKCSH and SEC63 knockouts could 
partially rescue the cyst phenotype. Reduced ciliogenesis could be a secondary effect of 
polycystin loss. Ciliary length depends on ciliary signaling routes such as cAMP/Ca2+ (39). 
These signaling pathways are affected by polycystins, although possibly not the polycystins 
themselves, but by polycystin-like proteins in the primary cilia (42). Future research should 
address the effect of PRKCSH and SEC63 mutation on PKD1 and PKD2, as well as look at 
primary cilia in PKD1 and PKD2 knockouts. Even before we understand the precise 
pathogenetic basis of polycystic liver disease, it may be valuable to use pharmacological 
screens to detect improved ciliogenesis in PLD gene knockout cells. The impaired ciliogenesis 
represents a first, easily detectable abnormal readout of PLD cells.  
5.) Do stem cells occur in liver cysts and what are their characteristics? (chapter 6) 
In chapter 6 we apply conditions for adult liver stem cell culture on cells deriving from cyst 
epithelium and fluid, and find development of liver cyst stem cells. To our knowledge, we 
were the first to culture cyst cholangiocytes from different patients efficiently and reliably. 
Characteristics of the cultured cholangiocytes were consistent with cyst epithelial origin. We 
found presence of PRKCSH, SEC63, and PKD1 LOH in cultures from respective mutation 
carriers. The cyst stem cells were bipotent, and could differentiate into biliary cells and 
hepatocytes. In multiple cultures, expression of biliary marker keratin-19 together with 
primary cilia marker ARL13B was present. Culture with somatostatin analogue lanreotide 
reduced expansion of the cyst cultures.  
Summarizing, we believe cyst stem cell culture represents a significant step forward for the 
ADPLD research field and may in the future be used to unravel pro-cystogenic pathways and 
drug modifiers. 
Literature comparison 
The cultured liver cyst stem cells signify a novel opportunity for research of ADPLD. These 
cells possess the exact genetic background responsible for cyst development. This contrasts 
with previous attempts with cholangiocytes derived from induced pluripotent stem cells or 
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cell lines (44, 45). LOH, one of the hallmarks of cyst development (9-11, 46), is present only 
in these adult liver stem cells. This disease-specific genetic background increases the 
likelihood of detecting relevant abnormal pathways of ADPLD. 
Through genome-wide RNA sequencing it became clear that gene expression depends on the 
genetic background. Principal component analysis indicated that PRKCSH and PKD1 mutation 
cells cluster separately from remaining cells. A mutation-specific approach to elucidating 
disturbed pathways therefore may have a higher chance of yielding novel insights into 
ADPLD. Moreover, these cells allow nonbiased screens of small molecules or therapeutic 
agents (e.g. off-patent drugs) to develop new hypotheses or therapies. Especially when new 
therapeutics are available, patient-specific cyst cell cultures may be exploited for 
personalized medicine. Indeed, this has already been taken advantage of for colon 
carcinoma cells (25), whose organoid cultures are considered as an ex-vivo platform to 
personalize anti-disease treatment. 
A small, but significant additional development is the use of cyst fluid cells. Stem cells that 
derive from free-floating cholangiocytes in fluid may grow. Fluid is routinely obtained by 
aspiration sclerotherapy, and other sources of floating cholangiocytes may also exist. 
Although cholangiocarcinomas can be notoriously difficult to detect, blood-borne 
metastases may be cultured using the techniques described in Chapter 6. Especially later 
stage cholangiocarcinomas could be targets for this, and screening any obtained cultures for 
drug sensitivities may benefit patient treatment. As far-fetched as this may appear, exactly 
this has been done already with prostate cancer metastasizing in blood (47). 
Strengths and limitations 
One of the main limitations of our study described in Chapter 6 is that we did not show the 
presence of LGR5+ cells in biliary tissue or epithelia of liver cysts. However, we clearly show 
that in isolating cholangiocyte-like cells and placing them in conditions suitable for the 
expansion of adult liver stem cells, an LGR5+ population exists or can be induced. Their 
genetic background confirms the LOH hypothesis of liver cysts, and indicates a population of 
cyst stem cells that lose heterozygosity. It remains unclear whether bipotent LGR5+ stem cell 
contribute to cyst expansion, or that they are only a side phenomenon that happens to be 
exploitable for in vitro culture. Future studies may look at the presence and role of LGR5+ 
cyst stem cells in in vivo liver cysts. 
Outlook 
For the cyst-derived liver stem cells there are many additional directions for future research. 
First and foremost is to use the new cell lines for drug screens. Multiple off-patent drug 
libraries (e.g. Prestwick FDA-approved drug library (48)) exist, that allow for rapid screening 
for effective compounds with a short time to clinical application.  
A second direction is to produce primary cilia on the organoids. For this, better biliary 
differentiation is most likely required. The current strategy to induce differentiation into 
biliary cells involves removing all proliferation-stimulating factors. Although this allows for 
some differentiation to occur, the cells enter a quiescent state in which they degenerate 
within days. A differentiation growth factor cocktail is currently in development at the 
Hubrecht institute that allows the cells to differentiate and survive better. When this 
protocol is published, it will be interesting to study cilia formation in normal and cyst-derived 
organoids. 
A third aim is using the stem cells to better compare germline and somatic mutations. A 
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large biobank of different cyst stem cells is under development. When sufficient budget is 
available, or techniques have advanced to become less costly, WES or WGS may be applied 
to these cyst stem cells and their corresponding germlines. A first step has been undertaken 
by applying MIP analysis on these stem cells. 
6.) Can zebrafish model polycystic liver disease? (chapter 7) 
We attempted to develop polycystic liver disease zebrafish by knocking out the genes 
underlying ADPLD. Prkcsh and Sec63 mutagenized efficiently by CRISPR-Cas9, while Lrp5 
mutants developed only infrequently with higher injection doses. We successfully generated 
fish with mutations in both Prkcsh and Sec63. Although larvae developed, mutants died 
before reaching maturity. We found that larvae with Prkcsh and Sec63 mutation had a 
reduced length, and that Sec63 mutants did not inflate swim bladders. Larvae developed 
with in-frame Lrp5 deletions or insertions, and these grew to maturity. Compound 
heterozygotes for these in frame abnormalities did not display a phenotype with regard to 
gross morphology or length. None of the three mutants developed liver cysts, nor did 
Prkcsh/Sec63 double knockouts.  
Literature comparison 
The most significant conclusion of our zebrafish study is how discordant the phenotype of 
our fish is compared to a study describing morpholino knockdown fish (49). Whereas 
polycystic livers, curved body axis (a feature characteristic of fish with ciliopathies), and a 
response to pasireotide occurred in the knockdowns, none of our knockout fish presented 
with these abnormalities. A key oversight of this morpholino article was their description of 
a phenotype with a morpholino that did not actually target the PKD1. The larvae displayed 
polycystic livers, when in fact the morpholino targeted the reverse mRNA transcript of a 
random ion channel instead of PKD1. 
Not all was bad when comparing to previous literature. Our SEC63 knockout larvae displayed 
an absence of swim bladders, and decreased fish length. Both features are present in SEC63 
fish with homozygous Stm67 mutation (50). Our PRKCSH mutants similarly displayed a 
decreased total body length, but without a further phenotype. Importantly, larvae co-
injected with the CRISPR-Cas9 construct, but without mutation, did not display any 
phenotype.  
In doing this, we have not only established the phenotype of ADPLD gene knockout larvae, 
but also a new technique for quick genotype-phenotype screens in zebrafish. Our embryos 
were injected at the single-cell stage, and harvested at 5dpf. The larvae generally had 
different mutations present in a mosaic pattern of the body, following CRISPR-Cas9 injection. 
Nonetheless, if mutations occurred, the phenotype was consistent with that described in an 
established knockout line. We believe our technique may be a valuable addition to short-
term screening methods in zebrafish. 
Strengths and limitations 
The absence of liver cysts in our zebrafish may be caused by limitations in our study design, 
or by differences in the physiology of Danio rerio in comparison to Homo sapiens. Due to 
embryonic lethality and failure to thrive of our mutagenized zebrafish larvae, we could not 
evaluate adult livers of knockout fish. Although generally assumed to develop during 
embryology, the absence of liver cysts in zebrafish during this stage could mean two things. 
One, zebrafish do not develop liver cysts due to known ADPLD mutations, or two, zebrafish 
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develop liver cysts due to known ADPLD mutations under different conditions. Precursor 
cells may simply require more time to develop into cysts. A crucial difference exists between 
our fish and the situation in patients with ADPLD.  LOH is unlikely to play a role in our 
knockout fish, which already frequently develop compound heterozygotic mutations.  
If zebrafish cannot grow liver cysts, a different cholangiocyte physiology is a possible 
explanation. It seems that, in the current body of zebrafish literature, no cilia have ever been 
described on bile ducts. One review even noted this absence of evidence for the cellular 
structures (51). If one assumes that primary cilia play an important role in the development 
of cysts, although currently a disputed view, complete, physiological lack of cilia implicates 
lack of cysts. There can be no zebrafish cholangiociliopathy if no cilia on cholangiocytes occur 
in normal, healthy Danio rerio. 
Outlook 
Although zebrafish larvae did not develop hepatic cysts within the experimental setting we 
applied, future studies may work around the problems observed in post-natal development 
of ADPLD-relevant mutants. One way to do this is by limiting the presence of mutations to 
the liver. Ablain and colleagues have recently made available the tools and methodology for 
tissue-specific CRISPR-Cas9 mutagenesis (52).  The system works by cloning a plasmid with a 
tissue-specific promotor, a codon-optimized Cas9 enzyme, one or multiple gRNAs of choice, 
GFP and Tol2 gene transfer vector. For the zebrafish liver, a frequently used promotor is the 
FABP10 gene promotor (53). gRNAs targeting zebrafish PRKCSH, SEC63 and LRP5 are 
described in chapter 7, while the remaining components are available from commercial 
vendors. It is possible that zebrafish with this transgene in their germline may develop to 
maturity, and that their adult liver or mesonephron displays cysts. If not, one of the 
previously described hypotheses may be a cause for the lack of a phenotype.  
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Future prospects 
Hepatic cystogenesis: paradigm shift 
In late years, a shift in thinking has occurred on the relation of liver cyst development and 
primary cilia. This shift has major implications for the pathophysiology of the disease, which 
were unforeseen at the start of this thesis. Although no components of the thesis are 
invalidated, acquired data will have to be appreciated from a different vantage point. 
Analogies may be drawn to medicine, in which different fields have seen radical changes in 
treatment approach as research progresses. Examples include late versus early oral nutrition 
in acute pancreatitis patients shortly after admission (54, 55), fixed versus age-dependent 
reduction of FEV1/FVC < 70% as a criterion for chronic obstructive pulmonary disease (56), 
and step-up/pyramid approach versus a top-down/early aggressive treatment of rheumatoid 
arthritis (57). In each of these instances, the former approach replaced the latter, with great, 
irreversible changes in patient outcomes as a consequence (57). This progressive 
understanding is often a difficult topic. Our view of the optimal evidence-based model can 
shift significantly.  
A similar process is occurring in the field of cystic diseases. Whereas researchers for years, 
up to and including the start of this thesis, had considered cysts to be caused primarily by 
ciliary dysfunction, the tables are turning. More researchers have been calling to consider 
ciliopathy a side-effect of the primary cause of cyst development, rather than the primary 
cause itself. A major paradigm shift in the field of liver cysts, and progressive understanding 
indeed, considering the many studies published from the initial view. In the next paragraph 
the pros and cons of the “ciliopathy first” approach are reviewed in light of current evidence. 
Hepatic cystogenesis: primarily primary cilia? 
Important questions regarding polycystins remain unanswered to date: what function 
leading to cystogenesis is lost in PKD, and, despite their undisputed ciliary localization, is the 
cilium also the primary cellular locale of polycystin function (table 1)? Some studies suggest 
that the polycystins perform their primary function in the plasma membrane or ER (58-60), 
although this is hard to prove in absence of more functional insights.  
Whichever function they perform, their relation to ADPLD proteins GIIB and SEC63p seems 
clear following a publication by Fedeles and Somlo in 2011 (8, 61). GIIB and SEC63p are 
important for biogenesis of both polycystins, and the amount of lost polycystin-1 leads to a 
dose-dependent effect on cyst formation.  
It is clear that primary cilia are affected by loss of polycystins (37, 38), but unclear how this 
relates to cystogenesis. Somlo’s research group found that knocking out crucial ciliary 
components IFT20 and KIF3A in combination with PKD1 or PKD2 leads to decreased 
cystogenesis in a mouse model of ADPKD (62). These results suggest that the presence of 
primary cilia in absence of polycystins is worse than the absence of primary cilia altogether 
with regard to cyst development. Removing primary cilia actually ameliorates the polycystin-
absence-induced cystogenesis.  
Somlo continued to ascribe an important role for primary cilia in cyst development. In a 
subsequent paper he provided five points of evidence for his view (63): First, both 
polycystins are expressed in the ciliary membrane; Second, the majority of gene products 
associated with fibrocystic disease are expressed in the cilia-basal body complex; Third, a 
forward genetic screen in zebrafish based on cystic pronephron phenotype identified a 
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number of cilia-related proteins, including PC2; Fourth, disruption of cilia alone is sufficient 
to develop cysts in prospective testing; and Fifth, generally considered the strongest 
evidence, fibrocystic disease-associated gene products, including PC2, are associated with 
left-right axis defects in animal models. To these points, it may be added that there are 
suggestions that the polycystins function as ciliary sensors of cell injury (64), inducing 
proliferation upon damage. 
Opponents also present a large body of evidence in their favor. Most notably, there is no 
direct evidence for the exact mechanism of polycystin action in the cilium leading to 
cystogenesis (42). Despite the many gene products associated with fibrocystic disease in the 
cilia-basal body complex, this may be related to effects outside of the primary cilium. For 
example, IFT mutants appear to also affect the microtubule cytoskeleton outside of primary 
cilia (65). Left-right axis defects may also occur in the context of non-ciliary disorders due to 
aberrant FGF or Notch signaling (66, 67) (although downstream these signaling abnormalities 
may still cause ciliopathy). Additionally, a paper by Clapham and colleagues in Nature 
described no clear effect on calcium signaling by the regular polycystins in the primary cilium 
(42). Instead, PKD1L1 and PKD1L2, 2 PKD-like proteins, form ciliary ion channels responsible 
for calcium signaling in the primary cilium. The PKD1L1-PKD2L1 complex controls ciliary 
calcium concentration and modifies cilia-dependent signaling pathways such as SMO-
activated GLI2 translocation and GLI1 expression (42). Further upsetting the classic view on 
primary cilia, in March 2016 Clapham and colleagues published a follow-up paper in Nature 
that concludes that primary cilia are not calcium-responsive mechanosensors following 
extensive testing (43). Not even nodal primary cilia responsible for left-right axis 
determination showed mechanosensitive calcium responses. Any changes in calcium 
signaling always started from cytoplasmic sources during their high-speed imaging tests used 
to detect calcium flow. Clapham and colleagues conclude that situs inversus and cystic 
disease caused by loss of polycystins are not due to loss of mechanically induced cilia-
initiated calcium signaling.  
In light of all these data, it remains possible that the effect of polycystin loss on primary cilia 
is a bystander effect rather than a primary or causative effect of cystogenesis.  
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Table 1. Arguments favoring and discrediting the role of primary cilia in cystogenesis 
Pro Contra 
PC1 and PC2 localized in the primary cilium PC1 and PC2 also localized in the plasma 
membrane and ER membrane 
Disruption of cilia alone is sufficient to 
develop cysts in prospective testing 
No direct evidence for polycystin related 
ciliary effect leading to cystogenesis 
Majority of gene products associated with 
fibrocystic disease are expressed in the cilia-
basal body complex 
Many cilia-related gene products may have a 
function outside of the primary cilium 
Ciliopathy, including PC2 mutation, leads to 
left-right axis defects 
Left-right axis defects can also occur in the 
context of non-cilia disorders due to 
aberrant FGF or Notch signaling 
Ciliary polycystins putatively function as 
sensors of cell injury 
Ciliary calcium signaling is not caused by the 
polycystin complex ion channel 
 Cilia-initiated calcium signaling does not 
occur 
 
Curing polycystic liver disease: state-of-the-art and future perspectives 
Due to the rapid development of new techniques, a small section of this thesis should be 
devoted to thoughts on how to cure this disease. Surprisingly, many of the tools to cure or 
eradicate the disease may already be available. Although some are not ready (yet?), because 
they are in the early stages of development, but with time and refinement, it is likely that 
application in clinical practice will become possible. This chapter will keep to the theme of 
going from bench to bedside and will start at the genetic level, going up to the organism. 
Genetic selection or editing 
It really is a brave new world with regard to genome editing techniques, such as pre-
implantation genetic diagnostics (PGD) or genome editing through CRISPR-Cas9 or related 
methods. PGD is a technique which selects embryos following genetic analysis on one of 
eight blastomere cells on day 3 of in vitro fertilized eggs (single blastomere technique) (68, 
69). Alternatively, a blastocyst biopsy targeting the trophectoderm on day 5 of development 
can yield more DNA without sacrificing any part of the embryo. In combination with 
cryopreservation, this allows more time for genetic testing. In other words, PGD can prevent 
hereditary disease (see table 2). PGD can cost between $11,500 and 18,500 (70), while some 
technical challenges exist in the form of IVF side effects (multiple pregnancy risk, ovarian 
hyperstimulation syndrome) and risks of misdiagnosis. CRISPR-Cas9, has already been used 
to experimentally treat beta-thalassemia in non-viable human embryos (71). It will become 
possible to choose or edit genes in the germline, but we run a great risk of losing (parts of) 
our humanity, or coming down a slippery slope. With suitable knowledge and adequate 
refinement, off-target or unintended harmful effects will most likely eventually be excluded. 
The question then is which conditions to treat. Thus far, only severe hereditary diseases 
qualify for PGD, whereas less severe genetic diseases are initially excluded. PGD has 
potential social benefits in reducing the overall burden of disease, as well preventing a 
lifetime cost of chronic disease. Once the technique has been established and becomes 
more acceptable, it is likely that less severe disease will qualify for treatment. This 
represents a slippery slope as we need to start to define which inherited diseases are 
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acceptably prevented and which need to be avoided. This is an ethical tight rope. Besides 
this point, embryo selection may devalue certain lives. Clearly, great care is warranted when 
choosing which hereditary afflictions we intend to treat.  
On the Dutch website for pre-implantation genetic diagnostics couples with a greatly 
increased risk of having a child with a severe genetic condition, or increased risk of loss of 
pregnancy due to a chromosomal abnormality can apply (72). A list for previously treated 
diseases exists: 
Table 2. Diseases treated by PGD in the Netherlands, based on data from 
http://www.pgdnederland.nl/ 
Disease Primary consequence 
Huntington’s disease Neurodegeneration: mental decline, behavioral 
symptoms, muscle discoordination 
Hereditary breast-ovarian cancer Hereditary breast-ovarian cancer 
Myotonic dystrophy type I Muscle wasting, cataracts, myotonia 
Familial adenomatous polyposis coli (FAP) Numerous adenomatous polyps, increased 
(colon)cancer risk 
Marfan’s syndrome Connective tissue disorder: cardiac 
complications 
Neurofibromatosis I Neural tumors 
Cystic fibrosis Pulmonary failure due to repeated infections 
Spinal muscular atrophia Muscle wasting 
Fragile X syndrome Autism, intellectual disability 
Hemophilia A/B Impaired hemostasis 
Duchenne muscular dystrophy Muscle wasting 
Chromosomal abnormalities Increased risk of pregnancy loss 
 
Some of these diseases (i.e. hereditary breast-ovarian cancer, FAP, cystic fibrosis) have much 
in common with ADPKD. For example, they are frequently (autosomal dominant) inherited 
disease, causing loss of function of specific organs, which severely impairs health at a 
relatively young age. In the case of ADPKD, renal failure may occur at a relatively early age, 
while glomerular filtration rates progressively decline even earlier. Besides other symptoms 
due to cyst mass effects, this by itself may be enough to warrant PGD, especially in families 
with a generally severe phenotype. Families occur with an early-manifesting phenotype (73), 
and the total number of early-onset ADPKD patients might equal the number of ARPKD 
patients in pediatric nephrology (74). Indeed, the first healthy twins born from pre-
implantation genetic diagnosis for ADPKD has been described in 2004 (75), and the KDIGO 
group (Kidney disease: improving global outcomes) has placed PGD on the research agenda 
(76). They recognize a need to examine the performance of the blastomere and 
trophectoderm biopsy techniques. Nonetheless, the advice from KDIGO is to discuss PGD as 
a reproductive choice with patients with ADPKD.  
ADPLD should be treated as a different entity. While severe ADPLD can have a large impact 
on quality of life, liver function does not get threatened, nor is the disease assumed to 
progress to cancer. PGD should be considered on a case-by-case basis, if at all. For example, 
if multiple members within a family require surgical intervention such as liver 
transplantation, an assessment of the ethicality of PGD may be wise. It is possible that with 
time ADPLD will become a suitable indication for genomic editing and PGD. 
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Concluding, even though genomic editing of the human germline may still lie in the future, 
PGD is currently available and applied to severe hereditary conditions. ADPKD is a suitable 
candidate condition for the treatment, while ADPLD may apply on a case-by-case basis. 
Meanwhile, it may be sensible to develop medical options for treatment. 
Pharmacological treatment 
Multiple routes can lead to new pharmacological treatment choices for ADPLD. First, large 
groups of off-patent, generic drugs can be tested in repurposing screens. Second, small 
molecules with different pharmacological properties can be evaluated for effects on cyst 
cells. Third, drugs with known effects may be chosen based on properties expected to be 
effective in inhibiting cysts. Fourth, drugs may be rationally designed to obtain wanted 
effect. Or fifth, a combination of these options. Of course, somatostatin analogues have a 
proven effect on curtailing cyst growth, but even these are not ideal due to cost ($7000-
11000/month (77), and currently ~€1000/month in the Netherlands) and limited benefits. 
There is an unmet need for new drugs. In this chapter, we evaluate which drugs can be 
rationally picked or may be designed based on literature to inhibit cyst growth (table 3).  
A relevant screening platform will be required.  
Pharmacological treatment: RNA level 
Mutations in PRKCSH, the gene most frequently mutated in ADPLD, are often related to 
splice-site mutations. For example, in the Netherlands, the PRKCSH c.292+1G>C has a high 
prevalence (1). Targeting incorrect splicing in ADPLD appears to be a fitting strategy. 
Recently, scientists have developed splice-switching oligonucleotides (SSOs). These 
chemically modified antisense oligonucleotides are capable of redirecting splice site 
selection, and have done so since first attempted to restore correct splicing in beta-
thalassemia (78). Researchers published one of the early successes of the technique in 2007, 
when exon-skipping by SSO was successful for restoring dystrophin to 3-12% of normal levels 
in a clinical trial for Duchenne’s muscular dystrophy (79). In contrast to other antisense 
oligonucleotides, the SSOs are modified in a manner that causes them to not be degraded by 
RNase H. Chemical modifications allow SSO with activity localized to specific organs such as 
the liver (80). Although a mutation such as PRKCSH c.292+1G>C cannot be removed, the 
splice site at the end of its affected exon can be skipped. This would cause a truncated GIIB 
protein to occur, which has potentially less harmful effects than a very early stop codon. A 
strategy that is worth exploring. 
Pharmacological treatment: targeting translation 
Although less frequent than splice-site mutations in ADPLD, nonsense mutations also occur 
within the spectrum of mutational causes. Recently, scientists have developed stopcodon 
read-through drugs. These drugs suppress translation termination at premature stopcodons 
by favoring codon binding by aminoacyl-tRNA incorporation/elongation over binding by 
termination factors (81). Aminoglycosides such as G418 (geneticin) and gentamicin have 
been studied since the late 90s for use as stopcodon read-through drugs. Historically, their 
main application was as antibiotic agents, where they prevent incorporation of amino acids 
in bacterial translation by binding the 30s ribosomal subunit. Although the aminoglycosides 
bind far more weakly to eukaryote ribosomes, read-through effects clearly occur in multiple 
studies (reviewed in (82)). Unfortunately, due to side effects such as nephro- and ototoxicity, 
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aminoglycosides are not viable long-term treatment options. 
A recently developed read-through drug by the name of ataluren has proven effectivity with 
a benign safety profile in clinical testing, which was subsequently launched in Europe for the 
treatment of cystic fibrosis (83). The drug is an oxadiazole with few off-target side effects 
and oral bioavailability. Its effectivity as a read-through drug is unsure in view of the data of  
several studies however (81), but a larger body of evidence has shown effectivity, including 
aforementioned clinical trials. Testing read-through drugs that affect the nonsense 
mutations in ADPLD may be an effective strategy. 
Pharmacological treatment: targeting posttranslational quality control 
A prime function of GIIB and SEC63p is their function in quality control. When the underlying 
genes are mutated, proteins undergo less rigorous quality control. Protein misfolding, 
followed by degradation in the proteasome is a consequence. Fedeles and colleagues 
proposed making use of this property of mutated cyst cells by applying proteasome 
inhibitors (8). These drugs can increase the quantity of misfolded proteins that are not 
degraded, which leads to an increased cellular unfolded protein burden to toxic levels. In 
animal models this increased the rate of cyst cell apoptosis. Secondly, they observed an 
increase in the steady-state levels of Pkd1 by MG132 treatment, which may (putatively) 
prevent or ameliorate cellular dysfunction due to lack of Pkd1. In Prkcshflox/flox; Ksp-Cre mice, 
i.v. carfilzomib (5mg/kg) with weekly carfilzomib for 6 weeks had a profound effect on cyst 
progression, without adverse effects. An independent study observed favorable effects of 
proteasome inhibitor MG115 in another disease model of ADPLD (64). It may be valuable to 
screen proteasome inhibitor effects on human cell lines, with apoptosis, PKD1 level and 
ciliogenesis as outcome measures. 
Pharmacological treatment: additional pathways 
A large number of drugs exist that have known or putative effects in preventing cyst 
progression, many of which are reviewed in (84).  These will each be briefly highlighted, with 
a special focus on those published in higher impact factor journals and those not described 
in this review article. The most well-known drugs, somatostatin analogues, do not fall within 
the scope of this paragraph about future therapeutics, since their effects are already well-
studied in clinical trials for ADPLD.  Similarly, mTOR inhibitors, are well-studied, but are 
generally considered to have inadequate effects in halting cyst progress (84-89). This drug 
class is unlikely to yield promising effects in further studies. 
Cyclin inhibitors 
Vitamin K3 is the first relevant drug, as it showed some promising effects in animal studies 
(90). Masyuk and colleagues found that cell division cycle 25 homolog A (Cdc25a) was 
overexpressed in cystogenesis, causing cell cycle deregulation. By inhibiting Cdc25a using 
vitamin K3 or PM-20, hepato-renal cystic areas decreased in PCK rats and Pkd2ws25/- mice. In 
another study, the cyclin-dependent kinase inhibitors r-roscovitine and S-CR8 appeared to 
block hepatic and renal cystogenesis (91). These two independent studies indicate that cyclin 
inhibition may be a valid therapeutic approach in ADPLD. 
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2-deoxyglucose 
2-deoxyglucose causes metabolic reprogramming through inhibition of glucose metabolism 
(92). A beautiful paper published in Nature Medicine, human and murine cyst cells of ADPKD 
display increased aerobic glycosis through a mechanism known as the Warburg effect. 
Named after Otto Warburg, this scientist showed that cancer cells generate energy through 
glycolysis with reduction of pyruvate through lactate even in circumstances of sufficient 
oxygen. The effect may sustain tumor cell proliferation through altering biosynthetic 
pathways. 2-deoxyglucose, by preventing this tumor effect, caused a decrease in kidney 
weight, volume and cystic index in two mouse models of ADPKD. The drug, or derivatives 
thereof, may prove a potent therapeutic strategy against cyst development.  
Metalloproteinase inhibitors 
Another newcomer on the field is marimastat. This pharmaceutical is part of the 
metalloproteinase inhibitor drug class, which prevent proteins involved in breaking down 
extracellular matrix (ECM) from functioning. In one study, Banales et al discovered an 
inhibiting effect on cyst growth (93). Theoretically, this occurs because cysts are no longer 
capable of growing through the now-undegradable ECM. Unfortunately, marimastat has not 
yet passed clinical trials aimed at human use of the drug. Trials for ADPLD patients may be 
considered if a clinical drug is developed with a tolerable safety profile. 
Ursodeoxycholic acid 
The same group studied ursodeoxycholic acid (UDCA) in experimental models of PLD, and 
found it inhibited cystogenesis (94). Supposedly, besides normalizing bile acid flow through 
cystic livers, the drug halts hyperproliferation via a PI3K/AKT/MEK/ERK1/2-dependent 
mechanism. In a recent clinical trial by d'Agnolo and colleagues (95), the drug failed to live 
up to expectations. UDCA when administrated for 24 weeks did not reduce total liver volume 
in advanced PLD. In a post-hoc analysis it did decrease liver cyst volume in ADPKD patients. 
As study authors mention however, the study was not powered for subgroup analyses of 
ADPKD and ADPLD patients. Further study is required. 
Wnt inhibition 
One final pathway worth modifying is that of canonical Wnt signaling, which recently proved 
to be involved in polycystic liver disease. Scientists are developing drugs that may modify the 
pathway in a clinical setting. An example of this is LGK974 (96), a porcupine inhibitor that 
blocks Wnt secretion, currently in clinical testing.  It has thus far proven effective against 
multiple tumor types in animal models, and may be worth screening in PLD drug tests. 
Calcium agonist and remaining drugs 
One of the putative primary pathogenic pathways involved in cyst development is decreased 
calcium signaling. Researchers studying this zoomed in on the Trpv4 calcium-entry channel in 
PCK rats, and found that activating the channel could inhibit cell proliferation and in vitro 
cyst growth (97). Although promising, the authors of the study conclude there are currently 
no drugs available to test the effect in clinical practice. 
Some smaller studies suggest drugs like celecoxib (through VEGF/Raf/MAPK/ERK signaling 
pathway inhibition) (98),  VEGF inhibitors (99), HDAC inhibitors (through improved cell cycle 
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regulation and ciliogenesis) (100, 101), isoliquiritigenin and thiophenecarboxylates (through 
inhibition of fluid secretion) (102, 103), and narengenin (104) might inhibit cystogenesis. 
PPAR-gamma inhibitors also inhibit cyst formation in study published in PLoS one (105, 106). 
Surprisingly, telmisartan, generally used as an angiotensin-2 receptor antagonist is used to 
block PPAR-gamma. Although far from conclusive data, it may be valuable to study these 
compounds in PLD drug screens. The step to animal experiments is long however, and the 
issue with mTOR inhibitors (successful in experimental models, but unable to alter the 
natural course of ADPKD) suggest that way to translation is difficult.  
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Table 3. Rationale for drugs in ADPLD based on mechanism of action, many of which are 
reviewed in (84). 
Drug class Examples Mechanism of action 
Splice-Switching 
Oligonucleotides (78-80) 
- Correct aberrant splicing, induce 
expression of a therapeutic 
splice variant, or induce 
expression of a novel 
therapeutic splice variant 
Read-through drugs (81-83) Aminoglycosides (e.g. 
Gentamicin, G418), 
negamycin, ataluren 
Causing ribosomes to ignore 
premature stop codons / 
nonsense mutations 
Proteasome-inhibitors (8, 
64) 
MG132, MG115, 
carfilzomib 
Preventing proteasome 
degradation of poor quality 
proteins 
CDC25a inhibitors (90) Vitamin K3, PM-20 Cell cycle regulation through 
inhibition of overexpressed 
cyclin-related proteins 
2-deoxyglucose (92) - Metabolic reprogramming, 
inhibition of glucose metabolism 
CDK inhibitors  (91) R-roscovitine, S-CR8 Cell cycle regulation through 
cyclin-dependent kinase 
inhibition 
Metalloproteinase inhibitors 
(93) 
marimastat Metalloproteinase inhibition to 
prevent tissue expansion 
mTOR inhibitors (84-89) Sirolimus, tacrolimus, 
everolimus 
mTOR pathway inhibition to 
prevent cell proliferation 
PPAR-gamma inhibitors (105, 
106) 
Pioglitazone, telmisartan Inhibition of PPAR-gamma 
pathway to prevent cell 
proliferation 
Ursodeoxycholic acid (94, 
95) 
- Prevention of biliary cell 
proliferation 
Estrogen receptor inhibitors 
(38) 
Tamoxifen Estrogen inhibition to prevent 
cell proliferation 
VEGF receptor inhibition (99) SU-5416 VEGF pathway inhibition to 
prevent cell proliferation 
Calcium stimulators (97) ? Intracellular calcium 
enhancement to prevent cell 
proliferation 
Wnt signaling inhibitors (96) LGK974 Canonical Wnt signaling 
inhibition 
Fluid secretion inhibition 
(102, 103) 
Isoliquiritigenin, 
Thiophenecarboxylates 
Fluid secretion inhibition (CFTR- 
or cAMP-mediated) 
HDAC inhibitors (100, 101) ACY-1215 various 
NSAID (98) Celoxib VEGF/Raf/MAPK/ERK signaling 
pathway inhibition 
naringenin (104) - - 
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Surgical treatment 
One final option for treatment of severe, refractory polycystic liver disease is currently liver 
transplantation. Liver transplantation represents a formidable procedure and the patient will 
be on lifelong immunosuppressive therapy to prevent rejection of the foreign liver tissue.  
A marriage between adult liver stem cell culture and CRISPR-Cas9 might remove this latter 
disadvantage, while remaining ethically sound. Scientists can isolate adult liver stem cells 
from the patient before transplantation, and may subsequently remove disease-causing 
mutations using CRISPR-Cas9 (107). Following suitable testing to prevent unwanted off-
target effects, liver cells can be cultured to sufficient quantities for retransplantation. 
Although still far of, this strategy will allow autologous liver stem cell transplantation. 
Testing is currently underway for copper accumulation disease in a dog model of Wilson’s 
disease (108), in which disease CRISPR-Cas9 repaired cells will have a survival advantage. If 
successful, the next step will be generating more complex liver tissue for transplantation.  
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Chapter 9 
Summary 
Autosomal dominant polycystic liver disease is a hereditary disorder causing multiple fluid-
filled cysts in the liver, which may cause significant discomfort to patients suffering from it. A 
gene defect in PRKCSH, SEC63, LRP5, GANAB, ALG8 or SEC61B leads to production of a faulty 
protein, causing an abnormal cellular response and finally random expansion of parts of the 
biliary tract (Chapters 1 and 2). Similar effects are seen with PKD1, PKD2 and PKHD1 
mutations, which cause autosomal dominant and recessive polycystic kidney disease (ADPKD 
& ARPKD). PKHD1 was recently found to cause liver cysts in an autosomal dominant fashion 
in mutation carriers. 
In the body, somatic second hits occur that then cause loss-of-heterozygosity (LOH) and 
reduction of the cognate protein activity below the threshold of pathogenicity. In this thesis, 
we studied cyst development at multiple biological levels. 
 
DNA 
We isolated and analyzed DNA from biliary cells obtained from 46 cyst fluid and cyst 
epithelium samples from 23 patients (Chapter 3). In 76% (22/29) and 67% (2/3) of liver cysts 
of PRKCSH and PKD1 mutation patients LOH is present respectively. We additionally found 
LOH in one cyst of a SEC63 mutation carrier. Abnormalities in novel regions outside of known 
regions underlying cyst formation were present in 12 of 23 patients. A BUB1 mutation and 
recurring 3p mutation indicate that risk factors for ADPLD may modify disease course, and 
germline modifier genes may be present.  
 
RNA 
We used RNA sequencing to determine the gene expression pattern of eight liver cyst cell 
cultures and compared that with four normal biliary cell cultures (Chapter 5). The cell 
cultures expressed many genes important in cystogenesis, including all known genes 
underlying cyst formation and ciliogenesis. Although no significantly different pathways 
between normal and cyst cultures were discovered, on principal component analysis plots 
PRKCSH and PKD1 mutation organoids clustered separately from other PLD organoids. 
Including a larger number of organoids with known mutations will likely yield more 
information with regard to clustering and mutation-specific disrupted pathways. 
 
Protein 
We used tandem affinity purification (TAP) to isolate ADPLD associated protein complexes, 
and analyzed them using mass spectrometry (MS) (Chapter 4). Known interactors were 
present. GIIB interacted with GIIA, and SEC63p with SEC61A1 and SEC61B. Interactions of 
GIIB and SEC63p with PEX proteins confirmed the ER origin of peroxisomes, and a possible 
relation to cyst development. Finally, GIIB, SEC63p and LRP5 shared a common interaction 
with filamin A (FLNA). FLNA is a scaffold important in diverse cellular signaling pathways, 
which include Wnt signaling and ciliogenesis.  
 
 
164 |   Chapter 9 
 
Organelle/cilium 
After knocking out PRKCSH or SEC63 in H69 and HEK293T cells, we studied ciliogenesis and 
Wnt signaling (Chapter 4). In both of these cell lines, formation of primary cilia was 
significantly reduced by loss of PRKCSH or SEC63. In H69 cholangiocytes, Wnt signaling is 
additionally disrupted significantly as measured by luciferase assay and axin 2 mRNA 
expression. These findings indicate cilium formation requires normal PRKCSH and SEC63 
expression, and that Wnt signaling may be disrupted due to their mutation depending on the 
cell type.  
Cell 
We used two separate techniques to create cell lines modelling ADPLD. First, as mentioned 
above, H69 and HEK293T were modified using CRISPr-Cas9 to lose PRKCSH or SEC63 
expression. Second, cholangiocytes from cyst epithelium and fluid were placed into 
conditions suitable for the expansion of liver stem cells (Chapter 5). These cells developed 
into liver organoids, which carried the genetic background of hepatic cysts. Both of these 
models are valuable for screening for critical components of ADPLD pathophysiology that 
might be exploited for pharmaceutical treatment. 
Organism 
Prkcsh, Sec63 and Lrp5 in 1-cell stage zebrafish embryos were disrupted by CRISPR-Cas9 
technology (Chapter 6). Larvae with single, double and triple mutations in the genes 
underlying cystogenesis developed. Both Prkcsh and Sec63 mutation larvae displayed 
decreased length, and a failure to reach adulthood. In case of Sec63 mutations, swim 
bladders did not inflate. Only larvae with in-frame Lrp5 mutations developed, and these 
could reach adulthood. No differences in fish length were observed. In none of the fish, any 
liver cysts developed. Even without liver cysts, the knockout zebrafish might be valuable for 
screening purposes, to evaluate the effects of potential pharmacological agents on surrogate 
parameters like fish length and swim bladder inflation. The developed gRNA sequenes may 
be used to develop zebrafish with liver-specific knockout of cyst genes.  
Concluding remarks 
Concluding, this thesis has broadened the view of the genetic basis of ADPLD, as well as 
pointing towards new mechanisms of disease and avenues for further research. The research 
indicates that researchers should exploit mutation-specific rather than disease-specific 
models to determine crucial components of ADPLD pathophysiology and therapeutical 
options.  
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Lay extra: From gene to organism. 
Genes are at the basis of life, generating organisms through multiple steps; genes in DNA 
specify RNA, which codes proteins, cells, tissue, organ and organism growth. Like a stack of 
dominos, if one falls down, it will have consequences for the next biological process. It is a 
small miracle that despite development being a game of statistics, humans generally grow 
up healthy and fit. Below the normal process of development is outlined in simple terms.  
DNA 
At the basis of this complexity lies the hereditary or genetic data present in the DNA. This 
molecule stores all the information required to create everything from a simple gene, to a 
multicellular organism. Due to its extraordinary stability, evolution ‘chose’ DNA for long-
term storage of genetic information. In human beings, every gene is present in two copies 
(‘alleles’) on two long strands called chromosomes. This is fortunate, as when one copy is 
broken (‘mutated’), the other copy can often serve as a backup. DNA is copied by enzymes 
called polymerases, of which multiple variants exist. For example, DNA polymerases are the 
enzymes that generate new copies of DNA. In the human body, most DNA polymerases have 
proof-reading capabilities. This means that after they copy DNA, they check (or proofread) 
whether the DNA was copied correctly, and correct their mistakes if necessary.  
In this manner, human DNA polymerases are highly accurate (=high fidelity), and make 
mistakes in as little as 1 in 100 million nucleotides (the letters of DNA) (1). Repair enzymes 
fix 99% of these errors, leaving an error rate of 1 in 10 billion nucleotides. All human genes 
(also known as the human genome) are 3.2 billion nucleotides x 2 (two copies/alleles), 
leaving us with 0.64 copy mistakes every time the DNA is copied before a cell divides. There 
are 37,2 trillion cells in the human body (2), and 240 billion cells in the human liver. This 
indicates there is a lot of chance for each gene to obtain a mutation (=DNA error) simply 
based on DNA replication during cell division. Other mechanisms of mutations also exist, 
such as UV-light or toxin induced DNA damage. Luckily however, humans possess most 
genes in pairs (known as alleles).  
RNA and proteins 
RNA polymerase generates RNA molecules from DNA. Like DNA, RNA consists of nucleotides, 
but with slightly different chemical components. As such, RNA is more unstable and fleeting, 
but has the additional capability to perform functions influencing its environment. RNA can 
store information and affect / process molecules at the same time. It can be copied from 
DNA with only slight modifications, and some of these RNA copies can subsequently perform 
the functions stored in the genes. For example, the enzymatic function of ribosomal RNA 
allows proteins to be formed. More important are the messenger RNAs, which work as 
instructions to build the proteins of the body. 
Genes on DNA usually encode such proteins. Although proteins cannot store genetic 
information, they are the most important component to create the cells of our bodies. 
Proteins have a myriad of functions. They are enzymes, building blocks, cellular signals and 
more. Enzymatic proteins can create, or catalyze, production of a variety of molecules. 
Proteins are also often a scaffold for other molecules to bind on. And importantly, proteins 
are responsible for action and reaction of cells in response to their environment.  
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Organelles and cells 
Proteins perform their function in different organelles of the cell. An example includes the 
endoplasmic reticulum, where many newly created proteins are processed by other, older 
proteins to function correctly. Another is the primary cilium, which is only present on some 
cells. This organelle functions as a cellular antenna, where proteins such as polycystin-1 and 
polycystin-2 are thought to respond to external stimuli to produce a response within the cell. 
This is the smallest living unit of most organisms, and virtually all cells are capable of the 
processes described above. From the instructions contained on DNA, RNA and proteins 
cause cells to develop. Different cell types exist. For example, the most important cell types 
of the liver are the hepatocytes and biliary cells. Hepatocytes are responsible for enzymatic 
processing of nutrients, vitamins, and waste, while biliary are responsible for removal of this 
processed waste through bile fluids.  
Each cell knows how to develop due to its environment, and other cells surrounding it. 
Crucial for these interactions are signaling proteins. Cell-cell and cell-environment 
interactions thus shape the tissues of the human body. 
Tissues, organs and organisms 
The development of the biliary tract in human embryos is a prime example of tissue 
formation. Cells from the so-called portal veins of the embryonic liver secrete proteins that 
induce adjacent cells to become biliary cells. These proteins belong to a class called ‘Wnt’ 
proteins. The Wnt proteins simply diffuse between the cells, and as such, the farther away 
the cell, the lower the amount of Wnt it receives. Whereas high-dose Wnt induces biliary 
cells, lower-dose Wnt induces periportal hepatocytes, liver cells surrounding incoming veins 
from the intestines, to develop. Absent Wnt causes centrovenular hepatocytes, liver cells 
surrounding veins towards the heart, to grow (3). Each of these cell-types has a slightly 
different function, based on the requirements from its environment. Biliary cells develop the 
primary cilia, which cellular antennae can sense bile flow and composition.  
Although the single Wnt gradient is a simplified view, it can be imagined that multiple 
signaling gradients occurring in different locations and times. Together they cause all tissues 
to develop. 
Organ development is the end result of this complex interaction between genes, proteins, 
cells, and tissues. The arteries, veins, hepatic parenchyma, biliary tracts, and immune system 
all come together to form the liver. The correct location and size of each of the tissues is 
essential for normal organ development, and for development of the human organism as a 
whole.  
Concluding remarks 
Only some of the genes that are responsible for liver cyst development are known, and it is 
unclear which processes they end up affecting to cause the disease. At each of the described 
levels problems leading to disease may occur. The tools and knowledge to interrogate each 
of the above processes in great detail now exist, and many of them were applied in this 
thesis. How and why is described in this thesis starting in Chapter 1. As a lay reader, either 
the summary, Dutch ‘samenvatting’ and Dutch ‘eenvoudig gezegd’ following directly 
hereafter may be more appropriate reading material however. 
 
As a small extra, the number of liver cells with a mutation in paragraph ‘DNA’ corresponds to 
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the number of liver cells with a mutation in the second copy of PRKCSH. This gene is 15712 
nucleotides in length. Although other mechanisms are also involved, e.g. a mechanism 
named interstitial deletion; this is at least a part of a statistical calculation that is the basis of 
random expansion of part of the liver into cysts.  
Glossary 
Gene: Most basic coding unit of DNA. Sequence of nucleotides encoding a protein, rRNA, 
tRNA, or other type of functioning RNA. 
Allele: One of a pair of genes (but may contain minor differences in nucleotide sequence). 
Chromosome: One of 23 strands of DNA in humans, two copies of each chromosome exist in 
most cells (‘diploid state’). 
Biliary cell: Cell of the biliary tract. 
Cholangiocyte: Identical to biliary cell. 
Hepatocyte: Main cell type of the liver.  
Portal vein: Blood vessel carrying blood from the intestines and spleen to the liver. 
Wnt signaling: Signaling pathway involved in development of tissue, cell 
division/proliferation and differentiation (the process of become a mature cell type like a 
biliary cell or hepatocyte). 
Primary cilium: The cell’s antenna. An organelle (part of a cell/cell structure) found on many 
cells in the human body. 
Endoplasmic reticulum: Network of tubular membranes within the cell, responsible for 
functions such as protein processing/maturation.  
 
 
 
 
 
  
168 |   Chapter 9 
 
Samenvatting 
Autosomaal dominante polycysteuze leverziekte (ADPLD) is een erfelijke aandoening, die 
meerdere met vocht gevulde cysten in de lever veroorzaakt. Deze cysten kunnen toch flinke 
klachten bij patiënten leiden. Een genetisch defect in PRKCSH, SEC63, LRP5, GANAB, ALG8 of 
SEC61B leidt tot productie van een foutief eiwit, dat leidt tot een abnormale cellulaire 
reactie en uiteindelijk willekeurige groei van delen van de galwegen (Hoofdstuk 1 en 2). 
Gelijke gevolgen worden met PKD1, PKD2 en PKHD1 mutaties gezien, welke autosomaal 
dominante en recessieve nierziekte (ADPKD & ARPKD) veroorzaken. In het lichaam treden 
somatische tweede abnormaliteiten op, die verlies-van-heterozygositeit (LOH) onderliggen. 
LOH veroorzaakt een vermindering van de relevante eiwit producten veroorzaakt, tot onder 
de drempel van pathogeniciteit. In deze thesis, hebben we cyste ontwikkeling op meerdere 
biologische niveaus bestudeerd. 
DNA 
We isoleerden en analyseerden DNA van biliaire cellen verkregen van 46 cystevocht en 
cyste-epitheel monsters van 23 patiënten (Hoofdstuk 3). In respectievelijk, 76% (22/29) en 
67% (2/3) van de levercysten van PRKCSH en PKD1 mutatie patiënten is LOH aanwezig. 
Bovendien vonden we LOH in een cyste van een SEC63 mutatie patiënt. Abnormaliteiten in 
nieuwe regio’s buiten de bekende regio’s betrokken bij cyste-ontwikkeling waren in 12 van 
23 patiënten aanwezig. Een BUB1 mutatie en herhaaldelijk voorkomende 3p mutaties wijzen 
erop dat risico factoren van ADPLD ziekteprogressie kunnen beïnvloeden. Ze wijzen er ook 
op dat kiembaan genen naast the cystegen het ziektebeeld zouden kunnen beïnvloeden. 
RNA 
We gebruikten RNA sequencing om het gene expressie patroon van acht lever cyste culturen 
te vergelijken met dat van vier normale biliare cel culturen (Hoofdstuk 5). De cel culturen 
brachten veel genen tot expressie die belangrijk zijn in cyste vorming; alle genen die 
cystogenese onderliggen, evenals genen betrokken bij ciliogenese. Alhoewel geen significant 
tussen cyste en normale culturen verschillende celsignaleringsroute werd ontdekt, toonde 
“principal component analyse” aan dat PRKCSH en PKD1 mutatie organoïden separaat 
groepeerden ten opzichte van normale organoïden. Door inclusie van een groter aantal 
organoïden met een bekende mutatie kan in een vervolgonderzoek waarschijnlijk meer 
informatie vergaard worden over groepering van de culturen en mutatie-specifieke 
verstoorde celsignaleringsroutes. 
Eiwit 
We hebben tandem affiniteit purificatie (TAP) gebruikt om ADPLD geassociëerde eiwit 
complexen op te zuiveren, en hebben deze geanalyseerd met massa spectrometrie (MS) 
(Hoofdstuk 4). Bekende directe interacties werden geïdentificeerd, zoals de associatie van 
Glucosidase II b (GIIB) met GIIA, en SEC63p met SE61A1 en SEC61B, wat de gebruikte 
methode valideerde. Interacties van GIIB en SEC63p met perixosomale biogenese eiwitten 
bevestigden de herkomst van perixosomen uit het endoplastisch reticulum. Tegelijk duidde 
de interactie op een mogelijke relatie van de organellen met cyste vorming. Tenslotte 
deelden GIIB, SEC63p en LRP5 een gemeenschappelijke interactie met filamine A (FLNA). 
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FLNA is een zgn. “steigereiwit”, waar meerdere cellulare signaleringsroutes mee associëren, 
waaronder componenten van de Wnt signalering en ciliogenese. 
Organel/cilium 
Na uitschakeling van PRKCSH of SEC63 in H69 en HEK293T cellen, bestudeerden wij de 
ciliogenese en Wnt signalering (Hoofdstuk 4). In beide cellijnen was ciliogenese significant 
verstoord door verlies van de genen. In H69 cholangiocyten werd Wnt signalering tevens 
verstoord, zoals gemeten door luciferase assay en axine 2 mRNA expressie. Deze vondsten 
wijzen erop dat ciliumvorming normale PRKCSH  en SEC63 expressie vereisen, evenals dat 
Wnt-signalering verstoord kan worden door mutatie, afhankelijk van het celtype. 
Cel 
We gebruikten twee verschillende technieken om cellijnen te creëren die ADPLD 
modelleren. Als eerste, zoals boven gezegd, werden H69 en HEK293T genetisch 
gemodificeerd door CRISPR-Cas9. Als tweede werden cholangiocyten uit cyste epitheel en 
vocht in condities geschikt voor de groei van leverstamcellen geplaatst (Hoofdstuk 5). Deze 
cellen ontwikkelden tot lever organoïden, welke de genetische achtergrond van levercysten 
bezitten. Beide modellen zijn waardevol voor screening van essentiële onderdelen van 
ADPLD pathofysiologie, die kunnen worden gebruikt voor medicatie-ontwikkeling. 
Organisme 
Prkcsh, Sec63 en Lrp5 werden in 1-cellige zebravis embryo’s verstoord door CRISPR-Cas9 
(Hoofdstuk 6). Larven met enkele, dubbele en driedubbele mutaties in de genen 
verantwoordelijk voor cyste-vorming ontwikkelden. Zowel Prkcsh als Sec63 mutant larven 
vertoonden een verminderde lengte, als ook niet-gedijen, waarbij de volwassenheid niet 
werd gehaald. In geval van Sec63 mutatie vulden zwemblazen zich niet. Alleen larven met in-
frame Lrp5 mutaties ontwikkelden en konden de volwassenheid bereiken. Er werden geen 
verschillen in vislengte gevonden bij deze mutanten. In geen van de vissen werden 
levercysten gevonden. Zelfs zonder levercysten zouden deze zebravissen echter waardevol 
kunnen zijn voor het screenen van effecten van mogelijke farmacologische agentia. 
Surrogaat parameters als vislengte en het opblazen van zwemblazen kunnen hier dan 
mogelijk voor worden gebruikt. Het uitschakelen van de cyste-vorming veroorzakende genen 
alleen in de lever met de ontwikkelde gRNAs is ook een mogelijke optie. 
Concluderend heeft deze thesis de visie op de genetische basis van ADPLD verbreed, als ook 
nieuwe ziekte-mechanismen en routes voor vervolgonderzoek aangewezen. Het onderzoek 
wijst erop dat onderzoekers mutatie-specifieke in plaats van ziekte-specifieke modellen 
moeten gebruiken om essentiële componenten van ADPLD pathofysiologie en 
therapeutische opties te ontdekken. 
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Eenvoudig gezegd 
 
Het ontstaan van levercysten 
Autosomaal dominante polycysteuze leverziekte (ADPLD) is een erfelijke ziekte, die 
meerdere met vocht gevulde blazen, ofwel cysten, in de lever veroorzaakt. Kinderen van een 
ADPLD-patiënt hebben een kans van 50% (1 op 2) om het ziektebeeld te krijgen. Groei van 
deze cysten veroorzaakt klachten door druk in de buik ontstaan. Er zijn momenteel zeven 
genen bekend die levercysten zonder andere lichamelijke afwijkingen veroorzaken. Dit zijn 
de PRKCSH, SEC63, LRP5, GANAB, ALG8, PKHD1 en SEC61B  genen (bij conventie worden gen-
namen schuin geschreven). PKHD1 kan in sommige gevallen ook tot cysten in de nieren 
leiden, zoals ook de daarnaast bekende PKD1 en PKD2 genen. 
De fout in het tweede genkopie 
Een patiënt heeft een fout in een van de twee kopieën van een gen die op het DNA bestaan. 
De meeste cellen heb dus gelukkig nog een goede kopie. Als door pech in de lever een fout 
ontstaat in het tweede kopie, ontstaat pas een levercyste. 
Gevolgen van verlies van beide genkopiëen 
Het is onduidelijk wat precies met de galwegcel gebeurt na verlies van beide genkopiëen. Elk 
fout in deze genen leidt tot een fout in een corresponderend RNA en eiwit, dat vervolgens 
leidt tot problemen in de cellen en organen van het lichaam.  
Eén van de meest opvallendste vondsten is het verlies of afwijkend raken van de antenne 
van de cel (het zogenaamde primaire cilium). Een theorie is dat door deze kapotte antenne 
een verwarde cel ontstaat, die te veel delingen doorgaat en te veel vocht produceert, en 
zodoende een cyste in de lever maakt. 
Wat we niet weten 
Op meerdere niveaus is het ontstaan van levercysten niet compleet duidelijk: 
1. Op DNA gebied zorgen de zeven bekende ‘ADPLD’ genen slechts voor maximaal de 
helft van de patiëntgevallen.  
2. Op RNA en eiwit niveau is het ontstaan van levercysten onduidelijk. Welke deel of 
eiwitsysteem van de cel verstoord raakt na de fout in het tweede genkopie is nooit 
overtuigend bewezen. 
3. Ook hoe de verstoring van de antennes van cellen, gerelateerd is aan cyste-groei 
vereist nader onderzoek.  
4. Als laatste zou een nieuwe, effectieve medicatie-optie buitengewoon nuttig zijn om 
ziekte vooruitgang bij patiënten te voorkomen. Een accuraat en makkelijk toe te 
passen model van het ziektebeeld zou daarbij goed van pas komen.  
In deze thesis werd onderzoek gedaan naar levercyste-vorming op meerdere biologische 
niveaus. 
DNA 
We isoleerden en analyseerden DNA van galwegcellen van 46 cysten van de 23 patiënten 
(Hoofdstuk 3). In ongeveer driekwart van de door PRKCSH en PKD1 ontstane levercysten 
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bevestigden we een fout in het tweede genkopie van de cellen. Bovendien vonden we een 
foutief tweede genkopie in een cyste van een SEC63 mutatie patiënt. Ook in nieuwe 
gebieden vonden we bij 12 van 23 patiënten fouten op het DNA.  
RNA 
We vergeleken RNA van acht levercyste kweken met dat van vier normale galwegcel kweken 
(Hoofdstuk 5). De celkweken hadden RNA van genen die belangrijk zijn in cyste vorming; 
genen die vorming van levercysten veroorzaken (PRKCSH, SEC63, LRP5, GANAB, PKD1 en 
PKD2), evenals genen betrokken bij de antennes van cellen. Een specifieke eiwitgroep als 
oorzaak voor de levercysten werd niet gevonden, waarschijnlijk is daarvoor bij een 
vervolgonderzoek een grotere groep vereist. 
Eiwit 
We onderzochten welke eiwitten aanwezig zijn rondom PRKCSH, SEC63 en LRP5 in de cel 
(Hoofdstuk 4). Een aantal bekende partnereiwitten werden gevonden. Dit waren het GANAB 
eiwit (glucosidase IIA) voor PRKCSH, en SEC61A1 en SEC61B voor SEC63. GANAB en SEC61B 
werden later onafhankelijk ontdekt als oorzaken voor levercysten. 
Interessanter was dat alle drie de eiwitten een verbinding hadden met het filamine A eiwit 
(FLNA). FLNA is een steigereiwit, een eiwit waarop andere eiwitten een groter celonderdeel 
bouwen. Meerdere celonderdelen zijn verbonden met FLNA, waaronder de Wnt eiwitfamilie 
waartoe LRP5 hoort, als ook de vorming van de antennes van cellen. 
Verlies van de antenne van de cel 
Na uitschakeling van PRKCSH of SEC63 in celkweken, bestudeerden wij de vorming van 
celantennes en de activiteit van de Wnt eiwitten (Hoofdstuk 4). Door verlies van PRKCSH of  
SEC63 vormden cellen minder celantennes. Ook werd in onderzochte galwegcellen de Wnt 
activiteit verstoord. Deze vondsten wijzen erop dat de celantennes en Wnt activiteit normale 
PRKCSH  en SEC63 genen vereisen. 
Cel 
In deze thesis hebben we gepoogd nieuwe modellen voor het ziektebeeld te maken. 
Daarvoor maakten we zelf foutjes in de genen PRKCSH, SEC63 en LRP5. Als tweede namen 
we cellen van de levercysten en plaatsten die in condities geschikt voor de groei van 
leverstamcellen (Hoofdstuk 5). Deze cellen ontwikkelden tot leverkweken, welke het 
precieze DNA van levercysten bezitten. Beide modellen zijn waardevol voor onderzoek van 
essentiële onderdelen van het biologisch mechanisme achter het ontstaan van 
levercystenvorming, die kunnen worden gebruikt voor de ontwikkeling van medicijnen. 
Organisme 
De Prkcsh, Sec63 and Lrp5 genen werden in zebraviseitjes uitgeschakeld (Hoofdstuk 6). 
Nieuwgeboren zebravisjes met verlies van de genen ontwikkelden, afhankelijk van het 
succes met verlies van 1 tot alle drie deze genen. Zowel Prkcsh als Sec63 mutant larven 
waren korter. De visjes konden niet opgroeien tot volwassenen. In geval van Sec63 mutatie 
vulden zwemblazen zich niet. De zwemblazen zijn een orgaan van vissen verantwoordelijk 
voor de verplaatsing van vissen in de diepte en hoogte.  
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Alleen visjes met milde fouten in het Lrp5 gen ontwikkelden zich tot een volwassen vis. In 
geen van de vissen werden levercysten gevonden. Zelfs zonder levercysten zijn deze 
zebravissen mogelijk waardevol voor het testen van nieuwe medicijnen. Er kan dan worden 
gekeken naar verbetering van de lengte van de vissen en het opblazen van zwemblazen 
onder invloed van deze medicijnen. Mogelijk kan ook geprobeerd worden om de genen 
achter de cystevorming alleen in de lever uit te schakelen. Hierdoor hebben de vissen een 
grotere kans om volwassen te worden, met een langere tijd voor cyste-ontwikkeling.  
 
Concluderend heeft deze thesis de visie op de genetische basis van ADPLD verbreed, als ook 
nieuwe ziekte-mechanismen en routes voor vervolgonderzoek aangewezen. Het onderzoek 
wijst erop dat onderzoekers gen-specifieke in plaats van ziekte-specifieke modellen moeten 
gebruiken om belangrijke onderdelen van het ontstaan van de levercysten en medicijnen te 
ontdekken. 
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Assistenzärzte mit wem ich gesprochen habe, meinen dass Sie sich am besten für unsere Fortbildung 
einsetzen. In Holland wird immer über die deutsche Gründlichkeit gesprochen, und ich meine dass 
Sie die auf einer guten Art vertreten.  
Frau dr. Blüm, auch Ihnen vielen Dank für die gute Begleitung. Sie sind immer sehr nett. Es tut mir 
immer noch Leid dass ich Sie einmal gerade etwas zu Spät bescheid gesagt habe über eine 
Notfallendoskopie, sodass Sie wieder ins Haus kommen müsste. Dass Sie damals nicht Böse waren 
sagt vieles über Sie. 
Frau Czarnecka, wenn ich >15 Patienten auf Station hatte und mehrmals Notfallambulanz in einer 
Woche machen musste, war ich nur sehr sehr dankbar für Ihre klare und freundliche Hilfe. Sie habe 
die Arbeit auf einer schwierigen Station wirklich erleichtert und ich freue mich immer noch mit Ihnen 
arbeiten zu können. 
Dr. Wirtz, wenn ich Stress hatte und vor allem nur versuchte den Tag durch zu kommen, hatten sich 
mich oft darauf Aufmerksam gemacht dass ich auch zur Fortbildung (Sonographie) auf der Station 
war. Auch Ihnen bin ich deswegen und wegen der guten Zusammenarbeit dankbar. 
An alle Assistenzärzte; Herr Al-Mestirihi, Frau Pieters, Frau Oubari, Herr Lampouras, Herr Al-Saify, 
und alle anderen. Es freut mich mit euch arbeiten zu können. 
Karl und Marlies, vielen Dank für unsere Begegnungen. Dank euch habe ich damals in Goch 
angefangen und ich schätze unsere Freundschaft.  
Beste oom Stuart, ik ben u dankbaar dat u mijn moeder en ons altijd gesteund heeft. U bent een van 
mijn grote voorbeelden en ik draag dan ook met trots mijn tweede naam. 
Beste Ma, ik heb je natuurlijk alles te danken, maar het blijft bijzonder dat je me altijd zo voor 
onderwijs en kennis hebt weten te motiveren dat ik zo ver heb mogen komen.  
Jalitha, Morten, Rosalina en Luciano, zonder jullie was ik nooit zover gekomen met de PhD en overige 
carrière. Ik heb veel geluk dat ik jullie als familie heb. Talloze verhuizingen, studies, banen ben ik 
inmiddels verder, maar door dik en door dun zijn jullie er. 
Lieve Eline, ik denk het grootste geluk van de PhD is dat wij elkaar hebben ontmoet. Een paar 
woorden kunnen niet bevatten wat je voor me betekent. Maar het belangrijkste: Jij maakt me 
gelukkig.  
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Research data management 
Appropriate research data management is important for safeguarding scientific integrity, open 
science, safekeeping of valuable datasets and the reuse of data. The FAIR (Findable, Accessible, 
Interoperable and Reusable) principles are a recently published method for proper management of 
data (1). The data obtained during my PhD at the Radboud university medical center (Radboudumc) 
are archived in general accordance to these principles. Electronic data are stored on a secure server 
of the Radboudumc  for the Gastroenterology department. The data is accessible by the head of the 
laboratory, as well as the junior researchers studying relevant topics. The Information and 
Communications Technology (ICT) of Radboudumc supports the server. Primary and secondary data 
of all projects that were stored in the local server were additionally backed-up to the university 
servers on a weekly basis. The animal study in Chapter 6 was carried out in accordance with 
European and institutional guidelines on animal welfare (2010/63/EU)). Published articles contain 
part of the data generated and analyzed during this thesis, the additional files being available upon 
request from the corresponding author. 
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